

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number  
**WO 2005/002527 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2004/021630
- (22) International Filing Date: 6 July 2004 (06.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/484,836 3 July 2003 (03.07.2003) US
- (71) Applicant (for all designated States except US): **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02142-1324 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GUARENTE, Leonard, P.** [US/US]; 72 Goodnough Road, Chesnut Hill, MA 02167 (US). **PICARD, Frederic** [CA/CA]; 7, rue Belleau, Levis, QC G6V 4A8 (CA).
- (74) Agent: **MYERS, Louis**; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: SIRT1 MODULATION OF ADIPOGENESIS AND ADIPOSE FUNCTION



(57) Abstract: SIRT1 regulates the physiology of cells of the adipocyte lineage. Modulators of SIRT1 activity can be used to ameliorate, treat, or prevent diseases and disorders associated with adipose physiology, e.g., obesity, an obesity-related disease or a fat-related metabolic disorder.



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# **SIRT1 MODULATION OF ADIPOGENESIS AND ADIPOSE FUNCTION**

## **GOVERNMENT SUPPORT**

5           The invention was supported, in whole or in part, with United States Government support under Contract Numbers AG21150-01; AG11119-11; and AG15339-04 awarded by the National Institutes of Health. The United States has certain rights in the invention.

## **CROSS REFERENCE TO RELATED APPLICATIONS**

10           This application claims priority to 60/484,836, filed July 3, 2003, the contents of which are hereby incorporated by reference in its entirety.

## **BACKGROUND**

15           Vertebrates possess two distinct types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). WAT stores and releases fat according to the nutritional needs of the animal. BAT burns fat and releases energy in the form of nonshivering heat. In vertebrates, a chronic positive energy balance translates into an increase in WAT fat depots and obesity.

          Adipocytes develop from fibroblast-like cells, both during normal mammalian development and in various pathological circumstances, e.g., muscular dystrophy, where the muscle cells die and are gradually replaced by fatty connective tissue. See e.g., Sul (1989) Curr. Opin. Cell Biol. 1:1116-1121.

## **SUMMARY**

20           SIRT1 regulates the physiology of cells of the adipocyte lineage. Modulators of SIRT1 activity can be used to ameliorate, treat, or prevent diseases and disorders associated with adipose physiology, e.g., obesity, an obesity-related disease, or a fat-related metabolic disorder.

25           The SIR2 gene family has diverse functions in yeast including gene silencing, DNA repair, cell-cycle progression, and chromosome fidelity in meiosis and aging. Mammalian homologs of SIR2 proteins are called sirtuins and are a homologous family of proteins. Many of

these proteins can function as NAD-dependent protein deacetylases. The protein product of the gene hSIR2 (SIRT1) is the human homolog of the *S. cerevisiae* Sir2 protein known to be involved in cell aging. Human SIRT1 mRNA is disclosed at GenBank Accession No. AF083106. It has been observed that expression of wild-type hSir2 in human cells reduces the transcriptional activity of p53. See, e.g., Vaziri et al., Cell 2001 Oct 19;107 (2):149-59.

In one aspect, the disclosure features a method that includes: evaluating a SIRT1 molecule from a subject; and recording information from the SIRT1 evaluation in association with metabolic information about the subject. The method can be used to evaluate a subject. In one embodiment, the SIRT1 molecule is SIRT1 mRNA, cDNA, or genomic nucleic acid. For example, the evaluating includes quantitative or qualitative assessment of SIRT1 mRNA or cDNA levels or evaluating the identity of at least one nucleotide in the SIRT1 molecule.

In another embodiment, the SIRT1 molecule is SIRT1 protein. For example, the evaluating includes quantitative or qualitative assessment of SIRT1 protein levels or determining the identity of at least one amino acid in the SIRT1 protein.

The evaluating can include evaluating a cell of the adipose lineage or of the keratinocyte lineage, or a neuronal cell, e.g., a neuron. For example, the evaluating includes evaluating a preadipocyte or adipocyte, e.g., a WAT cell or a BAT cell. The cell of the keratinocyte lineage can be a keratinocyte or a pre-keratinocyte.

The metabolic information can include information about a biometric parameter (such as weight, height, girth or other linear measurement, body mass index, subcutaneous fat content, or visceral fat content); or information about a hormone or a metabolite. For example, information about a hormone includes information about leptin, insulin, adiponectin, or resistin. The information can indicate the concentration of the hormone in a subject. For example, information about a metabolite includes information about triglycerides, fatty acids, LDL particles, HDL particles, or cholesterol. The information can indicate the concentration of the metabolite, e.g., concentration of LDL or HDL particles, in a subject, or a ratio between metabolites or particle size, e.g. LDL and HDL particles. The method can also be adapted for other sirtuins, e.g., human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.

In another aspect, the disclosure features a method that includes: monitoring a parameter associated with a SIRT1 molecule from a subject; and providing a therapy to ameliorate a metabolic condition to the subject. The method can be used to evaluate a subject who is being treated for a metabolic condition. A related method can include:

treating a subject with a regimen for altering a metabolic condition; before, during, or after the regimen, monitoring a parameter associated with a SIRT1 molecule from the subject; and comparing results of the evaluation to reference information to provide an assessment of the subject.

5           For example, the regimen or therapy includes a diet, insulin treatment, an exercise regimen, hormone therapy, or administering a pharmaceutical composition. In one embodiment, the assessment is expressed as a risk/propensity for a metabolic disorder, e.g., obesity.

          The reference information can be obtained by a corresponding evaluation of a non-obese individual, e.g., a non-obese adult. The reference information can be obtained from the subject  
10       prior to the treating.

          In one embodiment, the subject is a human adult, e.g., between ages 20-100, or 20-80 or 40-70. In another embodiment, the subject is a juvenile, e.g., a human less than 18, 15, 12, 10, 7, or 5 years of age.

          The monitoring can includes evaluating a parameter associated with a SIRT1 molecule  
15       from a subject at at least two instances separated by at least 12, 24, 48, 96, or 200 hours. The method can also be adapted for other sirtuins, e.g., human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.

          In another aspect, the disclosure features a method of evaluating a subject. The method includes evaluating a SIRT1 molecule from a cell of the adipocyte lineage or the keratinocyte  
20       lineage; and comparing results of the evaluating to reference information.

          For example, the cell is a preadipocyte or adipocyte, e.g., WAT cells or BAT cells. In another example the cell is a prekeratinocyte or a keratinocyte.

          For example, the cell is obtained from a human subject. The subject can be identified as having or being at risk for, obesity, an obesity-related disorder, a body mass index in a particular  
25       range, or lipodystrophy.

          The reference information can includes results of a corresponding evaluation of a SIRT1 molecule from a corresponding cell from a control subject. The comparing can include determining whether the level of SIRT1 expression is at least 1.2, 1.5, 2, 5, or 10 fold different than a reference level evaluated by a corresponding method for a non-obese adult. The  
30       evaluating can include evaluating expression of a plurality nucleic acid species to obtain a profile/fingerprint that includes information about SIRT1 expression and at least one additional gene. The comparing can further include comparing expression levels of at least one gene in

addition to SIRT1, the comparison being between the subject and corresponding reference information for the additional gene..

The evaluating can include hybridizing a probe (e.g., to mRNA, cDNA), sequence specific amplification or primer extension, nucleic acid sequencing, mass spectroscopy, in situ  
5 hybridization, a Northern, subtractive hybridization, or SAGE.

The method can also be adapted for other sirtuins, e.g., human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.

In another aspect, the disclosure features a method that includes: providing a cell of a cell of the adipocyte lineage (e.g., pre-adipocyte or an adipocyte cell, e.g., a WAT cell or a BAT cell)  
10 or a cell of the keratinocyte lineage; and evaluating expression or activity of a SIRT1 gene in the cell. In one embodiment, fewer than 100, 50, 10, or 5 different genes are evaluated in parallel with SIRT1.

The method can further include contacting the cell with an agent that alters SIRT1 expression or activity prior to the evaluating.

15 The step of evaluating can include one or more of evaluating SIRT1 mRNA levels; evaluating SIRT1 protein levels; evaluating SIRT1 enzymatic activity (e.g., deacetylase activity); evaluating SIRT1 interaction with a SIRT1 binding partner; evaluating SIRT1 interaction with a regulatory DNA sequence (e.g., using a chromatin immunoprecipitation); evaluating expression of a gene regulated by PPAR, e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha (e.g., evaluating  
20 PPAR-gamma expression or activity or evaluating UCP1 expression or activity).

In another aspect, the disclosure features a method that includes: identifying a subject has having obesity, being at risk for obesity using clinical criteria, or being overweight; obtaining a sample of cells from the subject; and evaluating expression of a SIRT1 gene in cells of the sample.

25 In another aspect, the disclosure features a method that includes: evaluating the identity of one or more nucleotides of a sirtuin gene (e.g., a SIRT1 gene) from a subject, thereby providing a first sequence; providing a reference sequence consisting of one or more nucleotides of a sirtuin gene (e.g., a SIRT1 gene) from a reference subject who is indicated for obesity or a body mass index that is at least within the 25<sup>th</sup> percentile above or below normal; and comparing  
30 the first sequence to the reference sequence. The method can further include making a medical, financial, or familial decision as a function of the comparison.

In another aspect, the disclosure features a method that includes: identifying a plurality of human individuals characterized as being underweight, overweight, obese or as having a body mass index in a particular range; comparing distribution of one or more SIRT1 gene polymorphisms among individuals of the plurality.

5 In another aspect, the disclosure features a method that includes: identifying a subject as having obesity, being at risk for obesity using clinical criteria, or being overweight; and administering an effective amount of an agent that modulates, e.g., increases, SIRT1 activity to the subject. For example, the agent increases SIRT1 mRNA or protein levels in the subject. In one embodiment, the agent increases SIRT1 mRNA or protein levels or SIRT1 enzymatic  
10 activity in a cell of the adipocyte lineage, e.g., pre-adipocytes or adipocytes of the subject.

In one embodiment, the agent includes a nucleic acid that includes a sequence encoding SIRT1 or a SIRT1 core domain and an operably linked promoter, or a complement of such a nucleic acid. In another embodiment, the agent includes a polypeptide that contains a SIRT1 core domain. In still another embodiment, the agent is NAD or an NAD precursor or derivative,  
15 e.g., an iso-nicotinamide. See, e.g., Biochemistry. 2003 Aug 12;42(31):9249-56. The agent can also be a compound of Formula I, II, III, or IV.

The agent can be administered in an amount that is also effective for inhibiting pre-adipocyte differentiation, that effective for promoting fat mobilization in WAT cells, that effective for promoting fat burning in BAT cells, and/or that is effective to increase leptin  
20 secretion.

The method can further include monitoring a parameter associated with SIRT1, a metabolite, or a hormone, prior to, during or after the administering.

In another aspect, the disclosure provides a method of ameliorating at least one symptom due to a diabetic disorder or insulin resistance, or treating or preventing a diabetic disorder. The  
25 method includes administering to a subject an amount of a SIRT1 activator. The amount can be effective to ameliorate the symptom, or treat or prevent the diabetic disorder. For example, the amount can be effective to decrease insulin resistance and increase insulin sensitivity, e.g., to a detectable degree, or at least 0.5, 2, 4, or 5 fold. The amount may be effective to increase fat mobilization and/or burning of fat. For example, the SIRT1 activator is a polyphenol, e.g., a  
30 trans-stilbene, e.g., a compound of formula I, II, III, or IV. Exemplary compounds include resveratrol (3, 5, 4'-trihydroxy-trans-stilbene), butein (3,4,2', 4'- tetrahydroxychalcone); piceatannol (3, 5, 3', 4'-tetrahydroxy-trans-stilbene); isoliquiritigenin (4,2',4'-

trihydroxychalcone); fisetin (3,7,3',4'-tetrahydroxyflavone); and quercetin (3,5,7,3',4'-pentahydroxyflavone). For example, the subject has Type II diabetes. The method can further include increasing  $\beta$ -adrenergic activity, e.g., providing adrenalin or an agent or therapeutic activity that increases adrenalin in the subject.

5 In another aspect, the disclosure provides a method of ameliorating at least one symptom due to a disorder related to gastric motility, e.g., treating postoperative ileus. For example, the method can be used to increase movement along the digestive tract, e.g., in the intestine. The method includes administering to a subject an amount of a SIRT1 modulator, e.g., activator, for example, the activator can be delivered to the stomach or intestine, e.g., using a suppository,  
10 ingestion, or other method. The amount can be effective to increase gastric motility or ameliorate a post-operative condition. For example, the SIRT1 activator is a polyphenol, e.g., a trans-stilbene, e.g., a compound of formula I, II, III, or IV. Exemplary compounds include resveratrol (3, 5, 4'-trihydroxy-tans-stilbene), butein (3,4,2', 4'- tetrahydroxychalcone); piceatannol (3, 5, 3', 4'-tetrahydroxy-trans-stilbene); isoliquiritigenin (4,2',4'-  
15 trihydroxychalcone); fisetin (3,7,3',4'-tetrahydroxyflavone); and quercetin (3,5,7,3',4'-pentahydroxyflavone). For example, the subject has Type II diabetes. The method can further include increasing  $\beta$ -adrenergic activity, e.g., providing adrenalin or an agent or therapeutic activity that increases adrenalin in the subject.

In another aspect, the disclosure provides a method of increasing fat or lipid metabolism  
20 in a subject. The method includes administering to a subject an amount of a SIRT1 activator, e.g., in an amount effective to increase mobilization of fat to the blood from WAT cells and/or to increase fat burning by BAT cells. For example, the amount can be effective to increase the amount of fat metabolism by at least 0.5, 2, 4, or 5 fold.

The method can include, e.g., prior to the administering, identifying a subject as being in  
25 need of increased fat or lipid metabolism, e.g., by weighing the subject, determining the BMI of the subject, or evaluating fat content of the subject or SIRT1 activity in cells of the subject. The method can also include monitoring the subject, e.g., during or after the administering. The administering can include one or more dosages, e.g., delivered in boluses or continuously.

In another aspect, the disclosure provides a method of decreasing fat or lipid metabolism  
30 in a subject. The method includes administering to a subject an amount of a SIRT1 inhibitor, e.g., in an amount effective to decrease mobilization of fat to the blood from WAT cells and/or to



decrease fat burning by BAT cells. For example, the amount can be effective to decrease the amount of fat metabolism by at least 0.5, 2, 4, or 5 fold.

The method can include, e.g., prior to the administering, identifying a subject as being in need of decreased fat or lipid metabolism, e.g., by weighing the subject, determining the BMI of the subject, or evaluating fat content of the subject or SIRT1 activity in cells of the subject. The method can also include monitoring the subject, e.g., during or after the administering. The administering can include one or more dosages, e.g., delivered in boluses or continuously. Monitoring can include evaluating a hormone or a metabolite. Exemplary hormones include leptin, adiponectin, resistin, and insulin. Exemplary metabolites include triglycerides, cholesterol, and fatty acids.

In another aspect, the disclosure provides a method of ameliorating at least one symptom due to a inflammation, or treating or preventing an inflammatory disorder. The method includes administering to a subject an amount of a SIRT1 activator. The amount can be effective to ameliorate the symptom, or treat or prevent inflammation or inflammatory disorder. For example, the SIRT1 activator is a polyphenol, e.g., a trans-stilbene, e.g., a compound of formula I, II, III, or IV. Exemplary compounds include resveratrol (3, 5, 4'-trihydroxy-tans-stilbene), butein (3,4,2', 4'- tetrahydroxychalcone); piceatannol (3, 5, 3', 4'-tetrahydroxy-trans-stilbene); isoliquiritigenin (4,2',4'-trihydroxychalcone); fisetin (3,7,3',4'-tetrahydroxyflavone); and quercetin (3,5,7,3',4'-pentahydroxyflavone). For example, the subject has rheumatoid arthritis, lupus, restenosis, psoriasis, graft v. host response, or multiple sclerosis.

In another aspect, the disclosure provides a method of modulating production of a secreted factor, e.g., leptin, adiponectin, or resistin production, in cells of a subject, e.g., in adipocytes of a subject. The method includes administering to a subject an amount of a SIRT1 modulator, e.g., a SIRT1 activator or inhibitor. The amount can be effective to modulate secretion of the secreted factor, e.g., by an increase of at least 1.5, 2, 5, or 10 fold or a decrease of at least 10, 20, 30, 40, 50, 70, or 80%. For example, the SIRT1 activator is a polyphenol, e.g., a trans-stilbene, e.g., a compound of formula I, II, III, or IV. Exemplary compounds include resveratrol (3, 5, 4'-trihydroxy-tans-stilbene), butein (3,4,2', 4'- tetrahydroxychalcone); piceatannol (3, 5, 3', 4'-tetrahydroxy-trans-stilbene); isoliquiritigenin (4,2',4'-trihydroxychalcone); fisetin (3,7,3',4'-tetrahydroxyflavone); and quercetin (3,5,7,3',4'-pentahydroxyflavone).

In another aspect, the disclosure provides a method of modulating activity of an adipocyte transcription factor, e.g., a PPAR, e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha, in cells of a subject, e.g., in adipocytes of a subject. The method includes administering to a subject an amount of a SIRT1 modulator, e.g., a SIRT1 activator or inhibitor. The amount can be effective to modulate transcriptional function, e.g., by an increase of at least 1.5, 2, 5, or 10 fold or a decrease of at least 10, 20, 30, 40, 50, 70, or 80%. Exemplary SIRT1 activators and inhibitors are described herein.

In another aspect, the disclosure features a method that includes: identifying a subject as being underweight, at risk for weight loss or cachexia using clinical criteria, or being cachexic; and administering an effective amount of an agent that modulates, e.g., decreases, SIRT1 activity to the subject.

In one embodiment, the agent decreases SIRT1 mRNA or protein levels in the subject. In another embodiment, the agent decreases SIRT1 mRNA or protein levels in pre-adipocytes or adipocytes of the subject. For example, the agent decreases SIRT1 enzymatic activity in pre-adipocytes or adipocytes of the subject.

Exemplary agents include a dsRNA or siRNA that includes a sequence of at least 19 nucleotides that is complementary to a sequence encoding SIRT1; a polypeptide that competes with a SIRT1 substrate for interaction with SIRT1; an antibody or antibody fragment that binds to SIRT1; nicotinamide or vitamin b3; an agent other than nicotinamide and vitamin b3; or a compound of Formula V or VI.

The method can further include monitoring a parameter associated with SIRT1, a metabolite, or a hormone during or after the administering.

In another aspect, the disclosure features a method that includes: providing a compound that interacts with SIRT1 or that modulates SIRT1 activity; contacting the compound to a cell of the adipocyte lineage; and evaluating the cell.

In one embodiment, the evaluating includes evaluating expression of a gene regulated by an adipocyte transcription factor, e.g., a PPAR transcription factor (e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha), PGC1, or a C/EBP transcription factor.

In one embodiment, the cell includes a reporter gene regulated by the adipocyte transcription factor and the evaluating includes evaluating the reporter gene.

In one embodiment, the evaluating includes evaluating the differentiation state of the cell or secretion of a hormone (e.g., leptin, resistin, or adiponectin) by the cell.

In one embodiment, the evaluating includes evaluating fat mobilization by the cell, evaluating fat burning by the cell, or evaluating association of SIRT1 and genomic nucleic acid in the cell. For example, evaluating the association includes crosslinking proteins to nucleic acid, immunoprecipitating SIRT1 or a fragment thereof, and evaluating the nucleic acid associated with SIRT1 immunoprecipitates.

In one embodiment, the step of providing a compound that interacts with SIRT1 or that modulates SIRT1 includes contacting the compound to SIRT1 or a fragment thereof in vitro.

In another aspect, the disclosure features a method that includes: contacting the compound to a preadipocyte cell; and evaluating a parameter associated with a SIRT1 molecule of the cell. A related method includes contacting the compound to a cell of the adipocyte lineage, a cell of the keratinocyte lineage or a neuronal cell. The method can include comparing the parameter to a reference parameter, e.g., for a corresponding cell to which the compound has not been contacted. A difference in the parameter and a reference parameter indicates that the compound alters SIRT1 activity in the preadipocyte.

The method can include evaluating the differentiation state of the preadipocyte cell, or evaluating lipid or fat of the preadipocyte cell. For example, the evaluating includes fractionating cell contents or an optical evaluation.

In another aspect, the disclosure features a method that includes: contacting the compound to an organism; and evaluating a parameter associated with a SIRT1 molecule of a fat cell or precursor thereof, from the organism, wherein a difference in the parameter between the parameter and a reference parameter indicates that the compound modulates SIRT1 activity in a cell of the organism.

Another method includes: contacting the compound to a SIRT1 protein in vitro; evaluating an interaction between the compound and the protein; contacting the compound to a cell or organism; and evaluating a differentiation state of the cell or a metabolic parameter of the organism. In one embodiment, evaluating the interaction includes evaluating catalytic activity of the protein in the presence of the compound.

In another aspect, the disclosure features a method that includes: providing a library of compound (e.g., small molecule compounds). For each compound of a plurality of compounds from the library, the method includes: contacting the compound to a SIRT1 protein in vitro; evaluating an interaction between the compound and the SIRT1 protein; if the compound interacts with the SIRT1 protein, contacting the compound to a cell or organism; and evaluating

a differentiation state or a metabolic parameter of the cell or organism. For example, the cell includes a reporter gene and/or other combination of heterologous nucleic acids described herein.

In another aspect, the disclosure features a method that includes: providing a library of compound (e.g., small molecule compounds). For each compound of a plurality of compounds  
5 from the library, the method includes evaluating the compound using a method described herein.

In another aspect, the disclosure features a method of maturing a lead compound. The method includes: providing a plurality of derivatives/variants of a compound that detectably interacts with a SIRT1 protein; contacting each compound of the plurality to a cell or organism; and evaluating a differentiation state or a metabolic parameter of the cell or organism. The  
10 method can further include recording SAR data that associates results of the evaluating and structural information about each compound of the plurality; and/or modeling an interaction between a three-dimensional structural model of a SIRT1 protein or region thereof and a compound of the plurality.

In another aspect, the invention provides a method of evaluating a test compound or a  
15 member of a library of test compounds. The method includes contacting the test compound to a SIRT1 protein or fragment thereof and NCoR or fragment thereof, and evaluating ability of the SIRT1 protein or fragment to interact with the NCoR protein or fragment. In one embodiment, the SIRT1 protein or fragment is first contacted with the NCoR protein or fragment to provide a complex and the test compound is contacted to the complex. In another embodiment, all three  
20 proteins (e.g., an any other component of interest, if desired) are added at the same time, or in still other embodiments, the test compound is first contacted to the SIRT1 protein or fragment thereof or the NCoR protein or fragment thereof.

For example, a test compound that reduces interaction between SIRT1 and NCoR can be indicated as an inhibitor of SIRT1 activity or an agent that reduces fat mobilization. A test  
25 compound that increases interaction between SIRT1 and NCoR can be indicated as an activator of SIRT1 activity or an agent that increases fat mobilization. In one embodiment, the contacting is effected *in vitro*, e.g., in a biochemical system, e.g., using purified or partially purified components. For example, any biochemical interaction assay can be used to evaluate interaction between the SIRT1 protein or fragment and the NCoR protein or fragment. Similar methods  
30 can be implemented using SMRT or a fragment thereof that interacts with SIRT1.

In another embodiment, the contacting is effected in a cell, e.g., a yeast cell (e.g., using a two hybrid system) or mammalian cell, e.g., a tissue culture cells, e.g., a cultured fibroblast, pre-

adipocyte, or adipocyte, e.g., a WAT or BAT cell. Typically the cultured cell includes one or more heterologous nucleic acids for expressing the SIRT1 protein or fragment and/or the NCoR protein or fragment.

Exemplary SIRT1 fragments include about amino acids 10-190, 1-214, 214-541, and  
5 541-747. Exemplary NCoR fragments include 1-751, 92-393, and 1460-1944.

In one embodiment, the compound is a polyphenol, e.g., a trans-stilbene, e.g., resveratrol or other compound of Formula I, II, III, or IV.

In another aspect, the invention features a database that includes a plurality of records, e.g., the records include (1) information about a test compound (e.g., an identifier), (2)  
10 information about ability of the test compound to modulate SIRT1 or other sirtuin, and (3) information about ability of the test compound to modulate a parameter of an adipose cell, e.g., a WAT or BAT cell, or transcription of a gene regulated by NCoR.

The method can also be implemented using other members of the SIR2 family, e.g., human SIRT2, 3, 4, 5, 6, or 7.

15 In another aspect, the invention provides a method of evaluating a test compound or a member of a library of test compounds. The method includes contacting the test compound to a SIRT1 protein or fragment thereof and PGC1 or fragment thereof, and evaluating ability of the SIRT1 protein or fragment to interact with the PGC1 protein or fragment. In one embodiment, the SIRT1 protein or fragment is first contacted with the PGC1 protein or fragment to provide a  
20 complex and the test compound is contacted to the complex. In another embodiment, all three proteins (e.g., an any other component of interest, if desired) are added at the same time, or in still other embodiments, the test compound is first contacted to the SIRT1 protein or fragment thereof or the PGC1 protein or fragment thereof.

For example, a test compound that reduces interaction between SIRT1 and PGC1 can be  
25 indicated as an inhibitor of SIRT1 activity or an agent that reduces fat burning. A test compound that increases interaction between SIRT1 and PGC1 can be indicated as an activator of SIRT1 activity or an agent that increases fat burning. In one embodiment, the contacting is effected *in vitro*, e.g., in a biochemical system, e.g., using purified or partially purified components. For example, any biochemical interaction assay can be used to evaluate interaction  
30 between the SIRT1 protein or fragment and the PGC1 protein or fragment. In another embodiment, the contacting is effected in a cell, e.g., a yeast cell (e.g., using a two hybrid system) or mammalian cell, e.g., a tissue culture cells, e.g., a cultured fibroblast, pre-adipocyte,

or adipocyte. Typically the cultured cell includes one or more heterologous nucleic acids for expressing the SIRT1 protein or fragment and/or the PGC1 protein or fragment.

Exemplary SIRT1 fragments include about amino acids 10-190, 1-214, 214-541, and 541-747.

5 In one embodiment, the compound is a polyphenol, e.g., a trans-stilbene, e.g., resveratrol or other compound of Formula I, II, III, or IV.

In another aspect, the invention features a database that includes a plurality of records, e.g., the records include (1) information about a test compound (e.g., an identifier), (2) information about ability of the test compound to modulate SIRT1 or other sirtuin, and (3)

10 information about ability of the test compound to modulate a parameter of an adipose cell, e.g., a WAT or BAT cell, or transcription of a gene regulated by PGC1.

The method can also be implemented using other members of the SIR2 family, e.g., human SIRT2, 3, 4, 5, 6, or 7.

In another aspect, the disclosure features a cultured mammalian cell that contains a  
15 heterologous reporter gene including a SIRT1 regulatory sequence operably linked to a sequence encoding a detectable protein other than SIRT1. For example, the detectable protein has an enzymatic activity (e.g.,  $\beta$ -gal, CAT, ADH, luciferase, etc.). In one embodiment, the cultured cell is a cell other than an adipocytes, but that can differentiate into an adipocyte. In another embodiment, the cultured cell is a pre-adipocyte or a fibroblast. In one embodiment, the cultured  
20 cell is an adipocyte.

For example, the detectable protein can fluoresce, e.g., GFP, a variant thereof, etc. In one embodiment, the cultured cell further includes a second reporter gene. For example, the second reporter gene is operably linked to a regulatory sequence of a gene encoding a protein produced specifically by an adipocytes, e.g., leptin.

25 In another aspect, the disclosure features a transgenic animal having at least one cell that contains a heterologous reporter gene including a SIRT1 regulatory sequence operably linked to a sequence encoding a detectable protein other than SIRT1.

In another aspect, the disclosure features a method of evaluating a compound, the method including: contacting the compound to a cell described herein that includes a heterologous  
30 reporter, e.g., for a gene regulated by SIRT1, e.g. a gene described herein regulated by SIRT1; and evaluating expression of the heterologous reporter.

The method can further include evaluating a metabolite in the cell, e.g., lipid or fat (e.g., triglycerides) of the cell.

In another aspect, the disclosure features a preparation that includes: a population of cells of the adipocyte lineage or an extract thereof; and a probe that is specific to a SIRT1 molecule.

5 In one embodiment, the cells include adipocytes or preadipocytes (e.g., a substantially pure population or a population at least 25, 30, 40, 50, 60, 70, 80, 90, or 95% pure). For example, the cells include BAT or WAT cells. The probe can be a nucleic acid probe that is complementary to a SIRT1 nucleic acid; an antibody or fragment thereof that specifically binds to SIRT1; or an acetylated substrate that can be deacetylated by a SIRT1 protein. Similar probes for other  
10 sirtuins can also be used. The cells may be lysed, processed or intact.

In another aspect, the disclosure features a preparation that includes: a population of cells of the keratinocyte lineage or an extract thereof; and a probe that is specific to a SIRT1 molecule. In one embodiment, the cells include keratinocytes or prekeratinocytes (e.g., a substantially pure population or a population at least 25, 30, 40, 50, 60, 70, 80, 90, or 95% pure). The probe can be  
15 a nucleic acid probe that is complementary to a SIRT1 nucleic acid; an antibody or fragment thereof that specifically binds to SIRT1; or an acetylated substrate that can be deacetylated by a SIRT1 protein. The cells may be lysed, processed or intact. Similar probes for other sirtuins can also be used. Similar preparations of neuronal cells can also be made.

In another aspect, the disclosure features a mammalian cell of the adipocyte or  
20 keratinocyte lineage (e.g., an adipocyte or pre-adipocyte cell or a keratinocyte or keratinocyte cell) that contains a dsRNA (e.g., siRNA) that is specific to SIRT1 (or other sirtuin) in an amount effective to alter sirtuin activity in the cell. For example, the mammalian adipocyte or pre-adipocyte cell is cultured. The mammalian cell may also be in a pharmaceutical composition or other form for administration to a subject.

25 In another aspect, the disclosure features a mammalian cell of the adipocyte or keratinocyte lineage (e.g., an adipocyte or pre-adipocyte cell or a keratinocyte or keratinocyte cell) that contains a heterologous nucleic acid that includes a sequence encoding a polypeptide that includes a SIRT1 core domain and an operably linked promoter, wherein activation of the promoter can produce the polypeptide in an amount sufficient to alter SIRT1 activity in the cell.  
30 For example, the mammalian adipocyte or pre-adipocyte cell is cultured.

In another aspect, the disclosure features a purified complex including SIRT1 or an PGC1 interacting fragment thereof, and (ii) PGC1 or a SIRT1 interacting fragment thereof. The

complex can further include (iii) a PPAR protein, e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha, or fragment thereof. The complex can be at least 10, 20, 40, 50, 60, 70, 80, 90, or 95% pure. The disclosure also features an antibody or other protein ligand that specifically recognizes the complex, but does not substantially bind to any of the complex components in isolation.

5 In another aspect, the disclosure features a purified complex including SIRT1 or an NCoR or SMRT interacting fragment thereof, and (ii) NCoR, or SMRT, or a SIRT1 interacting fragment thereof. The complex can further include (iii) a PPAR protein, e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha, or fragment thereof. The complex can be at least 10, 20, 40, 50, 60, 70, 80, 90, or 95% pure. The disclosure also features an antibody or other protein ligand that  
10 specifically recognizes the complex, but does not substantially bind to any of the complex components in isolation.

In another aspect, the disclosure features a method that includes: providing a cell of the adipose lineage or of the keratinocyte lineage, or a neuronal cell, e.g., a neuron; and modulating SIRT1 activity in the cell. For example, the cell can be a preadipocyte or adipocyte, e.g., a WAT  
15 cell or a BAT cell. The cell of the keratinocyte lineage can be a keratinocyte or a pre-keratinocyte.

In one embodiment, the modulating includes increasing SIRT1 activity, e.g., using a SIRT1 activator.

In another embodiment, the modulating includes decreasing SIRT1 activity, e.g., using a  
20 SIRT inhibitor.

In one embodiment, the modulating includes contacting the cell with a dsRNA (e.g., an siRNA).

In one embodiment, the modulating includes introducing a nucleic acid that includes a sequence that encodes a polypeptide including a SIRT1 core domain or a sequence  
25 complementary to a SIRT1 coding sequence, e.g., thereby providing a SIRT1 activity to the cell. The method can also be implemented with other sirtuins, e.g., human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.

In another aspect, the disclosure features a method that includes: providing a mammalian cell; modulating sirtuin activity (e.g., SIRT1) in the cell; and evaluating a lipid or fat-associated  
30 parameter of the cell. For example, the evaluating includes an optical evaluation of the cell.

In another aspect, the disclosure features a method that includes: providing a mammalian cell; modulating sirtuin activity (e.g., SIRT1) in the cell; and evaluating the differentiation state



of the cell using an indicator of adipocyte differentiation. For example, the indicator is expression of leptin, adiponectin, or resistin. In another example, the indicator is expression or activity of an adipocyte transcription factor (e.g., a C/EBP protein or a PPAR protein).

In one embodiment, the cell contains a nucleic acid that can express a C/EBP protein (e.g., C/EBP $\alpha$ ), e.g., a heterologous nucleic acid, and a reporter nucleic acid that includes a regulatory sequence of gene that is specifically or selectively expressed in adipocytes or a reporter nucleic acid that includes a regulatory sequence of a secreted protein produced by adipocytes. For example, the secreted protein produced by adipocytes is leptin, adiponectin, or resistin. Alternatively, the cell contains a nucleic acid that can express a PPAR protein (e.g., PPAR-gamma, PPAR-delta, or PPAR-alpha), e.g., a heterologous nucleic acid, and a reporter nucleic acid that includes a regulatory sequence that is bound by an AP2 protein.

#### Some Definitions

An “adipocyte” is a cell that is characterized by: high triglyceride content, expresses ion of adipogenic proteins and transcription factors such as PPAR $\gamma$  or C/EBP $\alpha$ , an ability to produce and secrete proteins such as leptin, and an ability to release fatty acids upon stimulation of the adrenergic pathway.

A “pre-adipocyte” is a cell that has committed to the adipocyte lineage (i.e., has expressed some early pro-adipocyte genes), but does not: (1) have the mature adipocyte phenotype of intracellular triglyceride accumulation, or (2) expresses adipogenic transcription factors, proteins and enzymes.

A “fibroblast” is a pluripotent cell that has no adipocyte or pre-adipocyte characteristic but that can be stimulated to differentiate into one cellular lineage (e.g. muscle or adipocyte) given proper hormonal stimulation.

A “cell of the adipocyte lineage” is a cell in the adipocyte lineage, e.g., an adipocyte (including a brown adipose cell or white adipose cell), a pre-adipocyte, a fibroblast, or other pluripotent cell that can differentiate into an adipocyte. Brown adipose cells are also termed “BAT cells”; white adipose cells are also termed “WAT cells.”

A “keratinocyte” is a skin cell that can express keratin.

A “cell of the keratinocyte lineage” is a cell in the keratinocyte lineage, e.g., an keratinocyte (including a brown adipose cell or white adipose cell), a pre- keratinocyte, a fibroblast, or other pluripotent cell that can differentiate into a keratinocyte.

The term “an aberrant expression” refers to level of expression of that nucleic acid or protein which differs from the level of expression of that nucleic acid or protein in a reference tissue, e.g., a healthy tissue. Expression can refer to transcription of a gene and/or translation of a transcript. For example, expression can be assessed by evaluating mRNA and/or protein  
5 levels. A cell can have an aberrant expression level of a gene due to overexpression or underexpression of that gene, e.g., relative to a reference cell, e.g., a cell from a healthy tissue or subject.

The term “agonist”, as used herein, refers to an agent that mimics or upregulates (e.g., increases, potentiates or supplements) an activity of a compound, e.g., a protein. An agonist can  
10 be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein. An agonist can also be a compound that upregulates expression of a gene or which increases at least one activity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, e.g., a substrate or binding partner.

“Antagonist” as used herein refers to an agent that downregulates (e.g., decreases, suppresses or inhibits) at least one activity of a compound, e.g., a protein. An antagonist can be a  
15 compound which inhibits or decreases an activity of a protein or an interaction between a protein and another molecule, e.g., a substrate or binding partner. An antagonist can also be a compound that downregulates expression of a gene or which reduces the amount of expressed protein present.

The term “antibody,” as used herein, refers to a protein that includes at least one immunoglobulin variable domain, or more typically, at least one pair that consists of a immunoglobulin heavy chain variable domain and a light chain variable domain that interact to form an antigen binding site. The term includes whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.), and includes exemplary fragments, e.g., Fab’s, scFv’s, and Fv fragments.  
25 Antibodies can be fragmented using conventional techniques or recombinant nucleic acid engineering. Fragments can be screened for utility in the same manner as described above for whole antibodies. As used herein, the term includes polyclonal, monoclonal, monospecific, or other purified preparations of antibodies and recombinant antibodies. Techniques for preparing monoclonal and polyclonal antibodies are well known in the art. Campbell, “Monoclonal  
30 Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology”, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); and St. Groh et al., J. Immunol. Methods, 35, pp. 1-21 (1980).

As used herein the term “bioactive fragment of a polypeptide” refers to a fragment of a full-length polypeptide, wherein the fragment has at least one detectable function. For example, a bioactive fragment may specifically agonize (mimic) or antagonize (inhibit) the activity of a wild-type polypeptide. The bioactive fragment preferably is a fragment capable of interacting with at least one other molecule, e.g., a co-factor protein, small molecule, or DNA, which a full length protein can bind. Exemplary bioactive fragments of SIRT1 include fragments that have deacetylase activity (e.g., 214-541) and fragments that can interact with NcoR (e.g., 10-190 or 1-214).

“Biological activities” include catalyzing a reaction (e.g., a deacetylation), binding to polypeptides, binding to other proteins or molecules, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc.

The term “biomarker” refers a biological molecule, e.g., a nucleic acid, peptide, hormone, etc., whose presence or concentration can be detected and correlated with a known condition, such as a disease state.

“Host cells”, or “recombinant host cells”, are used interchangeably herein. A reference to a “cell” can include not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. In certain implementations, cells of the adipocyte lineage (e.g., preadipocytes or adipocytes) can be used as host cells.

A “delivery complex” means a molecule that results in higher affinity binding of a nucleic acid, protein, polypeptide or peptide to a target cell surface and/or increased cellular or nuclear uptake by a target cell. Examples of targeting means include: sterols (e.g., cholesterol), lipids (e.g., a cationic lipid, virosome or liposome), viruses (e.g., adenovirus, adeno-associated virus, and retrovirus), or target cell-specific binding agents (e.g., ligands recognized by target cell specific receptors).

The term “DNA sequence encoding a polypeptide” refers to any nucleic acid that encodes a polypeptide, including, e.g., a cDNA, a cDNA fragment, a genomic DNA, a genomic DNA fragment, and a synthetic DNA. Moreover, certain differences in nucleotide sequences may exist between individual organisms, of the same or different species, which are called alleles. Such allelic differences may or may not result in differences in amino acid sequence of the encoded

polypeptide yet still encode a polypeptide with the same biological activity.

As used herein, the terms “gene”, “recombinant gene”, and “gene construct” refer to a nucleic acid associated with an open reading frame, e.g., including one or exons and (optionally) intron sequences and (optionally) regulatory sequences. A “recombinant gene” refers to nucleic acid encoding a polypeptide and comprising exon sequences, though it may optionally include intron sequences which are derived from, for example, a related or unrelated chromosomal gene. A gene can further include regulatory sequences, e.g., transcriptionally regulatory sequences (e.g., a promoter, enhancer) and translational regulatory sequences (e.g., 5' and 3' untranslated regions) and so forth.

“Homology”, “homologs of”, “homologous”, or “identity” or “similarity” refers to sequence similarity between two polypeptides or between two nucleic acid molecules, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are identical at that position. A degree of homology or similarity or identity between nucleic acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. A degree of identity of amino acid sequences is a function of the number of identical amino acids at positions shared by the amino acid sequences. A degree of homology or similarity of amino acid sequences is a function of the number of amino acids, i.e., structurally related, at positions shared by the amino acid sequences. An “unrelated” or “non-homologous” sequence shares less than 40% identity, though preferably less than 25% identity, with the reference sequence.

Hypertrophic growth is defined as an increase in adipocyte size that is stimulated by lipid accumulation. Hyperplastic growth is defined as an increase in the number of cells, e.g., adipocytes in adipose tissue and is thought to occur primarily by mitosis of pre-existing adipocytes that have reached critical levels of lipid accumulation and size.

“Obesity” refers to a condition in which a subject has a body mass index of greater than or equal to 30. “Over-weight” refers to a condition in which a subject has a body mass index of greater or equal to 25.0. The body mass index and other definitions are according to the “NIH Clinical Guidelines on the Identification and Evaluation, and Treatment of Overweight and Obesity in Adults” (1998). In particular, obesity can lead to type II diabetes in successive phases. Clinically, these phases can be characterized as normal glucose tolerance, impaired

glucose tolerance, hyperinsulinemic diabetes, and hypoinsulinemic diabetes. Such a progressive impairment of glucose storage correlates with a rise in basal glycemia.

“Obesity-related disease” and “Fat-related metabolic disorder” include, but are not limited to, anorexia nervosa, wasting, AIDS-related weight loss, bulimia, cachexia, lipid disorders including hyperlipidemia and hyperuricemia, insulin resistance, noninsulin dependent diabetes mellitus (NIDDM, or Type II diabetes), insulin dependent diabetes mellitus (IDDM or Type I diabetes), diabetes-related complications including microangiopathic lesions, ocular lesions, retinopathy, neuropathy, and renal lesions, cardiovascular disease (including cardiac insufficiency, coronary insufficiency, and high blood pressure), atherosclerosis, atheromatous disease, stroke, hypertension, Syndrome X, gallbladder disease, osteoarthritis, sleep apnea, forms of cancer such as uterine, breast, colorectal, kidney, and gallbladder, high cholesterol levels, complications of pregnancy, menstrual irregularities, hirsutism, muscular dystrophy, infertility, a weight-related disorder (characterized by a subject being over or under weight, e.g., being within the top or bottom 25<sup>th</sup> percentile of body mass index) and increased surgical risk. In preferred embodiments, a treated or diagnosed subject is a mammal, preferably a human.

Fat-related metabolic disorders include disorders in which (i) increased fat storage, reduced fat mobilization, and/or reduced fat burning is desired, and (ii) other disorders in which reduced fat storage, increased fat mobilization and/or increased fat burning is desired. Examples of the first category of disorders include, e.g., anorexia nervosa, wasting, AIDS-related weight loss, bulimia, cachexia. Examples of the latter category include, e.g., obesity, cardiovascular disease, osteoarthritis. The classification of other disorders (e.g., infertility, increased surgical risk, pregnancy complications) may depend on the weight of the subject, e.g., whether the subject is over- or underweight. Overweight subjects can be treated, e.g., with an agent that increases SIRT1 activity, and underweight subject can be treated, e.g., with an agent that decreases SIRT1 activity.

The term “percent identical” refers to sequence identity between two amino acid sequences or between two nucleotide sequences. Identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of

homology, similarity, or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. Various alignment algorithms and/or programs may be used, including FASTA, BLAST, or ENTREZ. FASTA and BLAST are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default settings. ENTREZ is available through the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md. In one embodiment, the percent identity of two sequences can be determined by the GCG program with a gap weight of 1, e.g., each amino acid gap is weighted as if it were a single amino acid or nucleotide mismatch between the two sequences. Other techniques for determining sequence identity are well-known and described in the art. Exemplary biopolymers have sequences that are at least 70, 75, 80, 85, 90, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to a sequence described herein.

The term “interact” as used herein is meant to include detectable interactions (e.g., biochemical interactions) between molecules, such as interaction between protein-protein, protein-nucleic acid, nucleic acid-nucleic acid, and protein-small molecule or nucleic acid-small molecule in nature.

The term “isolated” as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs, or RNAs, respectively that are present in the natural source of the macromolecule. The term isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an “isolated nucleic acid” is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term “isolated” is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both partially purified, purified (e.g., at least 10, 30, 70, 80, 90, 95, 98, 99% pure) and recombinant polypeptides.

The term “sirtuin” and “sirtuin” include amino acids sequences that have a SIR2 domain or a fragment thereof (the fragment need not also include the SIR2 domain). The fragments have at least one function of a sirtuin protein or are folded. Functional fragments can, for example, have deacetylase activity or interact with a sirtuin binding partner, e.g., PPAR-gamma, PGC1, or NcoR. A sirtuin can be encoded using a nucleic acid that includes artificially chosen codons. Sirtuins include proteins that are scored as hits in the Pfam family for SIR2 domains.

To identify the presence of a "SIR2" domain in a protein sequence, and make the determination that a polypeptide or protein of interest has a particular profile, the amino acid sequence of the protein can be searched against the Pfam database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters (available from the Sanger web site: [www.sanger-ac-uk/Software/Pfam/HMM\\_search](http://www.sanger.ac.uk/Software/Pfam/HMM_search)). The SIR2 domain is indexed in Pfam as entry number PF02146 and in INTERPRO as INTERPRO description (entry IPR003000). At present PF02146 includes 168 sequences. SIR2 domains can have a fold that is structurally similar to PDB entry 1ICI or 1M2H.

For example, the hmmsf program, which is available as part of the HMMER package of search programs, is a family specific default program for MILPAT0063 and a score of 15 is the default threshold score for determining a hit. Alternatively, the threshold score for determining a hit can be lowered (e.g., to 8 bits). A description of the Pfam database can be found in Sonhammer *et al.* (1997) *Proteins* 28(3):405-420 and a detailed description of HMMs can be found, for example, in Gribskov *et al.* (1990) *Meth. Enzymol.* 183:146-159; Gribskov *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.* (1994) *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.* (1993) *Protein Sci.* 2:305-314. For example, closely related homologs of human SIRT1 (NP\_036370.2) in *M.musculus* (NP\_062786.1; 737 amino acid) and *R. norvegicus* (XP\_228146.2; 700 amino acid). Additional homologs include *B.taurus* Bt.13818; *C.elegans* Cel.12479 ; *C.intestinalis* Cin.7948 ; *C.intestinalis* Cin.13319 ; *D.rerio* Dr.10536; *D.melanogaster* Dm.415; *G.gallus* Gga.11206; *M.musculus* Mm.150679; *M.musculus* Mm.348981 ; *M.musculus* Mm.348984; *R.norvegicus* Rn.42098; *X.laevis* Xl.8444; and *X.tropicalis* Str.10623.

Human sirtuins include, e.g., the following amino acids sequences: human sirtuin 1 (GenBank Accession No: NP\_036370.2) (SEQ ID NO: 15); human sirtuin 2 isoform 1 (GenBank Accession No: NP\_036369.2) (SEQ ID NO: 16); human sirtuin 2 isoform 2 (GenBank Accession No: NP\_085096.1) (SEQ ID NO: 17); human sirtuin 3 (GenBank Accession No: NP\_036371.1) (SEQ ID NO: 18); human sirtuin 4 (GenBank Accession No: NP\_036372.1) (SEQ ID NO: 19); human sirtuin 5 isoform 1 (GenBank Accession No: NP\_036373.1) (SEQ ID NO: 20); human sirtuin 5 isoform 2 (GenBank Accession No: NP\_112534.1) (SEQ ID NO: 21); human sirtuin 6 (GenBank Accession No: NP\_057623.1) (SEQ ID NO: 22); and human sirtuin 7 (GenBank Accession No: NP\_057622.1) (SEQ ID NO: 23). With respect to any embodiment described

herein for SIRT1, the embodiment can be adapted and implemented using another sirtuin, e.g., SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.

The terms “sirtuin nucleic acid” and “mammalian homolog of a SIR2 gene” includes all nucleic acids sequences that encode sirtuin proteins, and all nucleotide sequences that are complementary or fragments thereof that encode functional or folded fragments of a sirtuin protein. Exemplary sirtuin nucleic acids include human Sir2 SIRT1 mRNA (GenBank Accession No. AF083106)(SEQ ID NO: 1); mouse SIRT1 mRNA (GenBank Accession No: AF214646) (SEQ ID NO: 2); rat SIRT1 mRNA (GenBank Accession No: XM\_228146) (SEQ ID NO: 3); human Sir2 SIRT2 mRNA (GenBank Accession No: AF083107) (SEQ ID NO: 4); mouse Sir2 SIRT2 mRNA (GenBank Accession No: AF299337) (SEQ ID NO: 5); human Sir2 SIRT3 mRNA (GenBank Accession No: AF083108) (SEQ ID NO: 6); mouse Sir2 SIRT3 mRNA splice variants (GenBank Accession Nos: AF299339) (SEQ ID NO: 7) and AF 299338 (SEQ ID NO: 8)); human Sir2 SIRT4 mRNA (GenBank Accession No: AF083109)(SEQ ID NO: 9); human Sir2 SIRT5 mRNA (GenBank Accession No: AF083110) (SEQ ID NO: 10); human Sir2 SIRT6 mRNA (GenBank Accession No: AF233396)(SEQ ID NO: 11); mouse Sir2 SIRT6 mRNA (GenBank Accession No: NM\_181586) (SEQ ID NO: 12); human Sir2 SIRT7 mRNA (GenBank Accession No: AF233395) (SEQ ID NO: 13); mouse Sir2 SIRT7 mRNA (GenBank Accession No: NM\_153056) (SEQ ID NO: 14), as well as all genomic DNA, cDNA, and synthetic DNA sequences that correspond to, or are complementary or are fragments, e.g., encoding functional protein fragments of the aforementioned nucleic acid sequences.

The terms “modulated” and “differentially regulated” as used herein include upregulation (i.e., activation or stimulation (e.g., by agonizing or potentiating)) and downregulation (i.e., inhibition or suppression (e.g., by antagonizing, decreasing or inhibiting)).

As used herein, the term “nucleic acid” refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA) and combinations thereof. The term also includes, as equivalents, analogs of RNA or DNA made from nucleotide analogs, and single (sense or antisense) and double-stranded polynucleotides. ESTs, chromosomes, cDNAs, mRNAs, and rRNAs.

The term “polymorphism” refers to the coexistence of more than one form of a gene or portion (e.g., allelic variant) thereof in a population of organisms. A portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a “polymorphic region of a gene”. A polymorphic region can be a single nucleotide, the identity of



which differs in different alleles. A polymorphic region can also be several nucleotides long. A “polymorphic gene” refers to a gene having at least one polymorphic region.

The term “allele”, which is used interchangeably herein with “allelic variant”, refers to a nucleotide polymorphism which may be present in a cell, e.g., in a gene or elsewhere on a chromosome. Alleles occupy the same locus or position on homologous chromosomes, but may also be introduced, artificially, at heterologous positions. When a subject has two identical alleles of a gene, the subject is said to be homozygous for that gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. The term “wild-type allele” refers to an allele of a gene which is present in at least 40% of the population. There can be several different wild-type alleles of a specific gene. Wild-type alleles may encode an amino acid sequence set forth herein or a natural variant thereof.

As used herein, the term “promoter” means a DNA sequence that regulates expression of a particular DNA sequence operably linked to the promoter, and which effects expression of the particular DNA sequence in cells. The term encompasses “tissue specific” promoters, i.e., promoters which regulate expression of the selected DNA sequence as a function of cellular state, e.g., differentiation state. Typically tissue specific promoters are active only in specific cells (e.g., cells of a specific tissue). The term also covers so-called “leaky” promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well. Other promoters that can be used include non-tissue specific promoters and promoters that are constitutively expressed or that are inducible (i.e., expression levels can be controlled). The terms “protein”, “polypeptide”, and “peptide” are used interchangeably herein to refer to a polymer of amino acids. However, a protein may include more than one polypeptide chain. A polypeptide can be a gene product, although some polypeptides can be produced synthetically.

The term “recombinant protein” refers to a protein which is produced by recombinant DNA techniques. In an exemplary method, DNA encoding a polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein. In another exemplary method, homologous recombination is used to insert a heterologous regulatory sequence into an endogenous gene. Moreover, the phrase “derived from,” with respect to a recombinant gene, is meant to include within the meaning of “recombinant protein” those proteins having an amino acid sequence of a native polypeptide, or an amino acid sequence similar thereto which is generated by mutations including substitutions

and deletions (including truncation) of a naturally occurring form of the polypeptide.

“Small molecule” as used herein, refers to a composition, which has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon-containing) or inorganic molecules. In preferred embodiments, the small molecule has a  
5 molecular weight of less than 1500, 1000, 800, 700, or 500 Daltons.

As used herein, the term “specifically hybridizes” or “specifically detects” refers to the ability of a nucleic acid molecule to hybridize to at least a portion of, for example, approximately 6, 12, 15, 20, 30, 50, or 100 contiguous nucleotides of a nucleic acid comprising a mammalian  
10 homolog of a SIR2 gene, or a sequence complementary thereto, or naturally occurring mutants thereof, such that it has less than 15%, preferably less than 10%, and more preferably less than 5% background hybridization to a cellular nucleic acid (e.g., mRNA or genomic DNA) encoding a different protein. In preferred embodiments, the oligonucleotide probe detects only a specific nucleic acid, e.g., it does not substantially hybridize to similar or related nucleic acids, or  
15 complements thereof. Guidance for performing hybridization reactions can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes  
20 in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and 4) very high stringency hybridization conditions are 0.5M  
25 sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. In certain embodiments, a SIRT1 gene hybridizes to a nucleic acid that encodes the catalytic domain of a SIR2 protein described herein, e.g., human SIRT1.

A “subject” can be an animal, preferably a mammal, and most preferably a human.

“Transcriptional regulatory sequence” refers to DNA sequences, such as initiation  
30 signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In preferred embodiments, transcription of one

of the genes is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended.

5 The term “treating” as used herein encompasses preventing as well as ameliorating at least one symptom of the condition or disease, or providing a prophylaxis or otherwise preventing at least one symptom. Treating can also include rendering one or more physiological functions to a more normal or less pathological state.

10 The term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded  
15 DNA loops which, in their vector form are not bound to the chromosome. In one embodiment, a vector is a plasmid, but a vector can also be in another form, e.g., a linear nucleic acid.

Statistical significance can be determined by any art known method. Exemplary statistical tests include: the Students T-test, Mann Whitney U non-parametric test, and Wilcoxon non-parametric statistical test. Some statistically significant relationships have a P value of less  
20 than 0.05, or 0.02. Particular methods may show a difference, e.g., result, that are statistically significant (e.g., P value < 0.05 or 0.02).

This disclosure incorporates by reference Picard et al. (2004) *Nature* doi:10.103/nature02583, *Nature* 429(6993):771-6. All cited references, patents, and patent applications, inclusive of 60/484,836, filed July 3, 2003, and a PCT Serial Number (to be  
25 entered), entitled “SIRT1 MODULATION OF ADIPOGENESIS AND ADIPOSE FUNCTION,” bearing attorney docket number 13407-058WO1, filed July 6, 2004, are incorporated by reference for all purposes.

These and other aspects of the instant inventions are described further in the detailed description.

30

### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts results indicating that SIRT1 modulates the amount of fat that can be released upon lipolysis. Lipolysis is reduced when SIRT1 is overexpressed and is increased when SIRT1 is underexpressed.

5 FIG. 2 depicts the effect of SIRT1 on leptin transcription. SIRT1 represses C/EBP $\alpha$ -induced leptin transcription in a dose-dependent manner.

### DETAILED DESCRIPTION

10 SIRT1 modulates critical components of adipocyte physiology in mammals. For example, SIRT1 activates fat mobilization in white adipocytes (WAT cells) and can also contribute to the burning of fat in brown adipocytes (BAT cells).

In WAT cells, SIRT1 can modulate expression of genes, e.g. genes regulated by PPAR- $\gamma$ . For example, SIRT1 can interact with cofactors NCoR (nuclear receptor co-repressor) and SMRT (silencing mediator or retinoid and thyroid hormone receptors).

15 SIRT1 also modulates the differentiation of cells in the adipocyte lineage.

In brown fat cells (BAT cells), SIRT1 binds to the UCP1 promoter. The human UCP1 gene is located at about 4q28-q31 on chromosome 4. The UCP1 promoter can include about nucleotides 142052800 to 142058843 on the plus strand of human chromosome 4, these nucleotides correspond to about 3023229 to 3029272 of GENBANK® entry NT\_016606.16.

20 Useful promoter nucleic acids can include at least about 500, 800, 1kb, 2kb, 3kb, or 4kb of the above region, for example, regions of such size that include the mRNA start site, the TATA box, or the UCP1 ATG. For example, the promoter can terminate at the mRNA start site, the TATA box, or the UCP1 ATG. Such regions may include one or more of: a PPAR- $\gamma$  binding site, TRE/RARE binding site, NF-E2 binding site, and cAMP responsive elements. See, e.g., Rim et al. (2002) J. Biol. Chem. 277:34589-34600 for exemplary binding sites and exemplary promoter regions.

At the UCP1 promoter, SIRT1 can form a ternary complex with PGC1 and PPAR- $\gamma$ . An exemplary amino acid sequences for PGC1 includes:

```
>gi|7019499|ref|NP_037393.1| peroxisome proliferative activated
30 receptor gamma coactivator 1; ligand effect modulator-6; PPAR
gamma coactivator-1 [Homo sapiens]
```

MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSQSEI  
 ISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLVPDEEDGLPSFDALTDGDVTTDNEASPSM  
 PDGTPPPQEAEEPSSLKLLAPANTQLSYNECSGLSTQNHANHNHRIRTNPAIVKTENSWSNK  
 AKSICQQQKPQRRPCSELLKYLTNDPPHTKPTENRNSSRDKCTSKKKSHTSQSQHLQAKPT  
 5 TSLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTTPPHKANQDNPFRA SPKLKSSC  
 KTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLSKSSVLTGGHEERKTKRPSLRLFGDH  
 DYCQSINSKTEILINISQELQDSRQLENKDVSSDWQGQICSSTDSDQCYLRETLEASKQVSPCS  
 TRKQLQDQEIRAE LNKHFGHPSQAVFDDEADKTGELRDSDFSNEQFSKLPMFINSGLAMDG LFD  
 DSEDESDKLSYPWDGTQSYSLFNVSPSCSSFN SPCRDSVSPPKSLFSQRPQRMRSR SRSFSRHR  
 10 SCSRSPYSR SRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSR SRSRSPYSRRPRYDSYEEY  
 QHERLKREEYRREYEKRESERAKQ RERQRQKAIEERRVIYVGKIRPDTRTELDRFEVFGEIE  
 ECTVNLRDDGDSYG FITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKS NYADLDSNS  
 DDFDPASTKSKYDSLDFDSL LKEAQRSLRR (SEQ ID NO:32)

15 An exemplary amino acid sequence for PPAR-gamma is as follows:

gi|20336231|ref|NP\_005028.3| peroxisome proliferative activated  
 receptor gamma isoform 1; PPAR gamma [Homo sapiens]  
 MVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYK  
 20 YDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEG  
 CKGFFRRTIRLKLIIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLL  
 AEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMG  
 EDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGV  
 HEIIYTMLASLMNKDGVLISEGQGFMTRFLKSLRKPFQDFMEPKFEFAVKFNAL ELDDSDLAI  
 25 FIAVIILSGDRPGLLNKPIEDIQDNLLQALELQLKLNHP ESSQLFAKLLQKMTDLRQIVTEHV  
 QLLQVIKKTETDMSLHPLLQEIIYKDLY (SEQ ID NO:33)

gi|20336229|ref|NP\_056953.2| peroxisome proliferative activated  
 receptor gamma isoform 2; PPAR gamma [Homo sapiens]  
 30 MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKP  
 FTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHE  
 EPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIIYDRCDLNCRIHKKSRNKCQY

CRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPL  
 TKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEA  
 VQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSL  
 RKPFGDFMEPKFEFAVKFNALELDDSDLAI FIAV IILSGDRPGLLNVKPIEDIQDNLLQALELQ  
 5 LKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIIYKDLY (SEQ ID  
 NO:34)

An exemplary sequence of NcoR is:

sp|O75376|NCR1\_HUMAN Nuclear receptor corepressor 1 (N-CoR1) (N-CoR) - Homo sapiens  
 10 (Human).

MSSSGYPPNQGAFTSQSRYPFHSVQYTFPNTRHQQEFVAVPDYRSSHLEVSQASQLLQQQQQQQ  
 LRRRPSLLSEFHPGSDRPQERRTSYEPFHPGPSVDHDSLESKRPRLEQVSDSHFQRVSAAVLP  
 LVHPLPEGLRASADAKKDPAFGGKHEAPSSPISGQPCGDDQNASPSKLSKEELIQSMDRVDREI  
 AKVEQQILKLKKKQQQLEEEAAKPPEPEKPVSPPPVEQKHSIVQIIYDENRKKAEEAHKIFEG  
 15 LGPKVELPLYNQPSDTKVYHENIKTNQVMRKKLILFFKRRNHARKQREQKICQRYDQLMEAWEK  
 KVDRIENNPRRKAKESKTREYYEKQFPFIRKQREQQERFQRVGQRGAGLSATIARSEHEISEII  
 DGLSEQENNEKQMRQLSVIPPMFDAEQRRVKFINMNGLMEDPMKVYKDRQFMNVWTDHEKEIF  
 KDKFIQHPKNFGLIASYLERKSVPCVLYYYLTCKKNENYKALVRRNYGKRRGRNQIARPSQEE  
 KVEEKEEDKAEKTEKKEEEKKDEEEKDEKEDSKENTKEKDKIDGTAEETEEREQATPRGRKTAN  
 20 SQGRRKGRITRSMTNEAAAASAAAAAATEEPPPPLPPPPEPISTEPVETSRWTEEMEVAKKGL  
 VEHGRNWAAIAKMVGTKSEAQCKNFYFNYKRRHNLNLLQQHKQKTSRKPREERDVSQCESVAS  
 TVSAQEDIEDIEASNEEENPEDSEVEAVKPSEDSPENATSRGNTEPAVELEPTTETAPSTSPSLA  
 VPSTKPAEDESJETQVNDISAEAEQMDVDQQEHSAAEGSVCDPPPATKADSVDVEVRVPENH  
 ASKVEGDNTKERDLDRASEKVEPRDEDLVVAQQINAQRPEPQSDNDSSATCSADEDVDGEPEEQ  
 25 RMFPMDSKPSLLNPTGSILVSSPLKPNPLDLPQLQHRAAVIPPMVSCTPCNIPIGTPVSGYALY  
 QRHIKAMHESALLEEQRQREQIDLECRSSTSPCGTSKSPNREWEVLQAPHQVITNLPEGVRL  
 PTTRPTRPPPPLIPSSKTTVASEKPSFIMGGSISQGTPTYLTSHNQASYTQETPKPSVGSISL  
 GLPRQQESAQSATLPYIKQEEFSPRSQNSQPEGLLVRAQHEGVVRGTAGAIQEGSITRGTPTSK  
 ISVESIPSLRGSITQGTALPQTGIPTALVKGSISRMPEDSSPEKGREEAASKGHVIYEGKS  
 30 GHILSYDNIKNAREGTRSPRTAHEISLKRSYESVEGNIKQGMRESFVSAPLEGLICRALPRG  
 SPHSDLKERTVLSGSIMQGTPRATTESFEDGLKYPKQIKRESPPIRAFEGAITKGKPYDGITTI  
 KEMGRSIIHEIPRQDILTQESRKTPEVVQSTRPIIEGSISQGTPIKFDNNSGQSAIKHNKSLIT

GPSKLSRGMPPLEIVPENIKVVERGKYEDVKAGETVRSRHTSVVSSGPSVLRSTLHEAPKAQLS  
 PGIYDDTSARRTPVSYQNTMSRGSPMMNRTSDVTISSNKSTNHERKSTLTPTQRESIPAKSPVP  
 GVDPVVSHSPFDPHHRGSTAGEVYRSHLPTHLDPAMPFHRALDPAAAAYLFQRQLSPTPGYPSQ  
 YQLYAMENTRQTI LNDYITSQQMQVNLRPDVARGLSPREQPLGLPYPATRGIIDL TNMPPTILV  
 5 PHPGGTSTPPMDRITYIIPGTQITFPPRPYNSASMSPGHPHTLAAAASAEREREREREKERERER  
 IAAASSDLYLRPGSEQPGRPGSHGYVRSPSPSVRTQETMLQQRPSVFQGTNGTSVITPLDPTAQ  
 LRIMPLPAGGPSISQGLPASRYNTAADALAALVDAAASAPQMDVSKTKESKHEAARLEENLRSR  
 SAAVSEQQOLEQKTLVEKRSVQCLYTSSAFPSGKPQPHSSVVYSEAGKDKGPPPKSRYEEELR  
 TRGKTTITAA NFIDV IITRQIASDKDARERGSQSSDSSSSLSHRYETPSDAIEVISPASSPAP  
 10 PQEKLQTYQPEVVKANQAENDPTRQYEGPLHHYRPQQESPSPPQQQLPPSSQAEGMGQVPRTHRL  
 ITLADHICQIITQDFARNQVSSQTPQQPPTSTFQNSPSALVSTPVRTKTSNRYSPEQAQSVHH  
 QRPGRVSPENLVDKSRGSRPGKSPERSHVSSEPYEPI SPPQVPVHEKQDSL LLLSQRGAEPA  
 EQRNDARSPGSISYLP SFFTKLENTSPMVKSKKQEIFRKLNSSGGGDSDMAAAQPGTEIFNLPA  
 VTTSGSVSSRGHSFADPASNLGLEDIIRKALMGSFDDKVEDHGVVMSQPMGVVPGTANTSVVTS  
 15 GETRREEGDPSPHSGGVCKPKLISKSNSRKS KSPIPGQGYLGTERPSSVSSVHSEGDYHRQTPG  
 WAWEDRPSSTGSTQFPYNPLTMRMLSSTPPTPIACAPSAVNQAAPHQQNRIWEREPAPLLSAQY  
 ETLSDSD

(SEQ ID NO:35)

### Screening Assays

20 This disclosure includes methods of screening for compounds that sirtuin activity, particularly compounds that modulate sirtuin activity in cells of the adipocyte lineage, e.g., preadipocytes and adipocytes, e.g., BAT and WAT cells. Useful modulators include agents that increase a sirtuin activity and agents that decrease a sirtuin activity.

Exemplary “sirtuin activities” include deacetylase function (e.g., ability to deacetylate a  
 25 substrate, e.g., an acetylated histone, or p53), interaction with a sirtuin binding partner, e.g., a transcription factor such as a DNA binding transcription factor, a co-repressor, or a co-activator, interaction with sites on genomic DNA (e.g., by indirect recruitment to promoters) and modulation of transcription (e.g., activation or repression of transcription). Assays for such functions include many known assays and assay described herein. Exemplary assays include:  
 30 deacetylation assays described in US 20030207325, PCT US2004/001239, and mass spectroscopy methods. Exemplary assays for evaluating interaction with genomic nucleic acid

include chromatin immunoprecipitation or “CHiP” assays. Assays for evaluating modulation of transcription include those described in “Gene Expression and Transcript analysis.”

A compound can be evaluated to determine its effect on a biochemical, cellular, or organismal phenotype associated with a metabolic disorder, e.g., obesity, an obesity-related disorder, a fat-related disorder, a disorder characterized by insulin resistance, e.g., Type II diabetes, e.g., as described herein, or other disorder described herein.

One exemplary method includes screening for compounds using a method that includes evaluating the compounds for modulation of a sirtuin activity and evaluating the effect of the compound on a biochemical, cellular, or organismal phenotype associated with a metabolic disorder, e.g., obesity, an obesity-related disorder, or a fat-related disorder, e.g., as described herein. The evaluations can be performed in either order. For example, a library of compounds can be vetted using the first criterion (e.g., modulation of SIRT1 activity) to provide a smaller set of compounds, and then evaluating compounds from the smaller set for an effect on a metabolic phenotype. The vetting can also be done in the opposite order.

Compounds which interact with sirtuins can be identified, e.g., by in vitro or in vivo assays. For example, exemplary in vitro assays for SIRT1 activity include cell free assays, e.g., assays in which an isolated SIRT1 polypeptide (including a polypeptide that includes a fragment of at least 100 amino acids of SIRT1, e.g., a fragment described herein) is contacted with a test compound.

When both the assay for screening a compound for the ability to interact with a sirtuin and the assay for determining effect on sirtuin are performed in vivo, e.g., in cell based assays, the assays can be performed in the same or different cells. For example, one or both of the assays can be performed in tissue culture (e.g., 3T3 cells, 3T3-L1 cells, PC12 cells, or primary fibroblast cultures) or in an organism (e.g., a mammal, e.g., a human).

In preferred embodiments, the assays are performed in the presence of a cofactor of sirtuin such as NAD and/or NAD analogs. In some embodiments, the co-factor is added to the cell culture or in vitro assay, e.g., the NAD and/or an NAD analog to facilitate catalysis.. “NAD” refers to nicotinamide adenine dinucleotide. An “NAD analog” as used herein refers to a compound (e.g., a synthetic or naturally occurring chemical, drug, protein, peptide, small organic molecule) which possesses structural similarity to component groups of NAD (e.g., adenine, ribose and phosphate groups) or functional similarity (e.g., supports deacetylating a histone or p53 in the presence of Sir2). For example, an NAD analog can be 3-aminobenzamide or 1,3-



lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 KDa or 214 amino acids) are encoded by a variable region gene at the NH<sub>2</sub>-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH--terminus. Full-length immunoglobulin "heavy chains" (about 50 KDa or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids). The term "antigen-binding fragment" of an antibody (or simply "antibody portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to the antigen. Examples of antigen-binding fragments include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also encompassed within the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

In one embodiment, the antibody against a sirtuin or other protein is a fully human antibody (*e.g.*, an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, *e.g.*, a rodent (mouse or rat), goat, primate (*e.g.*, monkey). Preferably, the non-human antibody is a rodent (mouse or rat antibody). Method of producing rodent antibodies are known in the art. Non-human antibodies can be modified, *e.g.*, humanized or deimmunized. Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system (see, *e.g.*, WO 91/00906 and WO 92/03918). Other methods for

dihydroisoquinoline (H. Vaziri *et al.*, EMBO J. 16:6018-6033 (1997)). Another example is isonicotinamide.

Described below are exemplary methods for identifying compounds that interact with a sirtuin and can modulate activity or expression of a sirtuin. Compounds can be identified which  
5 interact with, e.g., bind to, a sirtuin and increase or decrease at least one sirtuin activity, e.g., deacetylation or interaction with a sirtuin binding partner. For example, deacetylation of a substrate by SIRT1 has been found to decrease adipogenesis.

The phrase “deacetylating a substrate” or “deacetylating a transcription factor” refers to the removal of one or more acetyl groups (*e.g.*,  $\text{CH}_3\text{CO}^2^-$ ) from the substrate or transcription  
10 factor that is acetylated on at least one amino acid residue. The substrate can be a single amino acid (*e.g.*, an acetylated lysine), a peptide (*e.g.*, a N-terminal peptide of a histone, or an acetylated p53 peptide), or a protein. An acetylated substrate can include a fluorophore, *e.g.*, which can be used to monitor the acetylation states of the substrate. The “Fleur-de-Lys™” substrate from Biomol® includes one such exemplary modification. “Acetylation status” refers  
15 to the presence or absence of one or more acetyl groups (*e.g.*,  $\text{CH}_3\text{CO}^2^-$ ) at one or more lysine (K) residues of a substrate, *e.g.*, a transcription factor. For example, the presence of an acetyl groups can be found at one or more of: K370, K371, K372, K381, and/or K382 of the p53 sequence. “Altering the acetylation status” refers to adding or removing one or more acetyl groups (*e.g.*,  $\text{CH}_3\text{CO}^2^-$ ). For example, adding or removing one or more acetyl groups of p53 at  
20 one or more lysine (K) residues, *e.g.*, K370, K371, K372, K381, and/or K382, *e.g.*, from p53 or a fragment thereof that includes one or more of the residues.

A variety of molecules may be utilized to modulate the expression, synthesis, or activity of a mammalian SIR2 homolog or a substrate thereof. Such molecules may include, but are not limited to small organic molecules, peptides, antibodies, nucleic acids, antisense nucleic acids,  
25 RNAi, ribozyme molecules, triple helix molecules, and the like.

The following assays provide methods (also referred to herein as “evaluating a compound” or “screening a compound”) for identifying modulators, *i.e.*, candidate or test compounds (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) which interact with and/or modulate activity of a sirtuin, *e.g.*, have a stimulatory or inhibitory effect on, for example,  
30 SIRT1 expression and/or activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a SIRT1 substrate. Such compounds can be agonists or antagonists of a sirtuin. In preferred embodiments, the screening assays described herein are used to identify

candidates which function as SIRT1 agonists. As described herein, such a SIRT1 agonist can be used to reduce adipogenesis. Some of these assays may be performed in animals, e.g., mammals, in organs, in cells. Others may be performed in animals, e.g., mammals, in organs, in cells, in cell extracts, e.g., purified or unpurified nuclear extracts, intracellular extracts, in purified  
5 preparations, in cell-free systems, in cell fractions enriched for certain components, e.g., organelles or compounds, or in other systems known in the art.

Some exemplary screening assays for assessing activity or function include one or more of the following features:

- use of a transgenic cell, e.g., with a transgene encoding a sirtuin or a mutant thereof;
- 10 - use of a cell modified to facilitate detection of adipogenesis, e.g., modified to include a reporter of adipogenesis,
- use of a mammalian cell that expresses a sirtuin;
- use of an enzymatic assay for a sirtuin, e.g., to evaluate deacetylation of a substrate, e.g., an amino acid, a peptide or a protein;
- 15 - detection of binding to a sirtuin, e.g., by a sirtuin binding partner or a test compound, for example, where the compound is, for example, a peptide, protein, antibody or small organic molecule; e.g., the compound modulates (e.g., stimulates or inhibits) an interaction between sirtuin and a sirtuin-binding partner;
- use of proximity assays that detect interaction between a sirtuin and a sirtuin-binding  
20 partner, e.g., a protein, e.g., a nuclear protein, e.g., a histone or transcription factor (e.g., p53), or fragments thereof, for example, fluorescence proximity assays;
- use of radio-labelled substrates, e.g.  $^{35}\text{S}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ , e.g., to determine acetylation status, metabolic status, and so forth; and
- use of antibodies specific for certain acetylated or de-acetylated forms of the substrate.

25 Additional screening assays are described in more detail below.

A "compound" or "test compound" can be any chemical compound, for example, a macromolecule (e.g., a polypeptide, a protein complex, or a nucleic acid) or a small molecule (e.g., an amino acid, a nucleotide, an organic or inorganic compound). The test compound can have a formula weight of less than about 10,000 grams per mole, less than 5,000 grams per mole,  
30 less than 1,000 grams per mole, or less than about 500 grams per mole. The test compound can be naturally occurring (e.g., a herb or a nature product), synthetic, or both. Examples of macromolecules are proteins, protein complexes, and glycoproteins, nucleic acids, e.g., DNA,

RNA (e.g., double stranded RNA or RNAi) and PNA (peptide nucleic acid). Examples of small molecules are peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds e.g., heteroorganic or organometallic compounds. One exemplary type of protein  
5 compound is an antibody or a modified scaffold domain protein. A test compound can be the only substance assayed by the method described herein. Alternatively, a collection of test compounds can be assayed either consecutively or concurrently by the methods described herein.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic  
10 compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.

15 A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino  
20 acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37:487-493 (1991) and  
25 Houghton *et al.*, *Nature* 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication No. WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90:6909-6913 (1993)), vinyllogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114:9217-9218 (1992)), analogous organic syntheses of

small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116:2661 (1994)), oligocarbamates (Cho *et al.*, *Science* 261:1303 (1993)), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59:658 (1994)), nucleic acid libraries (*see* Ausubel, Berger and Sambrook, all *supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*,  
5 Vaughn *et al.*, *Nature Biotechnology*, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et al.*, *Science*, 274:1520-1522 (1996) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds,  
10 U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like). Additional examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.  
15

Some exemplary libraries are used to generate variants from a particular lead compound. One method includes generating a combinatorial library in which one or more functional groups of the lead compound are varied, *e.g.*, by derivatization. Thus, the combinatorial library can include a class of compounds which have a common structural feature (*e.g.*, framework).

20 Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.*, ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd,  
25 Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

Test compounds can also be obtained from: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; *see, e.g.*, Zuckermann, R.N. *et al.* (1994) *J. Med. Chem.* 37:2678-85); spatially addressable  
30 parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological libraries include libraries of nucleic acids and

libraries of proteins. Some nucleic acid libraries encode a diverse set of proteins (e.g., natural and artificial proteins; others provide, for example, functional RNA and DNA molecules such as nucleic acid aptamers or ribozymes. A peptoid library can be made to include structures similar to a peptide library. (See also Lam (1997) *Anticancer Drug Des.* 12:145). A library of proteins  
5 may be produced by an expression library or a display library (e.g., a phage display library).

Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner U.S. Patent No. 5,223,409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage  
10 (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici (1991) *J. Mol. Biol.* 222:301-310).

### In vitro Assays

In some embodiments, interaction with, e.g., binding of a sirtuin can be assayed *in vitro*.

15 The reaction mixture can include, e.g., a co-factor such as NAD and/or a NAD analog, a substrate or other binding partner or potentially interacting fragment thereof. Exemplary binding partners include PGC1, NcoR, and PPAR-gamma, or interacting fragments thereof. Preferably the binding partner is a direct binding partner.

In other embodiments, the reaction mixture can include a sirtuin-binding partner, e.g., a  
20 transcription factor, e.g., a transcription and compounds can be screened, e.g., in an *in vitro* assay, to evaluate the ability of a test compound to modulate interaction between a sirtuin and a sirtuin-binding partner. This type of assay can be accomplished, for example, by coupling one of the components, with a radioisotope or enzymatic label such that binding of the labeled component to the other can be determined by detecting the labeled compound in a complex. A  
25 component can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, a component can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by  
determination of conversion of an appropriate substrate to product. Competition assays can also  
30 be used to evaluate a physical interaction between a test compound and a target.

Cell-free assays involve preparing a reaction mixture of the target protein (e.g., SIRT1) and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed and/or detected.

The interaction between two molecules can also be detected, e.g., using a fluorescence assay in which at least one molecule is fluorescently labeled. One example of such an assay includes fluorescence energy transfer (FET or FRET for fluorescence resonance energy transfer) (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. A FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

Another example of a fluorescence assay is fluorescence polarization (FP). For FP, only one component needs to be labeled. A binding interaction is detected by a change in molecular size of the labeled component. The size change alters the tumbling rate of the component in solution and is detected as a change in FP. See, e.g., Nasir *et al.* (1999) *Comb Chem HTS* 2:177-190; Jameson *et al.* (1995) *Methods Enzymol* 246:283; Seethala *et al.* (1998) *Anal Biochem.* 255:257. Fluorescence polarization can be monitored in multiwell plates, e.g., using the Tecan Polarion™ reader. See, e.g., Parker *et al.* (2000) *Journal of Biomolecular Screening* 5 :77 – 88; and Shoeman, *et al.* (1999) 38, 16802-16809.

In another embodiment, determining the ability of the sirtuin to bind to a target molecule can be accomplished using real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705). "Surface plasmon resonance" or "BIA" detects biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive

index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

In one embodiment, a sirtuin is anchored onto a solid phase. The sirtuin /test compound complexes anchored on the solid phase can be detected at the end of the reaction, e.g., the binding reaction. For example, SIRT1 can be anchored onto a solid surface, and the test compound, (which is not anchored), can be labeled, either directly or indirectly, with detectable labels discussed herein.

It may be desirable to immobilize either the sirtuin or a sirtuin binding partner to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a sirtuin, or interaction of a sirtuin with a second component in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ mammalian homolog of a SIR2 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or sirtuin, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of sirtuin binding or activity determined using standard techniques.

Other techniques for immobilizing either a sirtuin or a target molecule on matrices include using conjugation of biotin and streptavidin. Biotinylated sirtuin or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).

In order to conduct the assay, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted



components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that  
5 complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, e.g., using a labeled antibody specific for the immobilized component (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody).

In one embodiment, this assay is performed utilizing antibodies reactive with a sirtuin or  
10 target molecules but which do not interfere with binding of the sirtuin to its target molecule. Such antibodies can be derivatized to the wells of the plate, and unbound target or the sirtuin trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the sirtuin or target molecule, as well as enzyme-linked  
15 assays which rely on detecting an enzymatic activity associated with the sirtuin or target molecule.

Alternatively, cell free assays can be conducted in a liquid phase. In such an assay, the reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (see, for example, Rivas, G.,  
20 and Minton, A.P., (1993) *Trends Biochem Sci* 18:284-7); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (see, e.g., Ausubel, F. *et al.*, eds. *Current Protocols in Molecular Biology* 1999, J. Wiley: New York.); and immunoprecipitation (see, for example, Ausubel, F. *et al.*, eds. (1999) *Current Protocols in Molecular Biology*, J. Wiley: New York). Such resins and chromatographic techniques are  
25 known to one skilled in the art (see, e.g., Heegaard, N.H., (1998) *J Mol Recognit* 11:141-8; Hage, D.S., and Tweed, S.A. (1997) *J Chromatogr B Biomed Sci Appl.* 699:499-525). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

In a preferred embodiment, the assay includes contacting the sirtuin or biologically active  
30 portion thereof with a known compound which binds a sirtuin to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a sirtuin, wherein determining the ability of the test compound to

interact with the sirtuin includes determining the ability of the test compound to preferentially bind to the sirtuin or biologically active portion thereof, or to modulate the activity of a target molecule, as compared to the known compound.

The target molecules can, *in vivo*, interact with one or more cellular macromolecules, such as proteins. For the purposes of this discussion, such cellular and extracellular macromolecules are referred to herein as “binding partners.” Compounds that disrupt such interactions can be useful in regulating the activity of the target product. Such compounds can include, but are not limited to molecules such as antibodies, peptides, and small molecules. Exemplary targets/products for use in this embodiment include the sirtuin binding partners.

To identify compounds that interfere with the interaction between the target product and its binding partner(s), for example, a reaction mixture containing the target product and the binding partner is prepared, under conditions and for a time sufficient, to allow the two products to form complex. In order to test an inhibitory agent, the reaction mixture is provided in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the target and its cellular or extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the target product and the cellular or extracellular binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the target product and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal target product can also be compared to complex formation within reaction mixtures containing the test compound and mutant target product. This comparison can be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal target products.

These assays can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the target product or the binding partner onto a solid phase, and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the target products and the binding partners, e.g., by competition, can be identified by conducting the

reaction in the presence of the test substance. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are briefly described below.

5 In a heterogeneous assay system, either the target product or the partner, is anchored onto a solid surface (e.g., a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored species can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the species to be anchored can be used to anchor the species to the solid surface.

10 In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized  
15 species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

20 Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of  
25 reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

In an alternate embodiment, a homogeneous assay can be used. For example, a preformed complex of the target product and the interactive cellular or extracellular binding partner product is prepared in that either the target products or their binding partners are labeled,  
30 but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in

the generation of a signal above background. In this way, test substances that disrupt target product-binding partner interaction can be identified.

In yet another aspect, the sirtuin can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with SIRT1 (“SIRT1-binding proteins”) and are involved in SIRT1 activity. Such SIRT1 binding partners can be activators or inhibitors of signals or transcriptional control.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a SIRT1 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. (Alternatively the sirtuin can be the fused to the activator domain.) If the “bait” and the “prey” proteins are able to interact, *in vivo*, forming a sirtuin -dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., lacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the sirtuin. In another embodiment, the two-hybrid assay is used to monitor an interaction between two components, e.g., a sirtuin and, e.g., p53, that are known to interact. The two hybrid assay is conducted in the presence of a test compound, and the assay is used to determine whether the test compound enhances or diminishes the interaction between the components.

In another embodiment, modulators of sirtuin gene expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of the mammalian homolog of a SIR2 mRNA or protein evaluated relative to the level of expression of sirtuin mRNA or protein in the absence of the candidate compound. When expression of the mammalian homolog of a SIR2 mRNA or protein is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator

of a mammalian homolog of a SIR2 mRNA or protein expression. Alternatively, when expression of the mammalian homolog of a SIR2 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the SIRT1 mRNA or protein expression. The level of the mammalian homolog of a SIR2 mRNA or protein expression can be determined by methods for detecting mammalian homolog of a SIR2 mRNA or protein, e.g., using probes or antibodies, e.g., labelled probes or antibodies.

### Cell-Based Assays

In another embodiment, the assay, e.g., the assay for selecting compounds which interact with sirtuins can be a cell-based assay. Useful assays include assays in which a marker of adipocyte differentiation, a fat or lipid parameter is measured. The cell based assay can include contacting a cell expressing a sirtuin with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) an activity of a sirtuin, and/or determine the ability of the test compound to modulate expression of a sirtuin, e.g., by detecting sirtuin nucleic acids (e.g., mRNA or cDNA) or proteins in the cell. Determining the ability of the test compound to modulate sirtuin activity can be accomplished, for example, by determining the ability of the sirtuin to bind to or interact with the test molecule, and by determining the ability of the test molecule to modulate adipogenesis. Cell-based systems can be used to identify compounds that decrease expression and/or activity and/or effect of a sirtuin. Such cells can be recombinant or non-recombinant, such as cell lines that express the sirtuin gene. In some embodiments, the cells can be recombinant or non-recombinant cells which express a sirtuin binding partner. Exemplary systems include mammalian or yeast cells that express a sirtuin, e.g., from a recombinant nucleic acid. In utilizing such systems, cells are exposed to compounds suspected of increasing expression and/or activity of a sirtuin. After exposure, the cells are assayed, for example, for sirtuin expression or activity. Alternatively, the cells may also be assayed for the activation or inhibition of the deacetylation function of a sirtuin, or modulation of adipogenesis. In one embodiment, the visual assessment can be used as evidence of adipogenesis.

A cell can be from a stable cell line or a primary culture obtained from an organism, e.g., a organism treated with the test compound.

In addition to cell-based and in vitro assay systems, non-human organisms, e.g., transgenic non-human organisms or a model organism, can also be used. A transgenic organism is one in which a heterologous DNA sequence is chromosomally integrated into the germ cells of the animal. A transgenic organism will also have the transgene integrated into the chromosomes of its somatic cells. Organisms of any species, including, but not limited to: yeast, worms, flies, fish, reptiles, birds, mammals (e.g., mice, rats, rabbits, guinea pigs, pigs, micro-pigs, and goats), and non-human primates (e.g., baboons, monkeys, chimpanzees) may be used in the methods described herein.

A transgenic cell or animal used in the methods of the invention can include a transgene that encodes, e.g., a sirtuin. The transgene can encode a protein that is normally exogenous to the transgenic cell or animal, including a human protein, e.g., a human sirtuin, e.g., SIRT1. The transgene can be linked to a heterologous or a native promoter. Methods of making transgenic cells and animals are known in the art.

Accordingly, in another embodiment, the invention features a method of identifying a compound as a candidate of treatment of a metabolic disorder, e.g., obesity, an obesity-related disorder, or a fat-related disorder. The method includes: providing a compound which interacts with, e.g., binds to, a sirtuin; evaluating the effect of the compound on adipocyte differentiation; and further evaluating the effect of the test compound on a subject, e.g., an animal model, e.g., an animal model for a metabolic disorder, e.g., obesity. The interaction between a test compound and the sirtuin can be evaluated by any of the methods described herein, e.g., using cell-based assays or cell-free in vitro assays.

#### Promoters and reporters

Reporter genes can be made by operably linking a regulatory sequence to a sequence encoding a reporter gene. A number of methods are available for designing reporter genes. For example, the sequence encoding the reporter protein can be linked in frame to all or part of the sequence that is normally regulated by the regulatory sequence. Such constructs can be referred to as translational fusions. It is also possible to link the sequence encoding the reporter protein to only regulatory sequences, e.g., the 5' untranslated region, TATA box, and/or sequences upstream of the mRNA start site. Such constructs can be referred to as transcriptional fusions.

Still other reporter genes can be constructed by inserting one or more copies (e.g., a multimer of three, four, or six copies) of a regulatory sequence into a neutral or characterized promoter.

Synthetic promoters can include one or more multimerized sites, e.g., a site that is specifically recognized by a transcription factor described herein, e.g., a PPAR (e.g., PPAR-alpha, PPAR-gamma, or PPAR-delta) or a C/EBP (e.g., CEPB. For example, an exemplary PPRE (PPAR-gamma response element) includes TTGCCCTTG, another includes TCACCCTTG.

Reporter constructs can be used to evaluate expression of any gene described herein or any gene whose expression is correlated with adipocyte or keratinocyte function.

The UCP1 promoter can include about nucleotides 142052800 to 142058843 on the plus strand of human chromosome 4. Useful promoter nucleic acids can include at least about 500, 800, 1kb, 2kb, 3kb, or 4kb of the above region, for example, regions of such size that include the mRNA start site, the TATA box, or the UCP1 ATG. For example, the promoter can terminate at the mRNA start site, the TATA box, or the UCP1 ATG.

The leptin promoter can include about nucleotides 127427395 to 127435395 on the plus strand of human chromosome 7. Useful promoter nucleic acids can include at least about 500, 800, 1kb, 2kb, 3kb, 4kb, 6kb, or 8kb of the above region, for example, regions of such size that include the mRNA start site, the TATA box, or the leptin ATG. For example, the promoter can terminate at the mRNA start site, the TATA box, or the leptin ATG.

The PPARG promoter can include about nucleotides 12,298,254 to 12,306,254 on the plus strand of human chromosome 3. Useful promoter nucleic acids can include at least about 500, 800, 1kb, 2kb, 3kb, 4kb, 6kb, or 8kb of the above region, for example, regions of such size that include the mRNA start site, the TATA box, or the PPARG ATG. For example, the promoter can terminate at the mRNA start site, the TATA box, or the PPARG ATG.

The resistin (RETN) promoter can include about nucleotides 7,631,989 to 7,639,989 on the plus strand of human chromosome 19. Useful promoter nucleic acids can include at least about 500, 800, 1kb, 2kb, 3kb, 4kb, 6kb, or 8kb of the above region, for example, regions of such size that include the mRNA start site, the TATA box, or the RETN ATG. For example, the promoter can terminate at the mRNA start site, the TATA box, or the RETN ATG.

Still other genes of interest include: genes that encode C/EBP- $\alpha$ , C/EBP- $\delta$  and Ap2.

Exemplary reporter proteins include chloramphenicol acetyltransferase, green fluorescent protein and other fluorescent proteins (e.g., artificial variants of GFP), beta-lactamase, beta-

galactosidase, luciferase, and so forth. The reporter protein can be any protein other than the protein encoded by the endogenous gene that is subject to analysis. Epitope tags can also be used.

### Pharmaceutical Compositions

5           An agent that modulates activity of SIRT1 or other sirtuin can be incorporated into a pharmaceutical composition, e.g., a composition that includes a pharmaceutically acceptable carrier.

As used herein the language “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active  
10           compounds can also be incorporated into the compositions.

A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal  
15           administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid;  
20           buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Toxicity and therapeutic efficacy of such compounds can be determined by standard  
25           pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used,  
30           care should be taken to design a delivery system that targets such compounds to the site of



affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

Examples of modulators of sirtuin activity include nucleic acids that encode a sirtuin, or fragments thereof, nucleic acids that inhibit sirtuin gene expression, and polypeptides that have a sirtuin activity, fragments thereof, as well as antibodies that bind to and/or inhibit a sirtuin (e.g., SIRT1). Such modulators can be provided as a pharmaceutical composition. Other types of modulators include small molecule inhibitors and activators, e.g., as described herein.

A therapeutically effective amount of protein or polypeptide (i.e., an effective dosage) includes ranges, e.g., from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic

solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable  
 5 syringes or multiple dose vials made of glass or plastic.

In one embodiment, a composition that includes a modulator of SIRT1 activity is used to modulate (e.g., increase) the amount of subcutaneous fat in a tissue, e.g., in facial tissue or in other surface-associated tissue of the neck, hand, leg, or lips. The modulator (e.g., SIRT1  
 10 inhibitor) can be used to increase the rigidity, water retention, or support properties of the tissue. For example, the composition can be applied topically, e.g., in association with another agent, e.g., for surface-associated tissue treatment. The composition may also be injected subcutaneously, e.g., within the region where an alteration in subcutaneous fat is desired.


Compositions can also be used to modulate fertility.

15 An additional treatment includes using a modulator of SIRT1 activity to alter keratinocyte aging or appearance, e.g., by administering (e.g., topically applying the modulator to a surface site, e.g., in an amount effective to modulate keratinocyte aging.

#### Exemplary Activators of SIRT1 Activity

One exemplary class of SIRT1 activators include polyphenols, e.g., a flavone, stilbene,  
 20 flavanone, cetchin, chalcone, isoflavone, anthocyanidin, or tannin.

In some instances, the SIRT1 activator is a compound of formula (I):




wherein;


25 X is, for example, alkenyl, C(O)CH=CH, or a hydroxy pyranone fused to one of the phenyl moieties to form a flavone; and

each n is, e.g., independently 1-3.


For example, the compound can be a polyhydroxy stilbene (e.g., polyhydroxy-*trans*-stilbene) as shown in formula (II), a polyhydroxy chalcone as shown in formula (III), or a  
 30 polyhydroxyflavone as shown in formula (IV). In general, the compound is substituted with at least 2, preferably 3, 4, of 5 hydroxy moieties.



formula (II)



formula (III)



formula (IV)

Exemplary compounds include resveratrol (3, 5, 4'-trihydroxy-trans-stilbene), butein (3,4,2', 4'- tetrahydroxychalcone); piceatannol (3, 5, 3', 4'-tetrahydroxy-trans-stilbene); isoliquiritigenin (4,2',4'-trihydroxychalcone); fisetin (3,7,3',4'-tetrahydroxyflavone); and quercetin (3,5,7,3',4'-pentahydroxyflavone). See, e.g., Howitz (2003) *Nature* 425:191-196.

In one embodiment, such compounds are provided in a non-liquid form, e.g., a semi-solid form, e.g., a tablet or gel. In another embodiment, the compounds is in liquid form, e.g., a beverage, e.g., a non-alcoholic beverage, e.g., a beverage that does or does not include a natural by product of grapes. The compounds can be made synthetically or by extraction from a natural product.


The compound can be a compound which increases SIRT1 activity, e.g., at least 0.5, 1, 2, 3, 4, 8, 10, or 12-fold, e.g., between 2 and 15-fold.

In certain implementations, compounds of this class, e.g., a trans-stilbene such as resveratrol, are administered in a dosage of at least 0.5, 1, 5, 10, 20, 50, or 100 mg per day to a subject, e.g., a human subject. The dosage can be provided in one or more boluses.

Exemplary Inhibitors of SIRT1 Activity

Exemplary inhibitors of SIRT1 activity include Compound A3 (8,9-dihydroxy-6H-(1)benzofuro[3,2-c]chromen-6-one), Compounds M15 (1-[(4-methoxy-2-nitro-phenylimino)-methyl]-naphthalene-2-ol) and Sirtinol (2-[(2-hydroxy-naphthalen-1-ylmethylene)-amino]-N-(1-phenyl-ethyl)-benzamide). Such compounds are available, e.g., from ChemBridge or can be synthesized. See, e.g., Grozinger et al. (2001) *J. Biol. Chem.*, Vol. 276, Issue 42, 38837-3884.


Additional exemplary compounds are described in WO 03/046207. Some exemplary compounds have the structure of Formula V:



In Formula V, the letter X is a member selected from the group consisting of O and S. The symbols  $L^1$  and  $L^2$  each represent members independently selected from the group consisting of O, S, ethylene and propylene, substituted with 0-2 R groups, wherein exactly one of the symbols  $L^1$  and  $L^2$  represents a member selected from the group consisting of O and S. Each instance of the letter R of symbols  $L^1$  and  $L^2$  independently represents a member selected from the group consisting of  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl and  $-CO_2R^4$ . The symbols  $R^1$  and  $R^2$  each represent members independently selected from the group consisting of hydrogen,  $C_{1-6}$ alkoxy,  $C_{0-6}$ alkoxy-aryl and hydroxy. Alternatively, the symbols  $R^1$  and  $R^2$  are taken together with the carbons to which they are attached to form a six-membered lactone ring.

The symbol  $R^3$  represents a member selected from the group consisting of hydrogen,  $C_{1-6}$ alkyl, aryl,  $-OR^4$ ,  $-NR^4R^4$ ,  $-CO_2R^4$ ,  $-C(O)R^4$ ,  $-C(O)NR^4R^4$ ,  $-CN$ ,  $-NO_2$  and halogen. Each instance of the symbol  $R^4$  independently represents a member selected from the group consisting of hydrogen and  $C_{1-6}$ alkyl.

The compound of Formula V can have the following structure:




In this case, the symbol  $R^1$  is a member selected from the group consisting of hydrogen,  $C_{1-6}$ alkoxy and  $C_{0-6}$ alkoxy-aryl; the symbol  $R^2$  is a member selected from the group consisting of hydrogen and hydroxy; the symbol  $R^3$  is a member selected from the group consisting of hydrogen and  $-OR^4$ ; and the symbol  $R^4$  is  $C_{1-6}$ alkyl.


In another variation, the symbol  $R^1$  is a member selected from the group consisting of  $C_{1-6}$ alkoxy,  $C_{0-6}$ alkoxy-aryl and hydroxy. For example, the symbol  $R^1$  is a member selected from the group consisting of hydroxy, methoxy and benzyloxy. In another preferred embodiment, the term aryl is a member selected from the group consisting of phenyl and naphthyl.

Another exemplary compound has the structure of Formula VI:


VI



In Formula VI, the symbol  $R^a$  is a member selected from the group consisting of hydrogen,  $C_{1-6}$ alkyl, aryl,  $-OR^e$ ,  $-NR^eR^e$ ,  $-CO_2R^e$ ,  $-C(O)R^e$ ,  $-C(O)NR^eR^e$ ,  $-CN$ ,  $-NO_2$  and halogen, while the symbol  $R^b$  is a member selected from the group consisting of:



In the components above, the symbol  $X^a$  can be O, S, or  $NR^e$ . The symbol  $R^c$  can be hydrogen,  $C_{1-6}$ alkyl and aryl optionally substituted with a hydrogen,  $C_{1-6}$ alkyl, aryl, -Ore, - $NR^eR^e$ , -CN, -NO<sub>2</sub> or halogen. The symbol  $R^d$  can be hydrogen,  $C_{1-6}$ alkyl, aryl, -Ore, - $NR^eR^e$ , or halogen. Each instance of the symbol  $R^e$  can be independently hydrogen or  $C_{1-6}$ alkyl. In one embodiment, a compound of Formula VI has the following structure



### Sirtuin Modulating Nucleic Acids

A sirtuin modulator can be a siRNA, anti-sense RNA, or a ribozyme, which can decreases the expression of the sirtuin. In some aspects, a cell or subject can be treated with a compound that modulates the expression of a gene, e.g., a nucleic acid which modulates, e.g., decreases, expression of a polypeptide which inhibits a sirtuin. Such approaches include oligonucleotide-based therapies such as RNA interference, antisense, ribozymes, and triple helices.

Gene expression can be modified by gene silencing using double-strand RNA (Sharp (1999) *Genes and Development* 13: 139-141). RNAi, otherwise known as double-stranded RNA interference (dsRNAi) or small interfering RNA (siRNA), has been extensively documented in a number of organisms, including mammalian cells, the nematode *C. elegans* (Fire, A., et al, *Nature*, 391, 806-811, 1998).

dsRNA can be delivered to cells or to an organism to antagonize a sirtuin or other protein described herein. For example, a dsRNA that is complementary to a SIRT1 nucleic acid can silence protein expression of SIRT1. The dsRNA can include a region that is complementary to a coding region of a SIRT1 nucleic acid, e.g., a 5' coding region, a region encoding a sirtuin core domain, a 3' coding region, or a non-coding region, e.g., a 5' or 3' untranslated region. dsRNA

can be produced, e.g., by transcribing a cassette (in vitro or in vivo) in both directions, for example, by including a T7 promoter on either side of the cassette. The insert in the cassette is selected so that it includes a sequence complementary to the SIRT1 nucleic acid. The sequence need not be full length, for example, an exon, or between 19-50 nucleotides or 50-200  
5 nucleotides. The sequence can be from the 5' half of the transcript, e.g., within 1000, 600, 400, or 300 nucleotides of the ATG. See also, the HISCRIBETM RNAi Transcription Kit (New England Biolabs, MA) and Fire, A. (1999) Trends Genet. 15, 358-363. dsRNA can be digested into smaller fragments. See, e.g., US Patent Application 2002-0086356 and 2003-0084471.

In one embodiment, an siRNA is used. siRNAs are small double stranded RNAs  
10 (dsRNAs) that optionally include overhangs. For example, the duplex region is about 18 to 25 nucleotides in length, e.g., about 19, 20, 21, 22, 23, or 24 nucleotides in length. Typically, the siRNA sequences are exactly complementary to the target mRNA. It may also be possible to agonize activity of a sirtuin by using an siRNA to inhibit a negative regulator of the sirtuin.

Double-stranded inhibitory RNA can also be used to selectively reduce the expression of  
15 one allele of a gene and not the other, thereby achieving an approximate 50% reduction in the expression of a sirtuin antagonist polypeptide. See Garrus *et al.* (2001), *Cell* 107(1):55-65.

"Ribozymes" are enzymatic RNA molecules which cleave at specific sites in RNA. Ribozymes that can specifically cleave nucleic acids that encode or that are required for the expression of sirtuins may be designed according to well-known methods.

## 20 Antibodies

Immunoglobulins can also be produced that bind to a sirtuin or a sirtuin binding partner (e.g., a transcription factor that interacts with a sirtuin). For example, an immunoglobulin can bind to a sirtuin and prevent sirtuin enzymatic activity or an interaction between a sirtuin and a sirtuin binding partner (e.g., NCoR or PGC1). In a preferred embodiment, the immunoglobulin  
25 is human, humanized, deimmunized, or otherwise non-antigenic in the subject.

An immunoglobulin can be, for example, an antibody or an antigen-binding fragment thereof. As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides that include one or more immunoglobulin variable domain sequences. A typical immunoglobulin includes at least a heavy chain immunoglobulin variable domain and a  
30 light chain immunoglobulin variable domain. An immunoglobulin protein can be encoded by immunoglobulin genes. The recognized human immunoglobulin genes include the kappa,

generating immunoglobulin ligands include phage display (e.g., as described in U.S. 5,223,409 and WO 92/20791).

#### Artificial Transcription Factors

5        Artificial transcription factors can also be used to regulate genes that are regulated by SIRT1, NCoR, PGC1, or PPAR-gamma. For example, an artificial transcription factor that has the binding specificity of PPAR-gamma can be used to substitute for or augment PPAR-gamma function. For example, the artificial transcription factor (e.g., that includes one or more zinc  
10        finger domains) can be engineered to bind to a nucleic acid sequence recognized by PPAR-gamma, e.g., TTGCCCTTG or TCACCCTTG.

      The protein can be designed or selected from a library. The protein can include one or more zinc finger domains. For example, the protein can be prepared by selection in vitro (e.g., using phage display, U.S. 6,534,261) or in vivo, or by design based on a recognition code (see, e.g., WO 00/42219 and U.S. 6,511,808). See, e.g., Rebar et al. (1996) *Methods Enzymol*  
15        267:129; Greisman and Pabo (1997) *Science* 275:657; Isalan et al. (2001) *Nat. Biotechnol* 19:656; and Wu et al. (1995) *Proc. Nat. Acad. Sci. USA* 92:344 for, among other things, methods for creating libraries of varied zinc finger domains.

      Optionally, the zinc finger protein can be fused to a transcriptional regulatory domain, e.g., an activation domain to activate transcription or a repression domain to repress  
20        transcription. The zinc finger protein can itself be encoded by a heterologous nucleic acid that is delivered to a cell or the protein itself can be delivered to a cell (see, e.g., U.S. 6,534,261. The heterologous nucleic acid that includes a sequence encoding the zinc finger protein can be operably linked to an inducible promoter, e.g., to enable fine control of the level of the zinc finger protein in the cell.

25        Zinc finger proteins or other artificial transcription factors can also be engineered to recruit SIRT1 function. For example, the proteins can be physically associated with a SIRT1-interacting fragment of NCoR, e.g., by a translational fusion, or can be physically associated with a NCoR-interacting fragment of SIRT1. The proteins may bind with an affinity of less than 5 nM, e.g., less than 1 or 0.1 nM. Such fragments of SIRT1 and NCoR are described herein.



### Gene and Cell-based Therapeutics

Nucleic acid molecules (e.g., DNA molecules) that nucleic acid agents for modulating sirtuin function can be inserted into a variety of DNA constructs and vectors for the purposes of gene therapy. Vectors include plasmids, cosmids, artificial chromosomes, viral elements, and  
5 RNA vectors (e.g., based on RNA virus genomes). The vector can be competent to replicate in a host cell or to integrate into a host DNA. Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses.

Examples of vectors include replication defective retroviral vectors, adenoviral vectors and adeno-associated viral vectors. Adenoviral vectors suitable for use by the methods of the  
10 invention include (Ad.RSV.lacZ), which includes the Rous sarcoma virus promoter and the lacZ reporter gene as well as (Ad.CMV.lacZ), which includes the cytomegalovirus promoter and the lacZ reporter gene. Methods for the preparation and use of viral vectors are described in WO 96/13597, WO 96/33281, WO 97/15679, and Trapnell et al., Curr. Opin. Biotechnol. 5(6):617-625, 1994, the contents of which are incorporated herein by reference.

15 A gene therapy vector is a vector designed for administration to a subject, e.g., a mammal, such that a cell of the subject is able to express a therapeutic gene contained in the vector. The therapeutic gene may encode a protein (e.g. SIRT1). The therapeutic gene can also be used to provide a non-coding transcript, e.g., an antisense RNA (e.g., an RNA anti-sense to a sirtuin gene, e.g., a SIRT1 gene, a ribozyme, or a dsRNA).

20 The gene therapy vector can contain regulatory elements, e.g., a 5' regulatory element, an enhancer, a promoter, a 5' untranslated region, a signal sequence, a 3' untranslated region, a polyadenylation site, and a 3' regulatory region. For example, the 5' regulatory element, enhancer or promoter can regulate transcription of the DNA encoding the therapeutic polypeptide or other transcript. The regulation can be tissue specific. For example, the  
25 regulation can restrict transcription of the desired gene to brain cells, e.g., cortical neurons or glial cells; hematopoietic cells; or endothelial cells. Alternatively, regulatory elements can be included that respond to an exogenous drug, e.g., a steroid, tetracycline, or the like. Thus, the level and timing of expression of the therapeutic nucleic acid can be controlled.

Gene therapy vectors can be prepared for delivery as naked nucleic acid, as a component  
30 of a virus, or of an inactivated virus, or as the contents of a liposome or other delivery vehicle. See, e.g., US 2003-0143266 and 2002-0150626. In one embodiment, the nucleic acid is formulated in a lipid-protein-sugar matrix to form microparticles., e.g., having a diameter

between 50 nm to 10 micrometers. The particles may be prepared using any known lipid (e.g., dipalmitoylphosphatidylcholine, DPPC), protein (e.g., albumin), or sugar (e.g., lactose).

The gene therapy vectors can be delivered using a viral system. Exemplary viral vectors include vectors from retroviruses, e.g., Moloney retrovirus, adenoviruses, adeno-associated viruses, and lentiviruses, e.g., Herpes simplex viruses (HSV). HSV, for example, is potentially useful for infecting nervous system cells. See, e.g., US 2003-0147854, 2002-0090716, 2003-0039636, 2002-0068362, and 2003-0104626. The gene delivery agent, e.g., a viral vector, can be produced from recombinant cells which produce the gene delivery system.

A gene therapy vector can be administered to a subject, for example, by intravenous injection, by local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The gene therapy agent can be further formulated, for example, to delay or prolong the release of the agent by means of a slow release matrix. One method of providing a therapeutic agent, is by inserting a gene therapy vector into cells harvested from a subject. The cells are infected, for example, with a retroviral gene therapy vector, and grown in culture. The subject is then replenished with the infected culture cells. The subject is monitored for recovery and for production of the therapeutic polypeptide or nucleic acid.

Cell based-therapeutic methods include introducing a nucleic acid that provides a therapeutic activity operably linked to a promoter into a cell in culture. The therapeutic nucleic acid can provide the desired modulation of SIRT1 activity in a cultured cell, e.g., an increase or decrease in SIRT1 activity to a cell of the adipocyte lineage. Further, it is also possible to modify cells, e.g., stem cells, using nucleic acid recombination, e.g., to insert a transgene, e.g., a transgene that provides a therapeutic activity. The modified stem cell can be administered to a subject. Methods for cultivating stem cells *in vitro* are described, e.g., in US Application 2002-0081724. In some examples, the stem cells can be induced to differentiate in the subject and express the transgene. For example, the stem cells can be differentiated into liver, adipose, or skeletal muscle cells. The stem cells can be derived from a lineage that produces cells of the desired tissue type, e.g., liver, adipose, or skeletal muscle cells.

As used herein, "antisense therapy" refers to administration or *in situ* generation of oligonucleotide molecules or their derivatives which specifically hybridize (e.g., bind) under cellular conditions with the cellular mRNA and/or genomic DNA, thereby inhibiting transcription and/or translation of that gene. In general, antisense therapy refers to the range of

techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences. An antisense construct can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which is complementary to at least a unique portion of the cellular mRNA.

5           Antisense RNA, DNA, and ribozyme molecules may be prepared by any method known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense  
10   RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

          Modifications to nucleic acid molecules may be introduced as a means of increasing  
15   intracellular stability and half-life. Exemplary modifications include the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

#### Gene Expression and Transcript analysis

20           Different aspects of the invention can include evaluating expression of one or more genes described herein (e.g., genes encoding aP2, PPAR-gamma, SIRT1, leptin, adiponectin, resistin, C/EPB and UCP1). Expression of a gene can be evaluated by detecting an mRNA, e.g., the transcript from the gene of interest or detecting a protein, e.g., the protein encoded by the gene of interest.

25           Exemplary methods for evaluating mRNAs include Northern analysis, RT-PCR, microarray hybridization, SAGE, differential display, and monitoring reporter genes. Exemplary methods for evaluating proteins include immunoassays (e.g., ELISAs, immunoprecipitations, Westerns), 2D-gel electrophoresis, and mass spectroscopy. It is possible to evaluate fewer than 100, e.g., less than 20, 10, 5, 4 or 3 different molecular species, e.g., to only evaluate the  
30   expression of the gene of interest, although it is typically useful to include at least one or two controls (e.g., a house keeping gene). It is also possible to evaluate multiple molecular species,

e.g., in parallel, e.g., at least 10, 50, 20, 100, or more different species. See, e.g., the usage of microarrays, e.g. as described below.

One method for comparing transcripts uses nucleic acid microarrays that include a plurality of addresses, each address having a probe specific for a particular transcript. At least one of which is specific for a gene of interest, e.g., a gene encoding p21, PPAR- $\gamma$ , SIRT1, leptin, adiponectin, resistin, C/EPB and UCP1). Such arrays can include at least 100, or 1000, or 5000 different probes, so that a substantial fraction, e.g., at least 10, 25, 50, or 75% of the genes in an organism are evaluated. mRNA can be isolated from a cell or other sample of the organism. The mRNA can be reversed transcribed into labeled cDNA. The labeled cDNAs are hybridized to the nucleic acid microarrays. The arrays are detected to quantitate the amount of cDNA that hybridizes to each probe, thus providing information about the level of each transcript.

Methods for making and using nucleic acid microarrays are well known. For example, nucleic acid arrays can be fabricated by a variety of methods, e.g., photolithographic methods (see, e.g., U.S. Patent Nos. 5,143,854; 5,510,270; and 5,527,681), mechanical methods (e.g., directed-flow methods as described in U.S. Patent No. 5,384,261), pin based methods (e.g., as described in U.S. Pat. No. 5,288,514), and bead based techniques (e.g., as described in PCT US/93/04145). The capture probe can be a single-stranded nucleic acid, a double-stranded nucleic acid (e.g., which is denatured prior to or during hybridization), or a nucleic acid having a single-stranded region and a double-stranded region. Preferably, the capture probe is single-stranded. The capture probe can be selected by a variety of criteria, and preferably is designed by a computer program with optimization parameters. The capture probe can be selected to hybridize to a sequence rich (e.g., non-homopolymeric) region of the nucleic acid. The  $T_m$  of the capture probe can be optimized by prudent selection of the complementarity region and length. Ideally, the  $T_m$  of all capture probes on the array is similar, e.g., within 20, 10, 5, 3, or 2°C of one another. A database scan of available sequence information for a species can be used to determine potential cross-hybridization and specificity problems.

The isolated mRNA from samples for comparison can be reversed transcribed and optionally amplified, e.g., by rtPCR, e.g., as described in (U.S. Patent No. 4,683,202). The nucleic acid can be labeled during amplification, e.g., by the incorporation of a labeled nucleotide. Examples of preferred labels include fluorescent labels, e.g., red-fluorescent dye Cy5 (Amersham) or green-fluorescent dye Cy3 (Amersham), and chemiluminescent labels, e.g.,

as described in U.S. Patent No. 4,277,437. Alternatively, the nucleic acid can be labeled with biotin, and detected after hybridization with labeled streptavidin, e.g., streptavidin-phycoerythrin (Molecular Probes).

The labeled nucleic acid can be contacted to the array. In addition, a control nucleic acid or a reference nucleic acid can be contacted to the same array. The control nucleic acid or reference nucleic acid can be labeled with a label other than the sample nucleic acid, e.g., one with a different emission maximum. Labeled nucleic acids can be contacted to an array under hybridization conditions. The array can be washed, and then imaged to detect fluorescence at each address of the array.

A general scheme for producing and evaluating profiles can include the following. The extent of hybridization at an address is represented by a numerical value and stored, e.g., in a vector, a one-dimensional matrix, or one-dimensional array. The vector  $x$  has a value for each address of the array. For example, a numerical value for the extent of hybridization at a first address is stored in variable  $x_a$ . The numerical value can be adjusted, e.g., for local background levels, sample amount, and other variations. Nucleic acid is also prepared from a reference sample and hybridized to an array (e.g., the same or a different array), e.g., with multiple addresses. The vector  $y$  is constructed identically to vector  $x$ . The sample expression profile and the reference profile can be compared, e.g., using a mathematical equation that is a function of the two vectors. The comparison can be evaluated as a scalar value, e.g., a score representing similarity of the two profiles. Either or both vectors can be transformed by a matrix in order to add weighting values to different nucleic acids detected by the array.

The expression data can be stored in a database, e.g., a relational database such as a SQL database (e.g., Oracle or Sybase database environments). The database can have multiple tables. For example, raw expression data can be stored in one table, wherein each column corresponds to a nucleic acid being assayed, e.g., an address or an array, and each row corresponds to a sample. A separate table can store identifiers and sample information, e.g., the batch number of the array used, date, and other quality control information.

Other methods for quantitating mRNAs include: quantitative RT-PCR. In addition, two nucleic acid populations can be compared at the molecular level, e.g., using subtractive hybridization or differential display to evaluate differences in mRNA expression, e.g., between a cell of interest and a reference cell.

These and other aspects of the invention are described further in the following examples, which are illustrative and in no way limiting.

#### EXAMPLE 1: 3T3-L1 Murine WAT SIRT1 Expression

5 We found that SIRT1 is expressed in murine subcutaneous inguinal WAT (hips), epididymal WAT (abdominal cavity), and retroperitoneal WAT (abdominal cavity).

Two SVB male mice, aged 19 weeks, (average weight=37.8 g +/-0.4 g) were maintained in a temperature-controlled (25 °C) facility with a strict 12 h light/dark cycle and were given free access to food and water. The standard rodent chow was obtained from Purina (diet # 5001; 10 Ralston, Purina) and contained 23 % protein, 4.5 % fat, 6 % fiber, 8 % ash, and 56 % carbohydrate. Tissues from the mice were harvested in a non-fasting condition according to the MIT Animal Care Committee.

Samples of inguinal, epididymal, and retroperitoneal WAT were taken from the mice and subjected to Western Blot analyses using actin as a control to determine if SIRT1 was expressed 15 in each of the three samples. Protein samples were prepared from WAT adipocytes by lysis in RIPA buffer supplemented with protease inhibitors. Twenty micrograms of protein were resolved in 9% SDS-PAGE and transferred to nitrocellulose membranes. SIRT1 protein was probed with mSIRT1 antibody (Upstate Inc.) and detected by ECL (Amersham). An actin antibody (Santa Cruz) was used in the Western Blot as a control. Pronounced SIRT1 expression 20 levels were detected in each of the three WAT samples.

#### EXAMPLE 2: SIRT1 is induced in conditions of lipolysis

Levels of SIRT1 expression in WAT of six SVB male mice, age 19 weeks, (average weight=37.8 g ± 0.4 g) were determined under the following conditions. Two mice were sacrificed in a control condition after having been fed and kept at room temperature consistent 25 with conditions of Example 1. Two mice were sacrificed after an overnight fast at room temperature to stimulate lipolysis. Two mice were sacrificed after having been allowed to feed during overnight exposure to an average temperature of 4°C to stimulate fat release (lipolysis) and thermogenesis. Samples of epididymal WAT were taken from each mouse and subject to Western Blot analyses using actin as a control as in Example 1. SIRT1 protein

expression levels were highest in the mice that had stimulated fat release. SIRT1 expression was thereby shown to be positively associated with a decrease in fat content in WAT.

### EXAMPLE 3: 3T3-L1 SIRT1 Expression Patterns

#### 1. Materials and Methods.

##### 3T3-L1 Mouse Fibroblasts.

The 3T3-L1 mouse fibroblasts used in this example, and in Examples 4-10 hereinafter, were prepared in accordance with standard protocol as follows. 3T3-L1 cells (ATCC CL-173, Rockville, MD) were grown to confluence (day 0) in medium A (Dulbecco's modified Eagle's Medium with 10% fetal calf serum, 100 units/ml penicillin, and 100µg/ml streptomycin).

Confluent cell were incubated in medium A containing 2 µM insulin, 1 µM dexamethasone, and 0.25 mM isobuthyl methyl xanthine for two days. Thereafter, confluent fibroblasts were treated with insulin for five days and at the end of such treatment were in a condition for functional study. Adipogenesis was evaluated by analysis of the expression of adipocyte-specific markers and by staining of lipids with Oil Red O (Chawla & Lazar, 1994, Proc. Natl. Acad. Sci. USA 91, 1786-1790).

#### 2. SIRT1 Expression Patterns.

Western Blot analyses of 3T3-L1 fibroblast SIRT1 expression using antibodies and actin control as in Example 1 were performed at days 0 through 5 of the differentiation described above and, SIRT1 expression was detected at confluence (day 0; before hormone addition), reached peak expression at day 5, and decreased thereafter. This finding established that SIRT1 protein is expressed endogenously by preadipocytes and that hormonally-induced adipogenesis inhibited SIRT1 protein expression.

### EXAMPLE 4: Upregulation of SIRT1 Inhibits 3T3-L1 Adipogenesis

#### 1. Materials and Methods.

##### Plasmids and Vectors

The plasmids pBABE, Jay P. Morgenstern, Hartmut Land, Nucleic Acids Research, Vol. 18:3587, 1990, and pSUPER (OligoEngine; www.oligoengine.com) were used to transform: (1) certain 3T3-L1 fibroblasts described hereinafter in this example, and (2) certain 3T3-L1 fibroblasts described hereinafter in examples 5-10. The plasmid pBABE was used as a control

vector and as a component of a vector comprising mouse mSIRT1 cDNA complementary to human SIRT1 mRNA (GenBank Accession No.: AF214646) (SEQ ID NO: 2).

The plasmid pSUPER was used as a control vector and as a component of vectors comprising either mSIRT1 RNAiWT of the sequence

5 5'-GATGAAGTTGACCTCCTCA-3' (SEQ ID NO: 24),

which interferes with SIRT1 expression, or SIRT1 mRNAi-mut of the sequence

5'-GATGAAGTCGACCTCCTCA-3' (SEQ ID NO: 25),

which is a mutation of mSIRT1 RNAiWT (SEQ ID NO: 24). SIRT1 mRNAi-mut has no effect on SIRT1 expression. The referenced RNAi sequences are common to human, mouse and rat

10 SIRT1 mRNA.

## 2. 3T3-L1 Fibroblast Transformation.

3T3-L1 fibroblasts were transformed through standard techniques with either a pBABE control vector ("control fibroblasts") or a vector comprising pBABE -mSIRT1 cDNA ("mSIRT1 cDNA fibroblasts"). Western Blot analyses of SIRT1 expression by the control and mSIRT1

15 cDNA fibroblasts were performed using antibodies and actin control as in Example 1.

mSIRT1 cDNA fibroblasts showed levels of SIRT1 expression that were markedly higher than those of the control fibroblasts. Oil Red O staining of the control and mSIRT1 cDNA fibroblasts showed a marked inhibition in differentiation of the mSIRT1 cDNA fibroblasts when compared to the level of differentiation of the control fibroblasts, establishing that upregulation

20 of SIRT1 inhibited adipogenesis.

## EXAMPLE 5: Downregulation of SIRT1 Enhances 3T3-L1 Adipogenesis

3T3-L1 fibroblasts were transformed with either a pSUPER control vector ("control fibroblasts"), a vector comprising pSUPER- mSIRT1 RNAi WT (SEQ ID NO: 24) ("mSIRT1

25 RNAi WT fibroblasts"), or pSUPER- mSIRT1 RNAiMUT (SEQ ID NO: 25), ("mSIRT1 RNAiMUT fibroblasts"). Western Blot analyses of SIRT1 expression by the control, mSIRT1 RNAi WT, and mSIRT1 RNAiMUT fibroblasts were performed using antibodies and actin controls as in Example 1.

mSIRT1 RNAiMUT fibroblasts showed levels of SIRT1 expression that were

30 comparable with those of the control fibroblasts, and which were substantially higher than those of the mSIRT1 RNAi WT fibroblasts. Oil Red O staining of the control, mSIRT1 RNAi WT,



and mSIRT1 RNAiMUT fibroblasts showed a marked increase in differentiation of the mSIRT1 RNAi WT fibroblasts when compared to the level of differentiation of the control and mSIRT1 RNAiMUT fibroblasts.

These results established that downregulating SIRT1 enhances adipogenesis.

5    EXAMPLE 6: Upregulating SIRT1 Decreases 3T3-L1 Lipolysis Capacity and Downregulating SIRT1 Increases 3T3-L1 Lipolysis Capacity

The amount of fat generated by adipocyte lipolysis should be proportional to the fat content of the adipocyte. In the experiment of this example, four samples of 3T3-L1 fibroblasts were prepared essentially as in Example 3 (except for the change in protocol noted below), and transformed as in Examples 4 and 5 with either pBABE control vector ("pBABE control fibroblasts"), pBABE -mSIRT1 cDNA ("mSIRT1 cDNA fibroblasts"), pSUPER control vector ("pSUPER control fibroblasts"), or pSUPER- mSIRT1 RNAi WT (SEQ ID NO: 24) ("mSIRT1 RNAi WT fibroblasts").

10    In the experiment of this example, differentiated 3T3-L1 fibroblasts were used at day 7 for study and the fibroblast growth medium was replaced by a Ringers Krebs's buffer which did not contain any fatty acids, but which did contain isoproterenol ( $10^{-5}$ M) to induce 3T3-L1 fibroblast lipolysis. Fatty acid concentrations in each of the four samples were measured four hours later and the results of these measurements are shown in FIG. 1. Six wells were used for each of the four samples. Results from the different wells were averaged.

20    Lipolysis levels for the mSIRT1 cDNA fibroblasts were noticeably lower than those of the control (0.297 mM compared to 0.627 mM). Lipolysis in mSIRT1 RNAi WT fibroblasts, in contrast, was higher than in their respective control (0.727 mM compared to 0.508 mM). These observations established that upregulating SIRT1 expression in 3T3-L1 fibroblasts decreased 3T3-L1 lipolysis and that downregulating SIRT1 expression in 3T3-L1 fibroblasts increased 25    3T3-L1 lipolysis.

EXAMPLE 7: Upregulating SIRT1 Inhibits 3T3-L1 Leptin Production

The amount of leptin produced by an adipocyte should be proportional to the fat content of the adipocyte. In the experiment of this example, four samples (prepared in sixplicate) of 3T3-L1 fibroblasts were prepared essentially as in Example 3 (except for the change in protocol noted below), and transformed as in Examples 4 and 5 with either pBABE control vector

30

(“pBABE control fibroblasts”), pBABE -mSIRT1 cDNA (“mSIRT1 cDNA fibroblasts”), pSUPER control vector (“pSUPER control fibroblasts”), or pSUPER– mSIRT1 RNAi WT (SEQ ID NO: 24) (“mSIRT1 RNAi WT fibroblasts”).

Transformed and differentiated 3T3-L1 fibroblasts were used at day 7 for study and the fibroblast growth medium was replaced by a Ringers Kreb’s buffer which did not contain any fatty acids. Leptin concentration in each of the four samples was measured twenty-four hours later. Leptin levels for the mSIRT1 cDNA fibroblasts were noticeably lower than those of either the two controls or mSIRT1 RNAi WT fibroblasts. Each sample was compared against its own control. This observation established that upregulating SIRT1 inhibited 3T3-L1 leptin production.

#### EXAMPLE 8: Upregulating SIRT1 Inhibits Synthesis of Adipogenesis Transcription Factors

3T3-L1 fibroblasts were transformed through standard techniques with either a pBABE control vector (“control fibroblasts”) or a vector comprising pBABE -mSIRT1 cDNA (“mSIRT1 cDNA fibroblasts”) in accordance with Example 4. Protein and total RNA was extracted from the differentiated cells. Western Blot analyses of levels of the PPAR $\gamma$  and C/EBP $\alpha$  transcription factors present in the protein extracts from the control and mSIRT1 cDNA fibroblasts were performed using antibodies and actin control as in Example 1. Lower levels of PPAR $\gamma$  were observed in the protein and total RNA extracted from the mSIRT1 cDNA fibroblasts than in the samples extracted from the control fibroblasts.

Semi-quantitative RT-PCR analysis was also conducted to determine levels of the C/EBP $\beta$ , C/EBP $\delta$ , C/EBP $\alpha$ , PPAR $\gamma$  transcription factors and aP2 (PPAR $\gamma$  target gene) present in the protein and total RNA extracted from the control and mSIRT1 cDNA fibroblasts. In this analysis, GAPDH was used as an internal control for cDNA input in the PCR. Upregulation of SIRT1 decreased levels of all of the assayed transcription factors except C/EBP $\beta$ . This finding indicated that SIRT1 may target C/EBP $\beta$  and thereby reduce production of the other transcription factors in the C/EBP $\beta$  transcriptional cascade.

#### EXAMPLE 9: Downregulating SIRT1 Enhances Levels of Adipogenesis Transcription Factors

3T3-L1 fibroblasts were transformed through standard techniques with either a pSUPER control vector (“control fibroblasts”) or a vector comprising pSUPER –mSIRT1 RNAiWT (SEQ ID NO: 1) (“mSIRT1 RNAiWT fibroblasts”) in accordance with Example 5. Protein and total

RNA was extracted from the differentiated cells. Western Blot analyses of levels of the PPAR $\gamma$  and C/EBP $\alpha$  transcription factors present in the protein extracts were performed using antibodies and actin control as in Example 1. Higher levels of PPAR $\gamma$  were observed in the protein and total RNA extracted from the mSIRT1RNAiWT fibroblasts than in the samples extracted from the control fibroblasts.

Semi-quantitative RT-PCR analysis was also conducted to determine levels of the C/EBP $\beta$ , C/EBP $\delta$ , C/EBP $\alpha$ , PPAR $\gamma$ , and aP2 (PPAR $\gamma$  target gene) present in the protein and total RNA extracted from the control and mSIRT1RNAiWT fibroblasts. In this analysis, GAPDH was used as an internal control for cDNA input in the PCR. Downregulation of SIRT1 was associated with increased levels of all of the assayed transcription factors except C/EBP $\beta$ . This finding also indicates that SIRT1 may target C/EBP $\beta$  and thereby reduce production of the other transcription factors in the C/EBP $\beta$  transcriptional cascade.

#### EXAMPLE 10: SIRT1 Does Not Interfere With C/EBP $\beta$ Translocation

SIRT1 may target C/EBP $\beta$  to reduce production of the other transcription factors in the C/EBP $\beta$  transcriptional cascade by either interfering with C/EBP $\beta$ 's translocation to the fibroblast nucleus, or by binding to C/EBP $\beta$  in the nucleus and thereby reducing C/EBP $\beta$  transcriptional activity. To test the first theory, mouse embryonic fibroblasts (MEF's) that were either wild-type (WT) or knock-out (KO) for the SIRT1 gene were differentiated into adipocytes using the techniques described in Example 3. The nuclei of these cells were stained at confluence and prior to hormonal treatment (DAPI, in blue); the cells were also stained for C/EBP $\beta$  at the same time. C/EBP $\beta$  was observed to be diffused in the cell to the same extent in the WT and KO MEF's.

Essentially the same protocol was applied a second time, except that the cells were stained four hours after stimulation with hormonal cocktail, at which point C/EBP $\beta$  was present in the nucleus. C/EBP $\beta$  was observed to be present to the same extent in the nuclei of the WT and KO MEF's, indicating that SIRT1 does not interfere with C/EBP $\beta$  translocation.

#### EXAMPLE 11: SIRT1 Modulates Intracellular Triglyceride Concentration.

Fibroblast intracellular triglyceride ("TG") levels should decrease upon inhibition of fibroblast differentiation resulting from overexpression of SIRT1. Consistent with Examples 4

and 5, it should be possible to measure in a quantitative manner the amount of intracellular triglycerides that can be observed by Oil Red O staining. To do so, 3T3-L1 fibroblasts were prepared as in Example 3 and transformed as in Examples 4 and 5 with either pBABE control vector ("pBABE control fibroblasts"), pBABE -mSIRT1 cDNA ("mSIRT1 cDNA fibroblasts"), pSUPER control vector ("pSUPER control fibroblasts"), or pSUPER- mSIRT1 RNAi WT (SEQ ID NO: 24) ("mSIRT1 RNAi WT fibroblasts").

At day 7, the cells were lysed in methanol and neutral lipids were extracted by the Folch method and resuspended in isopropanol. Triglyceride levels were measured by calorimetric methods using a commercial kit (Trig/GB #450032, Roche Diagnostics, Indianapolis, IN). Six wells per condition were analyzed.

TG levels for the mSIRT1 cDNA fibroblasts were noticeably lower than those of the control. TG levels in mSIRT1 RNAi WT fibroblasts, in contrast, were higher than in their respective control. These observations established that upregulating SIRT1 expression in 3T3-L1 fibroblasts decreased 3T3-L1 TG concentration levels and that downregulating SIRT1 expression in 3T3-L1 fibroblasts increased 3T3-L1 TG concentration levels.

EXAMPLE 12: SIRT1 represses C/EBP $\alpha$ -induced leptin transcription in a dose-dependent manner

The assay described in this example is useful in determining whether a compound that mimics or modulates the activity of a sirtuin affects leptin transcription induced by transcription factors such as the C/EBP transcription factors. For example, the assay is useful in determining whether a compound that mimics or modulates the activity of SIRT1 also represses C/EBP $\alpha$  - induced leptin transcription. The assay also provides a good model to evaluate the activity of a sirtuin (e.g., SIRT1) *in vivo*.

All cells were transfected with a vector containing 6.5 kb of the leptin promoter cloned upstream of the luciferase gene. Approximately one-half of the cells were co-transfected with either or both of a vector comprising P<sub>v</sub>-Sport-C/EBP $\alpha$  or with different doses of a pCMV plasmid containing the full-length human SIRT1 sequence. See, e.g., Hollenberg et al., *J Biol Chem.* 1997 Feb 21;272(8):5283-90). The next day, all cells were harvested and luciferase activity was measured in all cells.

Observed levels of luciferase activity in the transiently transfected cells should have been proportional to the amount of leptin produced by the cell through binding of transcription factors

to its promoter. Inhibition of a leptin-related transcription factor as a result of administering an active agent to the transiently transfected cells should have been observed through detection of lower luciferase levels indicative of decreased leptin expression. SIRT1 repressed C/EBP $\alpha$  - induced leptin transcription in a dose-dependent manner. See FIG. 2 or the Table below (Table 1).

Table 1

ng of hSIRT1	Control	C/EBP $\alpha$
none	1600	68538
100	722	28054
250	352	17584
500	253	46

### Example

This disclosure incorporates by reference Picard et al. (2004) *Nature* doi:10.103/nature02583, *Nature*. 2004 Jun 17;429(6993):771-6.

SIRT1 activates a critical component of calorie restriction in mammals; that is, fat mobilization in white adipocytes. Upon food withdrawal Sirt1 protein binds to and represses genes controlled by the fat regulator PPAR- $\gamma$  (peroxisome proliferator-activated receptor-gamma), including genes mediating fat storage. Sirt1 represses PPAR- $\gamma$  by docking with its cofactors NCoR (nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptors). Mobilization of fatty acids from white adipocytes upon fasting is compromised in Sirt1 $^{+/-}$  mice. Repression of PPAR-gamma by Sirt1 is also evident in 3T3-L1 adipocytes, where overexpression of Sirt1 attenuates adipogenesis, and RNA interference of Sirt1 enhances it. In differentiated fat cells, upregulation of Sirt1 triggers lipolysis and loss of fat. As a reduction in fat is sufficient to extend murine lifespan, our results provide a possible molecular pathway connecting calorie restriction to life extension in mammals.

We evaluated whether the mammalian Sir2 orthologue, Sirt1, senses nutrient availability in WAT and mediates corresponding effects on fat accumulation. To probe whether Sirt1 may actually modulate adipogenesis, we used mouse 3T3-L1 fibroblasts as an in vitro model. Adipogenesis in these cells is promoted by the nuclear receptor PPAR- $\gamma$ . Upon induction of

adipogenesis by insulin, dexamethasone and isobutylmethylxanthine, we observed that Sirt1 protein levels increased and peaked at day 5 after hormonal stimulation. Sirt1 expression in 3T3-L1 cells was then modified through retroviral infection with either pBABE-Sirt1 or pSUPER-Sirt1 RNA interference (RNAi) for overexpression (tenfold) or downregulation (sevenfold) of the Sirt1 gene, respectively. 3T3-L1 cells undergo one or two mitotic divisions after induction as a prelude to terminal differentiation. This occurred normally in cells that overexpressed or underexpressed Sirt1 as evaluated by 5-bromodeoxyuridine (BrdU) incorporation. However, compared with cells infected with the control vector, stable 3T3-L1 cells overexpressing Sirt1 accumulated much less fat as determined by Oil red O staining after 7 days of differentiation or direct measurement of intracellular triglyceride content. In contrast, downregulation of Sirt1 expression resulted in a significant increase in triglyceride accumulation after differentiation. These results indicate that Sirt1 acts a negative modulator of adipogenesis in the 3T3-L1 model.

We differentiated virally transduced 3T3-L1 cells in the absence of insulin but with rosiglitazone, a very potent, selective PPAR-gamma agonist that acts downstream of the insulin pathway. Although rosiglitazone treatment promoted adipogenesis to a greater extent than the regular differentiation cocktail, it did not alter the phenotypes of cells with increased or decreased levels of Sirt. Accordingly, Sirt1 affects regulators that act downstream of insulin/IGF-1 signalling.

Differentiation of 3T3-L1 fibroblasts increases levels of the transcription factor C/EBP- $\delta$ , which stimulates the expression of PPAR-gamma and C/EBP- $\alpha$ . PPAR-gamma induces expression of target genes, such as the fatty-acid-binding protein Ap2 (also known as FABP). Moreover, PPAR-gamma can maintain expression of itself, perhaps by binding to PPAR-gamma sites in the promoter of the PPAR-gamma gene (*Pparg*). To gain an insight into the mechanisms by which Sirt1 represses fat accretion, we measured protein and messenger RNA expression of key factors in the transcriptional program in the different virus-infected 3T3-L1 adipocytes. We observed a reduction in C/EBP- $\alpha$ , C/EBP- $\delta$  and Ap2 mRNA, but not C/EBP- $\beta$ , upon Sirt1 overexpression. A reduction in PPAR-gamma and C/EBP-alpha was also observed by western blotting. In contrast, cells in which Sirt1 had been downregulated showed higher levels of PPAR- $\gamma$ , C/EBP- $\delta$ , C/EBP-alpha and Ap2. Thus, Sirt1 functions to reduce expression of genes that drive white adipocyte differentiation and fat storage.

We fully differentiated 3T3-L1 cells and subsequently (12 days after induction) applied the Sirt1 activator resveratrol over a wide range of concentrations. After staining the cells for fat content, a strong reduction in fat was observed at 50 and 100  $\mu$ M resveratrol. The loss of fat was due to activation of Sirt1, because there was no drug-mediated fat reduction in cells in which  
5 Sirt1 levels were knocked down. To validate further these visual results, we measured triglyceride content and free fatty acid (FFA) release in these cells. Triglyceride content was reduced and release of FFA was stimulated by resveratrol in the control cells, but not in the Sirt1 knockdown cells. These findings strongly suggest that upregulation of Sirt1 stimulates fat mobilization in fully differentiated 3T3-L1 adipocytes.

10 To determine whether Sirt1 stimulates fat mobilization in bona fide adipocytes, we cultured primary rat white adipocytes and activated fat mobilization with the known  $\beta$ -adrenergic inducer adrenalin. Addition of resveratrol greatly stimulated the release of FFA triggered by adrenalin, consistent with the findings in the 3T3-L1 cells. In a converse experiment using these rat adipocytes, we addressed whether inhibition of Sirt1 would blunt the mobilization of fat by  
15 adrenalin. Addition of the known Sirt1 inhibitor nicotinamide<sup>16</sup> indeed reduced the release of FFA triggered by adrenalin. The above findings indicate that Sirt1 not only represses the differentiation program of adipocytes, but also activates the mobilization of fat in fully differentiated cells.

Sirt1 is an NAD-dependent deacetylase that can repress activity of p53 and forkhead  
20 proteins. Repression of adipogenesis and fat retention in 3T3-L1 cells by Sirt1 might be explained by inhibition of another transcription factor, PPAR- $\gamma$ , as its activity is crucial for differentiation and maintenance of adipocytes. Thus, we determined by chromatin immunoprecipitation (ChIP) assays whether Sirt1 binds to PPAR-gamma sites in the promoters of the *Ap2* and *Pparg* genes. In 3T3-L1 cells, Sirt1 and PPAR-gamma were both bound to  
25 similar promoter regions of *Ap2* and *Pparg*. The interaction of Sirt1 with both promoter sequences was stronger in Sirt1-overexpressing cells and was lost in Sirt1 knockdown cells. Binding of Sirt1 to a control DNA region 2.5 kilobases (kb) upstream of the PPAR-gamma site near *Pparg* was not observed. Furthermore, luciferase reporter assays showed that Sirt1 repressed transactivation by PPAR-gamma. These findings indicate that Sirt1 and PPAR-gamma bind to  
30 the same DNA sequences and suggest that Sirt1 is a co-repressor of PPAR- $\gamma$ .

To gain further evidence that Sirt1 is a PPAR-gamma co-repressor, we next determined whether the two proteins interact. Sirt1 was detected in PPAR-gamma immunoprecipitates from differentiated 3T3-L1 adipocytes. The PPAR-gamma cofactor NCoR20 was also co-immunoprecipitated by anti-Sirt1 antiserum but not by pre-immune serum. Glutathione S-transferase (GST) pull-down experiments revealed that two NCoR fragments interact with Sirt1: repression domain 1 (RD1) and the CBF/Su(H) interaction domain. Reciprocally, NCoR RD1 was found to interact with the amino-terminal region of Sirt1 (amino acids 1–214, GST-Sirt1(Nt)), and the CBF1/Su(H) interaction domain of NCoR interacts with the homology domain of Sirt1 (amino acids 214–541, GST-Sirt1(SHD)). In analogous experiments, GST pull-down assays revealed an interaction between the Sirt1 homology domain and SMRT.

The interaction between Sirt1 and NCoR (and SMRT) suggests that Sirt1 represses PPAR-gamma activity by docking with the cofactors. Consistent with this, ChIP assays revealed that NCoR also binds to known PPAR-gamma sites of promoters of adipogenic genes. To test the possibility that Sirt1 functionally represses PPAR-gamma by means of NCoR, we infected Sirt1-overexpressing 3T3-L1 fibroblasts with an NCoR RNAi virus. Western blots showed that doubly infected cells overexpressed Sirt1 and underexpressed NCoR. As expected, overexpression of Sirt1 in the absence of the NCoR RNAi virus prevents fat accretion. In contrast, this reduction was largely prevented on simultaneous treatment with NCoR RNAi demonstrating that NCoR is required for repression of fat accumulation by Sirt1.

To test for a role of Sirt1 in fat mobilization in vivo, we first determined whether Sirt1 was expressed in WAT in mice. Sirt1 was found in all white adipose depots examined, with no notable distribution differences. Next, to probe for an in vivo function, we used mice with germline mutations in the Sirt1 gene. Unfortunately, the total absence of Sirt1 in mice (Sirt1<sup>-/-</sup>) results in a high degree of post-natal lethality and other severe phenotypes, precluding their use in this study. Therefore, we compared wild type to Sirt1<sup>+/-</sup> mice, which are phenotypically normal. No significant differences in epididymal WAT mass were observed between the wild type and heterozygous cohorts. As yeast Sir2 is important during calorie restriction, we assayed by ChIP the recruitment of Sirt1 to PPAR- $\gamma$ -binding sites in the Ap2 and PPAR-gamma promoters in WAT of mice that were either fed or fasted. In mice fed ad libitum, Sirt1 was not bound to Ap2 or PPAR-gamma promoter sequences. However, Sirt1 was bound to these sequences after overnight food deprivation, showing that Sirt1 is recruited to PPAR- $\gamma$ -binding sites of PPAR-gamma promoters upon fasting.



As a test of the effect of Sirt1 on fatty acid mobilization in adipocytes, we next addressed whether fatty acid release from WAT upon fasting was altered in Sirt1<sup>-/-</sup> mice. Heterozygous gene ablation was associated with a 40–45% lowering in circulating FFA levels in the blood after overnight food deprivation compared with wild type ( $P < 0.05$ ). To verify that these effects of Sirt1 genotype were due to differences in fat release from WAT and not re-uptake of FFA from the blood by oxidative tissues, we cultured the same number of white adipocytes from Sirt1<sup>+/+</sup> and Sirt1<sup>-/-</sup> mice, challenged them with adrenalin, and measured the release of FFA. Again, FFA release was reduced in the Sirt1<sup>+/-</sup> cells compared with the Sirt1<sup>+/+</sup> cells.

The mammalian Sir2 orthologue, Sirt1, is activated by food deprivation to trigger fat mobilization in WAT. The pharmacological activation of Sirt1 also elicits the lipolysis of triglycerides and the release of FFA. Because a reduction in fat storage in WAT is a primary way by which calorie restriction extends lifespan in mammals, our results provide a possible mechanism for understanding the regulation of mammalian lifespan by diet. Sirt1 represses WAT by inhibiting the transcription factor PPAR- $\gamma$ . Starvation of animals causes Sirt1 to interact with PPAR-gamma promoter sites and thereby repress target genes that drive fat storage.

The pathway of regulation described here may impact on age-related diseases. The accumulation of WAT during ageing is associated with several adverse complications, such as insulin resistance, type 2 diabetes and atherosclerosis. Given the impact of Sirt1 on PPAR-gamma activity and because PPAR-gamma activity helps determine age-related insulin resistance, Sirt1 may have an important role in metabolic diseases and link the effects of food consumption to body fat mass and diseases of ageing. It is likely that calorie restriction exerts other effects on mammals to increase longevity, besides reducing WAT, as longevity in mice with reduced fat is not as great as animals on a long-term calorie restriction regimen. Tissues that metabolize fat and carbohydrate may also be important in delivering some of the benefit of calorie restriction.

## Methods

### Animal experimentation

Wild-type FVB male age-matched (12–16 weeks old) mice were used for the present studies. Sirt1<sup>+/+</sup> and Sirt1<sup>+/-</sup> genotypes have been described previously<sup>21</sup>. All mice were housed under controlled temperature ( $25 \pm 1^\circ\text{C}$ ) and lighting conditions. Food provided was normal chow. All mice were cared for in accordance with the MIT animal care committee. Blood was collected from the retro-orbital sinus and kept on ice until centrifugation (1,500g, 15

min at 4 °C), and the plasma was stored at -20 °C until analysis. All animals were killed by decapitation. WAT depots were collected, weighed and quickly frozen in liquid nitrogen and stored at -70 °C until further processing by immunoblotting. Non-esterified free fatty acids were determined by enzymatic assays (Wako Pure Chemical Industries).

5 Cell culture, retroviral infection and transfection. 3T3-L1, HEK293, 293T and Phoenix cells (ATCC, Rockville, MD) were cultured in Dulbecco's modified Eagle's medium with 10% FCS, and antibiotics. Primary adipocytes from Sprague-Dawley rats were prepared as described previously<sup>25</sup>. Transfections for luciferase assays were done as described using pSPORT6-PPAR- $\gamma$ 2, pGL3-PPRE26 and pcDNA3-Sirt1. Data were corrected for transfection efficiency.

10 Retroviral infection was performed as described in Tontonoz et al. (1994) Cell 79:1147. Phoenix cells were transfected with either pBABE, pBABE-Sirt1, pSUPERretro (Oligoengine), pSUPERretro-Sirt1 RNAi (5'-GATGAAGTTGACCTCCTCA-3', SEQ ID NO:24) or pSUPER-NCOR RNAi (5'-GCTGCATCCAAGGGCCATG-3', SEQ ID NO:25) using Lipofectamine (Invitrogen). After 48 h of transfection, the medium containing retroviruses was collected,  
15 filtered, treated by polybrene (1  $\mu\text{g ml}^{-1}$ ) and transferred to 3T3-L1 target cells. Infected cells were selected with puromycin (2.5  $\mu\text{g ml}^{-1}$ ) for 7 days.

To stimulate adipogenesis and accumulation of lipids in cells, medium was supplemented to confluent cells (day 0) with 2  $\mu\text{M}$  insulin or  $10^{-7}$  M rosiglitazone (Alexis Biochemicals), as stated in the text, 1  $\mu\text{M}$  dexamethasone, and 0.25 mM isobuthylmethylxanthine (IBMX) for 2  
20 days. The cells were then incubated with insulin or  $10^{-7}$  M rosiglitazone, changing the medium every second day. Fat accumulation was visualized by staining of lipids with Oil red O. Intracellular triglyceride levels were measured in cell lysates by an enzymatic method using a reagent kit from Boehringer Mannheim.

#### RNA and protein preparation and analysis

25 Total RNA from cultured cells were extracted (Qiagen) and analyzed by semi-quantitative polymerase chain reaction with reverse transcription. GAPDH and 18S RNA levels were determined as a control for loading. Proteins from mouse tissues were extracted in a solution of pH 7.4 containing 20 mM HEPES, 250 mM sucrose, 4 mM EDTA, 1% Triton and protease inhibitor cocktail. 3T3-L1 cells were lysed in NET-N buffer (20 mM Tris-HCl, pH 8  
30 containing 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM EDTA and a protease inhibitor cocktail).

Chromatin immunoprecipitation. For in vitro ChIP, infected 3T3-L1 cells were differentiated as mentioned above. For in vivo ChIP, epididymal WAT was dissected, minced and fixed overnight in PBS containing 1% formaldehyde and protease inhibitor cocktail. Tissues were then rinsed five times in PBS. Further ChIP assays were performed as described previously, using 1:200 antibody dilutions to immunoprecipitate DNA–protein complexes. DNA was then purified using Qiagen PCR purification kit and PCR reaction was performed using primers for Ap2 (5'-AAATTCAGAAGAAAGTAAACACATTATT-3', SEQ ID NO:26; 5'-ATGCCCTGACCATGTGA-3', SEQ ID NO:27) and PPAR-gamma proximal (amplifying a region at 0.3 kb upstream of ATG: 5'-GAGCAAGGTCTTCATCATTACG-3', SEQ ID NO:28; 5'-CCCCTGGAGCTGGAGTTAC-3', SEQ ID NO:29) and distal (amplifying a region at 2.8 kb upstream of ATG: 5'-CTCTCCCACCCTCGCCATAC-3', SEQ ID NO:30; 5'-TTGCCAGAGAAGCCAGTGACA-3', SEQ ID NO:31) promoters.

Pull-down and co-immunoprecipitation assays. Differentiated 3T3-L1 or HEK293 cells were lysed in NET-N buffer by agitation at 4°C for 30 min. After a brief sonication, lysates were cleared by centrifugation and immunoprecipitated. Antibodies used were anti-Sirt1 (Upstate), anti-NCoR (Upstate), anti-PPAR-gamma (SantaCruz), anti-C/EBP-alpha (SantaCruz) and anti-Sirt1 antiserum or preimmune serum. Immunoprecipitates were then analysed by immunoblotting. Equivalent amounts of GST or GST–Sirt1 fusion proteins were bound to glutathione-Sepharose (Pharmacia) and incubated with 35S-methionine-labelled NCoR or SMRT fragments prepared using TNT transcription-translation system (Promega). The reactions were washed five times with binding buffer (10 mM Na-HEPES containing 10% glycerol, 1 mM EDTA, 1 mM DTT, 150 mM NaCl and 0.05% NP-40) and bound proteins were eluted and resolved on denaturing SDS–polyacrylamide gel electrophoresis gels for analysis by autoradiography.

Statistical analysis. The main and interactive effects were analyzed by analysis of variance (ANOVA) factorial or repeated measures when appropriate. When justified by the ANOVA analysis, differences between individual group means were analyzed by Fisher's PLSD test. Differences were considered statistically significant at  $P < 0.05$ .

### Example

Further observations were made. A mouse genetically deficient for SIRT1 activity cannot regulate body temperature in the cold. The mouse appears unable to induce the UCP1

gene or related transcriptional programs. We used chromatin immunoprecipitations to characterize genes which may include regulatory sequences that are directly or indirectly bound by SIRT1. We discovered that, at least in brown fat cells, the UCP1 promoter is bound by SIRT1. SIRT1 responds to stress and activates UCP1 transcription. At least in part, the transcriptional activation is a result of the PGC1 co-factor, which is present in BAT cells, but absent in WAT cells. PGC1 modifies SIRT1 from a repressor to an activator. PGC1, SIRT1, and PPAR $\gamma$  are able to form a ternary complex which functions as a transcriptional activator. SIRT1 may have a similar function in other cells that express PGC1, e.g., muscle and liver cells.

Moreover, resveratrol increases UCP1 expression in BAT cells.

Increasing SIRT1 activity in WAT cells contributes to shedding of fat into the blood and the burning of fat in BAT. These activities can increase insulin sensitivity and can be used, e.g., to treated Type II diabetes, e.g., by decreasing insulin resistance.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

## WHAT IS CLAIMED IS:

1. A method of evaluating a subject, the method comprising:  
evaluating a SIRT1 molecule from a subject; and  
recording information from the SIRT1 evaluation in association with metabolic  
5 information about the subject.
2. The method of claim 1 wherein the SIRT1 molecule is SIRT1 mRNA, cDNA, or  
genomic nucleic acid.
- 10 3. The method of claim 2 wherein the evaluating comprises quantitative or qualitative  
assessment of SIRT1 mRNA or cDNA levels.
4. The method of claim 2 wherein the evaluating comprises evaluating the identity of at  
least one nucleotide in the SIRT1 molecule.
- 15 5. The method of claim 1 wherein the SIRT1 molecule is SIRT1 protein.
6. The method of claim 5 wherein the evaluating comprises quantitative or qualitative  
assessment of SIRT1 protein levels.
- 20 7. The method of claim 1 wherein the evaluating comprises evaluating a cell of the  
adipose lineage.
8. The method of claim 7 wherein the evaluating comprises evaluating a preadipocyte or  
25 adipocyte.
9. The method of claim 8 wherein the adipocyte is a WAT cell or a BAT cell.
10. The method of claim 1 wherein the metabolic information comprises information  
30 about a biometric parameter.

11. The method of claim 1 wherein the metabolic information comprises information about a hormone or a metabolite.

12. The method of claim 11 wherein information about a hormone comprises  
5 information about leptin, insulin, adiponectin, or resistin.

13. The method of claim 11 wherein information about a metabolite comprises information about triglycerides, fatty acids, LDL particles, HDL particles, or cholesterol.

10 14. A method of evaluating a subject who is being treated for a metabolic condition, the method comprising:

monitoring a parameter associated with a SIRT1 molecule from a subject; and  
providing a therapy to ameliorate a metabolic condition to the subject.

15 15. A method of evaluating a subject who is being treated for a metabolic condition, the method comprising:

treating a subject with a regimen for altering a metabolic condition;  
before, during, or after the regimen, monitoring a parameter associated with a  
SIRT1 molecule from the subject; and

20 comparing results of the evaluation to reference information to provide an assessment of the subject.

16. The method of claim 15 wherein the regimen comprises a diet, insulin treatment, an exercise regimen, or hormone therapy.

25 17. The method of claim 15 wherein the assessment is expressed as a risk/propensity for a metabolic disorder.

18. The method of claim 15 wherein the assessment is expressed as a risk/propensity for  
30 obesity.

19. The method of claim 15 wherein the reference information is obtained by a corresponding evaluation of a non-obese individual.

5 20. The method of claim 15 wherein the reference information is obtained from the subject prior to the treating.

21. The method of claim 15 wherein the subject is between ages 20-100, or 20-80 or 40-70.

10 22. The method of claim 15 wherein the monitoring comprises evaluating a parameter associated with a SIRT1 molecule from a subject at at least two instances separated by at least 24 hours.

15 23. A method of evaluating a subject, the method comprising:  
evaluating a SIRT1 molecule from a cell of the adipocyte lineage; and  
comparing results of the evaluating to reference information.

24. The method of claim 23 wherein the cell is a preadipocyte or adipocyte.

20 25. The method of claim 24 wherein the cells are WAT cells or BAT cells.

26. The method of claim 23 wherein the cell is obtained from a human subject.

25 27. The method of claim 26 wherein the subject is identified as having or being at risk for, obesity, an obesity-related disorder, a body mass index in a particular range, or lipodystrophy.

30 28. The method of claim 23 wherein the reference information comprises results of a corresponding evaluation of a SIRT1 molecule from a corresponding cell from a control subject.

29. The method of claim 23 wherein the comparing comprises determining whether the level of SIRT1 expression is at least 2 fold different than a reference level evaluated by a corresponding method for a non-obese adult.

5           30. The method of claim 23 wherein the evaluating comprises evaluating expression of a plurality nucleic acid species to obtain a profile that comprises information about SIRT1 expression and at least one additional gene.

10           31. The method of claim 23 wherein the comparing further comprises comparing expression levels of at least one gene in addition to SIRT1, the comparison being between the subject and corresponding reference information for the additional gene..

32. The method of claim 23 wherein the evaluating comprises hybridizing a probe.

15           33. The method of claim 23 wherein the evaluating comprises sequence specific amplification or primer extension.

34. The method of claim 23 wherein the evaluating comprises nucleic acid sequencing.

20           35. The method of claim 23 wherein the evaluating comprises mass spectroscopy, etc.

36. The method of claim 23 wherein the evaluating comprises in situ hybridization, a Northern, subtractive hybridization, or SAGE.

25           37. A method comprising:  
              providing a pre-adipocyte or an adipocyte cell; and  
              evaluating expression or activity of a SIRT1 gene in the pre-adipocyte or adipocyte cell.

30           38. The method of claim 37 wherein fewer than 100, 50, 10, or 5 different genes are evaluated in parallel with SIRT1.



39. The method of claim 37 further comprising contacting the pre-adipocyte with an agent that alters SIRT1 expression or activity prior to the evaluating.

40. The method of claim 37 wherein the adipocyte is a WAT cell or a BAT cell.

41. The method of claim 37 wherein the step of evaluating expression or activity comprises evaluating SIRT1 mRNA levels.

42. The method of claim 37 wherein the step of evaluating expression or activity comprises evaluating SIRT1 protein levels.

43. The method of claim 37 wherein the step of evaluating expression or activity comprises evaluating SIRT1 enzymatic activity.

44. The method of claim 43 wherein the enzymatic activity comprises deacetylase activity.

45. The method of claim 37 wherein the step of evaluating expression or activity comprises evaluating SIRT1 interaction with a SIRT1 binding partner.

46. The method of claim 37 wherein the step of evaluating expression or activity comprises evaluating SIRT1 interaction with a regulatory sequence.

47. The method of claim 46 wherein the step of evaluating comprises a chromatin immunoprecipitation.

48. The method of claim 37 that comprises evaluating expression of a gene regulated by a PPAR transcription factor.

49. The method of claim 37 that comprises evaluating PPAR-gamma expression or activity.

50. The method of claim 37 that comprises evaluating UCP1 expression or activity.

51. A method comprising:

5 identifying a subject has having obesity, being at risk for obesity using clinical  
criteria, or being overweight;  
obtaining a sample of cells from the subject; and  
evaluating expression of a SIRT1 gene in cells of the sample.

52. A method comprising:

10 evaluating the identity of one or more nucleotides of a SIRT1 gene from a subject,  
thereby providing a first sequence;  
providing a reference sequence consisting of one or more nucleotides of a SIRT1  
gene from a reference subject who is indicated for obesity or a body mass index that is at least  
within the 25<sup>th</sup> percentile above or below normal; and  
15 comparing the first sequence to the reference sequence.

53. The method of claim 52 further comprising making a medical, financial, or familial  
decision as a function of the comparison.

20 54. A method comprising:

identifying a plurality of human individuals characterized as being underweight,  
overweight, obese or as having a body mass index in a particular range;  
comparing distribution of one or more SIRT1 gene polymorphisms among  
individuals of the plurality.

25

55. A method comprising:

identifying a subject as having obesity, being at risk for obesity using clinical  
criteria, or being overweight; and  
administering an effective amount of an agent that increases SIRT1 activity to the  
30 subject.

56. The method of claim 55 wherein the agent increases SIRT1 mRNA or protein levels in the subject.

57. The method of claim 55 wherein the agent increases SIRT1 mRNA or protein levels  
5 in pre-adipocytes or adipocytes of the subject.

58. The method of claim 55 wherein the agent increases SIRT1 enzymatic activity in pre-adipocytes or adipocytes of the subject.

10 59. The method of claim 55 wherein the agent comprises a nucleic acid that comprises a sequence encoding SIRT1 or a SIRT1 core domain and an operably linked promoter, or a complement of such a nucleic acid.

15 60. The method of claim 55 wherein the agent comprises a polypeptide that contains a SIRT1 core domain.

61. The method of claim 55 wherein the agent is NAD or an NAD precursor.

20 62. The method of claim 55 wherein the agent comprises a compound of Formula I, II, III, or IV.

63. The method of claim 55 wherein the administered amount is also effective for inhibiting pre-adipocyte differentiation.

25 64. The method of claim 55 wherein the administered amount is also effective for promoting fat mobilization in WAT cells.

65. The method of claim 55 wherein the administered amount is also effective for promoting fat burning in BAT cells.

30 66. The method of claim 55 wherein the administered amount is also effective to increase leptin secretion.

67. The method of claim 55 further comprising monitoring a parameter associated with SIRT1 during or after the administering.

5        68. A method comprising:  
         identifying a subject as being underweight, at risk for weight loss or cachexia  
using clinical criteria, or being cachexic; and  
         administering an effective amount of an agent that decreases SIRT1 activity to the  
subject.

10        69. The method of claim 68 wherein the agent decreases SIRT1 mRNA or protein levels  
in the subject.

15        70. The method of claim 68 wherein the agent decreases SIRT1 mRNA or protein levels  
in pre-adipocytes or adipocytes of the subject.

         71. The method of claim 68 wherein the agent decreases SIRT1 enzymatic activity in  
pre-adipocytes or adipocytes of the subject.

20        72. The method of claim 68 wherein the agent comprises a dsRNA or siRNA that  
comprises a sequence of at least 19 nucleotides that is complementary to a sequence encoding  
SIRT1.

25        73. The method of claim 68 wherein the agent comprises a polypeptide that competes  
with a SIRT1 substrate for interaction with SIRT1.

         74. The method of claim 68 wherein the agent comprises an antibody or antibody  
fragment that binds to SIRT1.

30        75. The method of claim 68 wherein the agent is nicotinamide or vitamin b3.

76. The method of claim 68 wherein the agent is other than nicotinamide and vitamin b3.

77. The method of claim 76 wherein the agent comprises a compound of Formula V or VI.

5

78. The method of claim 68 further comprising monitoring a parameter associated with SIRT1 during or after the administering.

79. A method of evaluating a compound, the method comprising:

10 providing a compound that interacts with SIRT1 or that modulates SIRT1 activity;

contacting the compound to a cell of the adipocyte lineage; and  
evaluating the cell.

15 80. The method of claim 79 wherein evaluating comprises evaluating expression of a gene regulated by an adipocyte transcription factor.

81. The method of claim 80 wherein the adipocyte transcription factor is a PPAR transcription factor, PGC1, or a C/EBP transcription factor.

20

82. The method of claim 80 wherein the cell comprises a reporter gene regulated by the adipocyte transcription factor and the evaluating comprises evaluating the reporter gene.

25 83. The method of claim 79 wherein evaluating comprises evaluating the differentiation state of the cell.

84. The method of claim 79 wherein evaluating comprises evaluating secretion of a hormone by the cell.

30 85. The method of claim 79 wherein evaluating comprises evaluating fat mobilization by the cell.

86. The method of claim 79 wherein evaluating comprises evaluating fat burning by the cell.

87. The method of claim 79 wherein evaluating comprises evaluating association of SIRT1 and genomic nucleic acid in the cell.

88. The method of claim 87 wherein evaluating the association comprises crosslinking proteins to nucleic acid, immunoprecipitating SIRT1 or a fragment thereof, and evaluating the nucleic acid associated with SIRT1 immunoprecipitates.

89. The method of claim 79 wherein the step of providing a compound that interacts with SIRT1 or that modulates SIRT1 comprises contacting the compound to SIRT1 or a fragment thereof in vitro.

90. A method of evaluating a compound, the method comprising:  
contacting the compound to a preadipocyte cell; and  
evaluating a parameter associated with a SIRT1 molecule of the cell

91. The method of claim 90 further comprising comparing the parameter to a reference parameter.

92. The method of claim 91 wherein the reference parameter is determined by a corresponding method for a preadipocyte that has not been contacted with the compound and a difference in the parameter and a reference parameter indicates that the compound alters SIRT1 activity in the preadipocyte.

93. The method of claim 90 further comprising evaluating the differentiation state of the preadipocyte cell.

94. The method of claim 90 further comprising evaluating lipid or fat of the preadipocyte cell.

95. The method of claim 94 wherein the evaluating comprises fractionating cell contents or an optical evaluation.

96. A method of evaluating a compound, the method comprising:  
5                   contacting the compound to an organism; and  
                  evaluating a parameter associated with a SIRT1 molecule of a fat cell or precursor thereof, from the organism, wherein a difference in the parameter between the parameter and a reference parameter indicates that the compound modulates SIRT1 activity in a cell of the organism.

10                   97. A method of evaluating a compound comprising:  
                  contacting the compound to a SIRT1 protein in vitro;  
                  evaluating an interaction between the compound and the protein;  
                  contacting the compound to a cell or organism; and  
15                   evaluating a differentiation state of the cell or a metabolic parameter of the organism.

98. The method of claim 97 wherein evaluating the interaction comprises evaluating catalytic activity of the protein in the presence of the compound.

20                   99. A method of evaluating a library of compounds, the method comprising:  
                  providing a library of compound;  
                  for each compound of a plurality of compounds from the library,  
                  contacting the compound to a SIRT1 protein in vitro;  
25                   evaluating an interaction between the compound and the SIRT1 protein;  
                  if the compound interacts with the SIRT1 protein, contacting the compound to a cell or organism; and  
                  evaluating a differentiation state or a metabolic parameter of the cell or organism.

30                   100. The method of claim 99 wherein the cell includes a reporter gene and/or other combination of heterologous nucleic acids described herein.

101. A method of evaluating a library of compounds, the method comprising:  
providing a library of compound;  
for each compound of a plurality of compounds from the library, evaluating the  
5 compound using a method described herein.

102. A method of maturing a lead compound, the method comprising:  
providing a plurality of derivatives/variants of a compound that detectably  
interacts with a SIRT1 protein;  
10 contacting each compound of the plurality to a cell or organism; and  
evaluating a differentiation state or a metabolic parameter of the cell or organism.

103. The method of claim 102 further comprising recording SAR data that associates  
results of the evaluating and structural information about each compound of the plurality.  
15

104. The method of claim 102 further comprising modeling an interaction between a  
three-dimensional structural model of a SIRT1 protein or region thereof and a compound of the  
plurality.

20 105. A preparation comprising:  
a population of cells of the adipocyte lineage or an extract thereof; and  
a probe that is specific to a SIRT1 molecule.

106. The preparation of claim 105 wherein the cells comprise adipocytes or  
25 preadipocytes.

107. The preparation of claim 106 wherein the cells comprise BAT or WAT cells.

108. The preparation of claim 105 wherein the probe is a nucleic acid probe that is  
30 complementary to a SIRT1 nucleic acid.

109. The preparation of claim 105 wherein the probe is an antibody or fragment thereof.



110. The preparation of claim 105 wherein the probe is an acetylated substrate that can be deacetylated by a SIRT1 protein.

5 111. A mammalian adipocyte or pre-adipocyte cell that contains a dsRNA that is specific to SIRT1 in an amount effective to alter SIRT1 activity in the cell.

112. The cell of claim 111 wherein the mammalian adipocyte or pre-adipocyte cell is cultured.

10 113. A mammalian adipocyte or pre-adipocyte cell that contains a heterologous nucleic acid that comprises a sequence encoding a polypeptide that comprises a SIRT1 core domain and an operably linked promoter, wherein activation of the promoter can produce the polypeptide in an amount sufficient to alter SIRT1 activity in the cell.

15 114. The cell of claim 113 wherein the mammalian adipocyte or pre-adipocyte cell is cultured.

20 115. A purified complex comprising SIRT1 or an PGC1 interacting fragment thereof, and (ii) PGC1 or a SIRT1 interacting fragment thereof.

116. The complex of claim 115 that is at least 10% pure.

25 117. The complex of claim 115 that further comprises (iii) PPAR-gamma.

118. An antibody or other protein ligand that specifically recognizes the complex of claim 115, but does not substantially bind to any of the complex components in isolation.

30 119. An antibody or other protein ligand that specifically recognizes the complex of claim 117, but does not substantially bind to any of the complex components in isolation.

120. A method comprising:

providing a mammalian adipocyte or pre-adipocyte cell; and  
modulating SIRT1 activity in the cell.

5       121. The method of claim 120 wherein the modulating comprises increasing SIRT1  
activity.

122. The method of claim 120 wherein the modulating comprises decreasing SIRT1  
activity.

10       123. The method of claim 120 wherein the modulating comprises contacting the cell  
with a dsRNA.

124. The method of claim 120 wherein the modulating comprises introducing a nucleic  
acid that comprises a sequence that encodes a polypeptide comprising a SIRT1 core domain or a  
15       sequence complementary to a SIRT1 coding sequence.

125. The method of claim 120 wherein the adipocyte is a WAT or BAT cell.

20       126. A method comprising:  
providing a mammalian cell;  
modulating SIRT1 activity in the cell; and  
evaluating a lipid or fat-associated parameter of the cell.

25       127. The method of claim 126 wherein the evaluating comprises an optical evaluation of  
the cell.

128. A method comprising:  
providing a mammalian cell;  
modulating SIRT1 activity in the cell; and  
30       evaluating the differentiation state of the cell using an indicator of adipocyte  
differentiation.

129. The method of claim 128 wherein the indicator is leptin expression.

130. The method of claim 128 wherein the indicator is expression or activity of an adipocyte transcription factor.

5

131. The method of claim 128 wherein the cell contains a heterologous nucleic acid that can express a C/EBP protein and a reporter nucleic acid that comprises a regulatory sequence of gene that is specifically or selectively expressed in adipocytes.

10 132. The method of claim 128 wherein the cell contains a heterologous nucleic acid that can express a C/EBP protein and a reporter nucleic acid that comprises a regulatory sequence of a secreted protein produced by adipocytes.

15 133. The method of claim 132 wherein the secreted protein produced by adipocytes is leptin.

134. The method of claim 131 or 132 wherein the C/EBP protein is C/EBP $\alpha$ .

20 135. The method of claim 128 wherein the cell contains a heterologous nucleic acid that can express a PPAR protein and a reporter nucleic acid that comprises a regulatory sequence that is bound by an AP2 protein.

136. The method of claim 127 wherein the PPAR protein is PPAR $\gamma$ .

25




FIG. 1




FIG. 2

## SEQUENCE LISTING

&lt;110&gt; Massachusetts Institute of Technology

<120> SIRT1 MODULATION OF ADIPOGENESIS AND  
ADIPOSE FUNCTION

&lt;130&gt; 13407-058WO1

&lt;150&gt; US 60/484,836

&lt;151&gt; 2003-07-03

&lt;160&gt; 35

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 4086

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gtcgagcggg	agcagaggag	gcgagggagg	agggccagag	aggcagttgg	aagatggcgg	60
acgaggcggc	cctcgccctt	cagcccggcg	gtcCCCCctc	ggcggcgggg	gccgacaggg	120
aggccgcgtc	gtcccccgcc	ggggagccgc	tccgcaagag	gccgcggaga	gatggtcccg	180
gcctcgagcg	gagcccgggc	gagcccgggt	gggcggcccc	agagcgtgag	gtgccggcgg	240
cggccagggg	ctgcccgggt	gcggcgggcg	cggcgctgtg	gcgggaggcg	gaggcagagg	300
cggcggcggc	aggcggggag	caagaggccc	aggcgactgc	ggcggctggg	gaaggagaca	360
atgggcccgg	cctgcagggc	ccatctcggg	agccaccgct	ggccgacaac	ttgtacgacg	420
aagacgacga	cgacgagggc	gaggaggagg	aagaggcggc	ggcggcggcg	attgggtacc	480
gagataacct	tctgttcggg	gatgaaatta	tcactaatgg	ttttcattcc	tgtgaaagtg	540
atgaggagga	tagagcctca	catgcaagct	ctagtgactg	gactccaagg	ccacggatag	600
gtccatatac	ttttgttcag	caacatctta	tgattggcac	agatcctcga	acaattctta	660
aagattttatt	gccggaaaaca	atacctccac	ctgagttgga	tgatatgaca	ctgtggcaga	720
ttgttattaa	tatcctttca	gaaccaccaa	aaaggaaaaa	aagaaaagat	attaatacaa	780
ttgaagatgc	tgtgaaatta	ctgcaagagt	gcaaaaaaat	tatagttcta	actggagctg	840
gggtgtctgt	ttcatgtgga	atacctgact	tcaggtcaag	ggatggtatt	tatgctcgcc	900
ttgctgtaga	cttcccagat	cttccagatc	ctcaagcgat	gtttgatatt	gaatatttca	960
gaaaagatcc	aagaccattc	ttcaagtttg	caaaggaaat	atatcctgga	caattccagc	1020
catctctctg	tcacaaattc	atagccttgt	cagataagga	aggaaaaacta	cttcgcaact	1080
ataccagaaa	catagacacg	ctggaacagg	ttgcgggaat	ccaaaggata	attcagtgtc	1140
atggttcctt	tgcaacagca	tcttgccctga	tttgtaaata	caaagttgac	tgtgaagctg	1200
tacgaggaga	tatttttaat	caggtagttc	ctcgatgtcc	taggtgcccc	gctgatgaac	1260
cgcttgctat	catgaaacca	gagattgtgt	tttttggtga	aaattttacca	gaacagtttc	1320
atagagccat	gaagtatgac	aaagatgaag	ttgacctcct	cattgttatt	gggtcttccc	1380
tcaaagtaag	accagtagca	ctaattccaa	gttccatacc	ccatgaagtg	cctcagatat	1440
taattaatag	agaacctttg	cctcatctgc	attttgatgt	agagcttctt	ggagactgtg	1500
atgtcataat	taatgaattg	tgtcataggt	taggtggtga	atatgccaaa	ctttgctgta	1560
accctgtaaa	gctttcagaa	attactgaaa	aacctccacg	aacacaaaaa	gaattggctt	1620
atttgtcaga	gttgccaccc	acacctcttc	atgtttcaga	agactcaagt	tcaccagaaa	1680
gaacttcacc	accagattct	tcagtgattg	tcacactttt	agaccaagca	gctaagagta	1740
atgactgttt	agatgtgtct	gaatcaaaaag	gttgatatgga	agaaaaacca	caggaagtac	1800
aaactttctag	gaatgttgaa	agtattgctg	aacagatgga	aaatccggat	ttgaagaatg	1860
ttggttctag	tactggggag	aaaaatgaaa	gaacttcagt	ggctggaaca	gtgagaaaat	1920
gctggcctaa	tagagtggca	aaggagcaga	ttagtaggcg	gcttgatggg	aatcagtatc	1980
tggttttgcc	accaaatcgt	tacattttcc	atggcgctga	ggtatatcca	gactctgaag	2040
atgacgtctt	atcctctagt	tcttggtggca	gtaacagtga	tagtgggaca	tgccagagtc	2100
caagttttaga	agaacccatg	gaggatgaaa	gtgaaattga	agaattctac	aatggccttag	2160
aagatgagcc	tgatgttcca	gagagagctg	gaggagctgg	atgtgggact	gatggagatg	2220
atcaagaggc	aattaatgaa	gctatatctg	tgaaacagga	agtaacagac	atgaactatc	2280

catcaaacaa	atcatagtg	aataattgtg	caggtacagg	aattgttcca	ccagcattag	2340
gaacttttagc	atgtcaaaat	gaatgtttac	ttgtgaactc	gatagagcaa	ggaaaccaga	2400
aaggtgtaat	atcttatagg	tggtaaaata	gattgttttt	catggataat	ttttaacttc	2460
attatctctg	tacttgtaga	aactcaacac	taactttttt	ttttttaaaa	aaaaaaagg	2520
actaagtatc	ttcaatcagc	tgttggtgca	agactaactt	tcttttaaa	gttcatttgt	2580
atgataaatt	catatgtgta	tatatatttt	tttttggttt	gtctagttag	tttcaacatt	2640
tttaaagttt	tcaaaaagcc	atcggaatgt	taaattaatg	taaagggaca	gctaattctag	2700
accaaagaat	ggtatttttc	cttttctttg	taacattgaa	tggtttgaag	tactcaaaat	2760
ctgttacgct	aaacttttga	ttcttttaaca	caattatttt	taaacactgg	catttttccaa	2820
aactgtggca	gctaactttt	taaaatctca	aatgacatgc	agtgtgagta	gaaggaagtc	2880
aacaatatgt	ggggagagca	ctcggttgct	tttactttta	aaagtaatac	ttggtgctaa	2940
gaatttcagg	attattgtat	ttacgttcaa	atgaagatgg	cttttgtact	tcctgtggac	3000
atgtagtaat	gtctatattg	gctcataaaa	ctaacttgaa	aaacaaataa	atgctttgga	3060
aatgtttcag	ttgctttaga	aacattagtg	cctgcctgga	tccccttagt	tttgaaatat	3120
ttgccattgt	tgtttaataa	cctatcactg	tggtagagct	tgcattgac	ttttccacaa	3180
gtattaaact	gccaaaatgt	gaatatgcaa	agcctttctg	aatctataat	aatggtactt	3240
ctactgggga	gagtgttaata	ttttggactg	ctgttttcca	ttaatgagga	gagcaacagg	3300
cccctgatta	tacagttcca	aagtaataag	atgttaattg	taattcagcc	agaaagtaca	3360
tgtctcccat	tgggaggatt	tggtgttaaa	taccaaactg	ctagccctag	tattatggag	3420
atgaacatga	tgatgttaact	tgtaatagca	gaatagttaa	tgaatgaaac	tagttcttat	3480
aatttatctt	tattttaaaag	cttagcctgc	cttaaaaacta	gagatcaact	ttctcagctg	3540
caaaagcttc	tagtctttca	agaagttcat	actttatgaa	attgcacagt	aagcatttat	3600
ttttcagacc	atttttgaac	atcactccta	aattaataaa	gtattcctct	gttgcttttag	3660
tatttattac	aataaaaagg	gtttgaaata	tagctgttct	ttatgcataa	aacaccagc	3720
taggaccatt	actgccagag	aaaaaaatcg	tattgaaatg	ccatttccct	acttataaga	3780
tgtctcaatc	tgaattttatt	tggtacact	aaagaatgca	gtatatttag	ttttccattt	3840
gcatgatgtt	tgtgtgctat	agatgatatt	ttaaattgaa	aagtttggtt	taaattattt	3900
ttacagtga	gactgttttc	agctcttttt	atatgttaca	tagtctttta	tgtaatttac	3960
tggcatatgt	tttgtagact	gtttaatgac	tggatatctt	ccttcaactt	ttgaaataca	4020
aaaccagtgt	tttttacttg	tacactgttt	taaagtctat	taaaattgtc	atttgacttt	4080
tttctg						4086

&lt;210&gt; 2

&lt;211&gt; 3849

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 2

gcggagcaga	ggaggcgagg	gcggagggcc	agagaggcag	ttggaagatg	gcggacgagg	60
tggcgctcgc	ccttcaggcc	gccggctccc	cttcgcggc	ggccgccatg	gaggccgcgt	120
cgcagccggc	ggacgagccg	ctccgcaaga	ggccccgcg	agacgggcct	ggcctcgggc	180
gcagcccggg	cgagccgagc	gcagcagtg	cgccggcggc	cgcggggtgt	gaggcggcga	240
gcgccgcggc	ccggcgggcg	ctgtggcggg	aggcggcagg	ggcgggcgcg	agcgcgagc	300
gggaggcccc	ggcgacggcc	gtggccgggg	acggagacaa	tgggtccggc	ctgcggcggg	360
agccgagggc	ggctgacgac	ttcgacgacg	acgagggcga	ggaggaggac	gaggcggcgg	420
cggcagcggc	ggcggcagcg	atcggtacc	gagacaacct	cctgttgacc	gatggactcc	480
tcactaatgg	ctttcattcc	tgtgaaagtg	atgacgatga	cagaacgtca	cacgccagct	540
ctagtactg	gactccgcgg	ccgcggatag	gtccatatac	ttttgttcag	caacatctca	600
tgattggcac	cgatcctcga	acaattctta	aagattttatt	accagaaaca	attcctccac	660
ctgagctgga	tgatatgacg	ctgtggcaga	ttgttattaa	tatcctttca	gaaccaccaa	720
agcggaaaaa	aagaaaagat	atcaatacaa	ttgaagatgc	tgtgaagtta	ctgcaggagt	780
gtaaaaagat	aatagttctg	actggagctg	gggtttctgt	ctcctgtggg	attcctgact	840
tcagatcaag	agacgggtatc	tatgctcgcc	ttgcggtgga	cttccagac	ctccagacc	900
ctcaagccat	gtttgtatatt	gagtattttta	gaaaagacc	aagaccattc	ttcaagtttg	960
caaaggaaat	atatcccggga	cagttccagc	cgtctctgtg	tcacaaattc	atagctttgt	1020
cagataagga	aggaaaacta	cttcgaaatt	atactcaaaa	tatagatacc	ttggagcagg	1080
ttgcagggaat	ccaaaggatc	cttcagtgtc	atggttccct	tgcaacagca	tcttgccctga	1140
tttgtaaata	caaagttgat	tgtgaagctg	ttcgtggaga	catttttaat	caggtagttc	1200
ctcgggtgcc	taggtgcccc	gctgatgagc	cacttgccat	catgaagcca	gagattgtct	1260
tctttggtga	aaacttacca	gaacagtttc	atagagccat	gaagtatgac	aaagatgaag	1320
ttgacctcct	cattgtttatt	ggatcttctc	tgaagtgag	accagtagca	ctaattccaa	1380

gttctataacc	ccatgaagtg	cctcaaatat	taataaatag	ggaacctttg	cctcatctac	1440
atatttgatgt	agagctcctt	ggagactgcg	atgttataat	taatgagttg	tgtcataggc	1500
taggtggtga	atatgccaaa	ctttgttgta	accctgtaaa	gctttcagaa	attactgaaa	1560
aacctccacg	cccacaaaag	gaattggttc	atttatcaga	gttgccacca	acacctcttc	1620
atatttcgga	agactcaagt	tcacctgaaa	gaactgtacc	acaagactct	tctgtgattg	1680
ctacacttgt	agaccaagca	acaaacaaca	atgttaatga	tttagaagta	tctgaatcaa	1740
gttggtgtgga	agaaaaacca	caagaagtac	agactagtag	gaatgttgag	aacattaatg	1800
tggaaaaatcc	agattttaag	gctgttggtt	ccagtactgc	agacaaaaat	gaaagaactt	1860
cagttgcaga	aacagtgaga	aaatgctggc	ctaatagact	tgcaaaggag	cagattagta	1920
agcggcttga	gggtaatcaa	tacctgtttg	taccaccaa	tcgttacata	ttccacggtg	1980
ctgaggtata	ctcagactct	gaagatgacg	tcttgcctc	tagttcctgt	ggcagtaaca	2040
gtgacagtgg	cacatgccag	agtccaagtt	tagaagaacc	cttggaagat	gaaagtgaaa	2100
ttgaagaatt	ctacaatggc	ttggaagatg	atacggagag	gcccgaatgt	gctggaggat	2160
ctggatttgg	agctgatgga	ggggatcaag	aggttgttaa	tgaagctata	gctacaagac	2220
aggaattgac	agatgtaaac	tatccatcag	acaaatcata	acactattga	agctgtccgg	2280
attcaggaat	tgctccacca	gcattgggaa	ctttagcatg	tcaaaaaaat	gaatgtttac	2340
ttgtgaactt	gaacaaggaa	atctgaaaga	tgtattattt	atagactgga	aaatagattg	2400
tcttcttga	taatttctaa	agttccatca	tttctgtttg	tacttgtaca	ttcaacactg	2460
ttgggtgact	tcactcttcct	ttcaaggttc	atltgtatga	tacattcgta	tgtatgtata	2520
atlttgtttt	ttgcctaattg	agtttcaacc	ttttaaagtt	ttcaaaagcc	attggaattg	2580
taatgtaaag	ggaacagctt	atctagacca	aagaatggta	tttcacactt	ttttgtttgt	2640
aacattgaat	agttttaaagc	cctcaatttc	tgttctgctg	aactttttatt	tttaggacag	2700
ttaacttttt	aaacactggc	atlttccaaa	acttgtggca	gctaactttt	taaaatcaca	2760
gatgacttgt	aatgtgagga	gtcagcacccg	tgtctggagc	actcaaaact	tgggctcagt	2820
gtgtgaagcg	tacttactgc	atcgtttttg	tacttgctgc	agacgtggta	atgtccaaac	2880
aggcccttga	gactaatctg	ataaatgatt	tggaaatgtg	tttcagttgt	tctagaaaca	2940
atagtgcctg	tctatatagg	tccccttagt	ttgaatattt	gccattgttt	aattaaatac	3000
ctatcactgt	ggtagagcct	gcatagatct	tcaccacaaa	tactgccaag	atgtgaatat	3060
gcaaagcctt	tctgaatcta	ataatggtac	ttctactggg	gagagtgtaa	tattttggac	3120
tgctgttttt	ccattaatga	ggaaagcaat	aggcctctta	attaaagtcc	caaagtcata	3180
agataaattg	tagctcaacc	agaaagtaca	ctgttgccctg	ttgaggattt	ggtgtaatgt	3240
atcccaaggt	gttagccttg	tattatggag	atgaatacag	atccaatagt	caaagtgaac	3300
tagttcttag	ttattttaaaa	gcttagcctg	ccttaaaact	agggatcaat	tttctcaact	3360
gcagaaactt	ttagcctttc	aaacagttca	cacctcagaa	agtcagtatt	tatttttacag	3420
acttcttttg	aacattgccc	ccaaatttaa	atattcatgt	gggttttagta	tttattacaa	3480
aaaaatgatt	tgaaatatag	ctgttcttta	tgcataaaa	accagtttag	gaccattact	3540
gccagaggag	aaaagtatta	agtagctcat	ttccctacct	aaaagataac	tgaattttatt	3600
tggctacact	aaagaatgca	gtatattttag	ttttccattt	gcatgatgtg	tttgtgctat	3660
agacaatatt	ttaaattgaa	aaatttggtt	taaattattt	ttacagtga	gactgttttc	3720
agctcttttt	atattgtaca	tagactttta	tgtaatctgg	catatgtttt	gtagaccgtt	3780
taatgactgg	attatcttcc	tccaactttt	gaaatacaaa	aacagtgttt	tatactaaaa	3840
aaaaaaaa						3849

&lt;210&gt; 3

&lt;211&gt; 2103

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 3

atgtgggcca	ggcaagtgtt	tactggaccc	tcagactgtg	gccccgacga	gggaggggtc	60
acaaagcctc	agagagtaaa	tggacgactg	aatctggcac	cgcagacagc	tgccccggggc	120
cctgatagct	gcgagggctc	cgcggcgggc	gcgagctcgc	gccctggctc	ggccgcgcgc	180
cgcgcagctc	gccagcccta	ctgcggagcc	gcgcgcgagc	tcgccgctcg	cttgggcccgc	240
cttgcgctgc	tgcgcgagct	cgcgggggca	gcaggctctc	gcagttgtca	caacctctcg	300
ttggctgatg	agatcatcac	taatggcttt	cattcctgtg	aaagtgatga	cgatgacaga	360
gcatcacacg	caagctctag	tgactggact	ccaaggccac	ggataggtcc	atatactttt	420
gttcagcaac	acctcatgat	tggcaccgat	cctcgaacaa	ttcttaaaga	tttattacca	480
gaaacaattc	ctccacctga	gttggatgat	atgacactgt	ggcagattgt	tattaatatc	540
ctttcagaac	caccaaagcg	gaaaaaaaga	aaagatatta	atacaattga	agatgctgtg	600
aagttactac	aagagtga	aaagataata	gttctgactg	gagctggggg	ttctgtttcc	660
tgtgggatac	ctgacttcag	atcaagagat	ggtattttatg	ctcgccttgc	tgtggacttc	720



ccggatctcc	cagatcctca	agccatgttc	gatattgagt	attttagaaa	agacccaaga	780
ccattcttca	agtttgcaaa	ggaaatatat	cccggacagt	tccagccatc	tctgtgtcac	840
aaattcatag	ctttgtcaga	taaggaagga	aaactacttc	gaaattatac	tcaaaatata	900
gataccttgg	agcaggttgc	aggaatccaa	aggatcattc	agtgtcatgg	ttcctttgca	960
acagcatctt	gcctgatttg	taaatacaaa	gttgattgtg	aagctgttcg	tggagatatt	1020
tttaatcagg	tagttcctcg	gtgtcctagg	tgcccagctg	atgagccact	tgccatcatg	1080
aagccagaga	ttgtcttctt	tggtgaaaac	ttaccagaac	agtttcatag	agccatgaag	1140
tatgacaaaag	atgaagttga	cctcctcatt	gttattgggt	cttctctgaa	agtaagacca	1200
gtagcactaa	ttccaagttc	tataccccat	gaagtgcctc	aaatattaat	aaatagggaa	1260
cctctgcctc	atctacattt	tgatgtagag	cttcttggag	actgcgatgt	cataattaat	1320
gagttgtgtc	ataggttagg	tggcgagtat	gccaaacttt	gttgtaaccc	tgtaaagctt	1380
tcagaaaatta	ctgaaaaaac	tccacgaaca	caaaaggaat	tggttcattt	atcagagttg	1440
ccaccaacac	ctcttcatat	ttcagaagac	tcaagttcac	ctgaaagaac	tgtaccacaa	1500
gactcttctg	tgattgtctac	acttgtagac	caaacaataa	agaacaaagt	tgacgattta	1560
gaagtatctg	aacaaaaaag	ttgtgtggaa	gaaaaatcac	aggaagtaca	gacttatagg	1620
aatgttgaga	gcattaatgt	ggaaaaccca	gatttcaagg	ctgttgggtc	cagtactgga	1680
gacaaaaatg	aaagaacttc	tgttgacagaa	acagtggagaa	aatgctggcc	taatagactt	1740
gcaaaggagc	agattagtaa	gcgtcttgac	ggtaatcaat	acttgtttgt	accaccaaat	1800
cgttacatat	ttcatgggtg	tgaggtatac	tcagactctg	aagatgacgc	cttatcctct	1860
agttcctgtg	gcagtaacag	tgacagtggc	acatgccaga	gtccaagttt	agaagaaccc	1920
ttggaagatg	aaagtgaat	tgaagagttc	tacaatggct	tggaaagatga	tgctgacaga	1980
ccggagtgtg	ctggaggatc	tggagctgac	ggaggggac	aagaggcagt	taatgaagct	2040
atagccatga	aacaggaatt	aacagatgta	aactgtacac	cagacaaatc	agagcactat	2100
tga						2103

&lt;210&gt; 4

&lt;211&gt; 1963

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gtgttgtag	aaagcgcgct	tgcggccgca	atgtctgctg	agagttgtag	ttctgtgccc	60
tatcacggcc	actcccattt	ctggtgccgt	cacgggacag	agcagtcggt	gacaggacag	120
agcagtcggt	gacgggacac	agtgggttgt	gacgggacag	agcggtcggt	gacagcctca	180
agggcttcag	caccgcgccc	atggcagagc	cagacccttc	tcaccctctg	gagacccagg	240
caggaaggt	gcaggaggct	caggactcag	attcagactc	tgagggagga	gccgctggtg	300
gagaagcaga	catggacttc	ctgcggaact	tattctccca	gacgctcagc	ctgggcagcc	360
agaaggagcg	tctgctggac	gagctgaact	tggaaagggt	ggcccgttac	atgcagagcg	420
aacgctgtcg	cagagtcate	tgtttgggtg	gagctggaat	ctccacatcc	gcaggcatcc	480
ccgactttcg	ctctccatcc	accggcctct	atgacaacct	agagaagtac	catcttccct	540
acccagaggc	catcttttag	atcagctatt	tcaagaaaca	tccggaaccc	ttcttgcgcc	600
tcgccaagga	actctatcct	gggcagttca	agccaaccat	ctgtcactac	ttcatgcgcc	660
tgctgaagga	caaggggcta	ctcctgcgct	gctacacgca	gaacatagat	accctggagc	720
gaatagccgg	gctggaacag	gaggacttgg	tggaggcgca	cggcaccttc	tacacatcac	780
actgcgtcag	cgccagctgc	cggcacgaat	acccgctaag	ctggatgaaa	gagaagatct	840
tctctgaggt	gacgcccagg	tgtgaagact	gtcagagcct	ggtgaagcct	gatatcgtct	900
tttttggtga	gagcctccca	gcgcgtttct	tctcctgtat	gcagtcagac	ttcctgaagg	960
tggacctcct	cctggtcatg	ggtacctcct	tgcaggtgca	gccctttgcc	tccctcatca	1020
gcaaggcacc	cctctccacc	cctcgcctgc	tcatcaacaa	ggagaaagct	ggccagtcgg	1080
accctttcct	ggggatgatt	atgggcctcg	gaggaggcat	ggactttgac	tccaagaagg	1140
cctacaggga	cgtggcctgg	ctgggtgaat	gcgaccaggg	ctgcctggcc	cttgctgagc	1200
tccttggtag	gaagaaggag	ctggaggacc	ttgtccggag	ggagcacgcc	agcatagatg	1260
cccagtcggt	ggcgggggtc	cccaacccca	gcacttcagc	ttcccccaag	aagtccccgc	1320
cacctgccaa	ggacgaggcc	aggacaacag	agaggagaaa	acccagtgaa	cagctgcatac	1380
tcccaggcgg	gatgcgagc	tcctcaggga	cagctgagcc	ccaaccgggc	ctggccccct	1440
cttaaccagc	agttcttgtc	tggggagctc	agaacatccc	ccaatctctt	acagctccct	1500
ccccaaaact	ggggtccag	caaccctggc	ccccaacccc	agcaaattctc	taacacctcc	1560
tagaggccaa	ggcttaaaca	ggcatctcta	ccagccccac	tgtctctaac	cactcctggg	1620
ctaaggagta	acctccctca	tctctaactg	ccccacggg	gccagggcta	ccccagaact	1680
tttaactctt	ccaggacagg	gagcttcggg	ccccactct	gtctcctgcc	cccggggggc	1740
tgtggctaag	taaaccatac	ctaacctacc	ccagtgtggg	tgtgggcctc	tgaatataac	1800

5/29

ccacacccag	cgtaggggga	gtctgagccg	ggaggggtcc	cgagtctctg	ccttcagctc	1860
ccaaagtggg	tgggtgggccc	ccttcacgtg	ggacccactt	cccatgctgg	atgggcagaa	1920
gacattgctt	attggagaca	aattaaaaaac	aaaaacaact	aac		1963

&lt;210&gt; 5

&lt;211&gt; 1826

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 5

atcctatctc	ggcctcttct	tgtttccgct	gccgtcacgg	gacagagcag	tgggtgacag	60
tcccaggggc	ccccaccccg	ttcccatggc	cgagccggac	ccctctgacc	ctctggagac	120
ccaggcaggg	aaggtgcagg	aggtcagga	ttcagactcg	gacactgagg	gaggagccac	180
tgggtggagag	gcagagatgg	acttccctgag	gaatttatct	accagacccc	tgggcctggg	240
ttcccaaaag	gagcgtcttc	tagacgagct	gaccctcgaa	ggagtgcac	gctacatgca	300
gagcgcagcgc	tgccgcaagg	tcatctgttt	ggtgggagcc	ggaatctcca	cgtccgcggg	360
tatccctgac	ttccgctccc	cgtccactgg	cctctatgca	aacctggaga	agtaccacct	420
tccttaccaca	gaggccatct	ttgagatcag	ctacttcaag	aaacatccgg	aacctttctt	480
tgcccttgcc	aaggagctct	atcccgggca	gttcaagcca	accatctgcc	actacttcat	540
ccgcctgctg	aaggagaagg	ggctgctgct	gcgctgctac	acgcagaaca	tagacacgct	600
ggaacgagtg	gcggggctgg	agccccagga	cctggtggag	gccacaggca	ccttctacac	660
atcacactgt	gtcaacacct	cctgcagaaa	agaatacacg	atgggctgga	tgaaagagaa	720
gatctttctca	gaagcaactc	ccaggtgtga	gcagtgtcag	agtgtggtaa	agcctgatat	780
cgtgtttttc	ggtgagaacc	ttccatcgcg	cttcttctcc	tgcatgcagt	cagacttctc	840
caaggtggac	ctcctcatca	tcatgggcac	ctccctgcag	gtgcagccct	tcgcctccct	900
catcagcaag	gcaccactag	ccacccacag	gctgctcatt	aacaaggaaa	agacaggcca	960
gacggacccc	ttcctgggca	tgatgatggg	cctgggaggt	ggcatggatt	ttgactccaa	1020
gaaggcttac	aggagcgtgg	cctggctggg	tgactgtgat	caaggctgcc	tggctctcgc	1080
tgacctcttc	ggatggaaga	aggaaactgga	agacctgttc	cggagggagc	atgccaacat	1140
agatgccag	tcagggtcac	aggcccccaa	ccccagcact	accatctccc	ctggaaagtc	1200
cccaccgcct	gccaaaggag	cggccaggac	caaagagaaa	gaggaacagc	agtaacagta	1260
accatgacct	cccgcaggac	agcggacgcc	ggccagcact	gggccctctt	aacatgcagc	1320
ttgtgtgagc	tcaaagaccc	ttcgttcttt	aaccacgttc	ttgaaatcag	ggtccccaac	1380
tcaatcccag	agaagcggaa	tatacctaag	ggctgaggcc	tgtgcagtct	gtagctgggg	1440
cctctaacca	ccatagccgc	taaccaccca	ggcaagaagc	agccttcctt	aacttctaata	1500
tattcccaga	caacaggcta	ccccaaaacc	cctaacagtg	ccagaataag	gcattttctct	1560
attgttttga	gggggcctat	ggtaaataca	attaacctac	ccgcataagg	ggctggactc	1620
tacaaataga	acttcaccca	agggggtggg	gccttgtggg	atctctgagc	ctgaaggcct	1680
gccaactctc	tgcttccaac	aaagtgggta	ctaggctccc	tttcttgggg	accactttgc	1740
cagctgttgg	tggatgagca	agagaccttg	cttattagaa	acaaattaaa	aaacaaaaca	1800
aagcaactaa	aaaaaaaaaa	aaaaaa				1826

&lt;210&gt; 6

&lt;211&gt; 1869

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

ggcgccgggg	gcgggggtgg	gaggcggagg	cggggccggg	gcgcgcgggg	cggggcgcgc	60
ggggcggggc	gagtcgggag	gactcctcgg	actgcgcgga	acatggcggt	ctgggggttg	120
cgcgcgcggg	cagccctcgg	gctgtggggc	cgggtagtgt	aacgggtcga	ggccggggga	180
ggcgtggggc	gttttcaggc	ctgcggctgt	cggctggtgc	ttggcggcag	ggacgatgtg	240
agtgcggggc	tgagaggcag	ccatggggcc	cgcgggtgac	ccttgacccc	ggcgcgcgcc	300
ttgcagaggc	ctcccagacc	cgaggtgccc	aggcattccc	ggaggcagcc	gagggcagca	360
gctcccagtt	tcttcttttc	gagtattaaa	ggtggaagaa	ggtccatata	tttttctgtg	420
ggtgcttcaa	gtgttggttg	aagtggaggc	agcagtgcac	aggggaagct	ttccctgcag	480
gatgtagctg	agctgattcg	ggccagagcc	tgccagaggg	tgggtggtcat	ggtggggggc	540
ggcatcagca	caccagtggt	cattccagac	ttcagatcgc	cggggagtgg	cctgtacagc	600
aacctccagc	agtacgatct	cccgtacccc	gaggccattt	ttgaactccc	attctttctt	660
cacaacccca	agcccttttt	cactttggcc	aaggagctgt	accctggaaa	ctacaagccc	720
aacgtcactc	actactttct	ccggctgctt	catgacaagg	ggctgcttct	gcggctctac	780

6/29

acgcagaaca	tcgatgggct	tgagagagtg	tcgggcatcc	ctgcctcaaa	gctggttgaa	840
gctcatggaa	cctttgcctc	tgccacctgc	acagtctgcc	aaagaccctt	cccaggggag	900
gacattcggg	ctgacgtgat	ggcagacagg	gttccccgct	gcccgggtctg	caccggcggt	960
gtgaagcccg	acatttgttt	ctttggggag	ccgctgcccc	agaggttctt	gctgcatgtg	1020
gttgatttcc	ccatggcaga	tctgctgctc	atccttggga	cctccctgga	ggtggagcct	1080
tttgccagct	tgaccgaggc	cgtgcggagc	tcagttcccc	gactgctcat	caaccgggac	1140
ttggtggggc	ccttggcctt	gcacccctgc	agcagggacg	tggcccagct	gggggacgtg	1200
gttcacggcg	tggaaagcct	agtggagcct	ctgggctgga	cagaagagat	gcgggacctt	1260
gtgcagcggg	aaactgggaa	gcttgatgga	ccagacaaat	aggatgatgg	ctgccccac	1320
acaataaatg	gtaacatagg	agacatccac	atcccaattc	tgacaagacc	tcatgcctga	1380
agacagcttg	ggcaggtgaa	accagaatat	gtgaactgag	tggacacccg	aggctgccac	1440
tggaatgtct	tctcaggcca	tgagctgcag	tgactggtag	ggctgtgttt	acagtcaggg	1500
ccaccccgtc	acatatataa	aggagctgcc	tgctgttttg	ctgtgttgaa	ctcttcactc	1560
tgctgaagct	cctaattggaa	aaagctttct	tctgactgtg	accctcttga	actgaatcag	1620
accaactgga	atcccagacc	gagtctgctt	tctgtgccta	gttgaacggc	aagctcggca	1680
tctgttggtt	acaagatcca	gacttgggcc	gagcgggtccc	cagccctctt	catgttccga	1740
agtgtagtct	tgaggccctg	gtgccgcact	tctagcatgt	tgggtctcct	tagtggggct	1800
atttttaatg	agagaaaatc	tgttctttcc	agcatgaaat	acatttagtc	tcctcaaaaa	1860
aaaaaaaca						1869

&lt;210&gt; 7

&lt;211&gt; 1428

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 7

ggggattcgg	atggcgcttg	accctctagg	cgccgtcgtc	ctgcagagca	tcatggcgct	60
aagcggtcga	ctggcattgg	ccgcgctcag	actgtggggt	ccgggagtg	tacaggtggg	120
agaaggccca	tatccctctg	tgtgggagcc	tcaggcggct	ttggaggtgg	aggaagcagt	180
gagaagaagt	tttctctgca	ggatgtagct	gagctgcttc	ggaccagagc	ctgcagtagg	240
gtggtggtea	tgggtggggc	cggcatcagc	acaccagtg	gcaccccgga	cttcagatcc	300
ccaggagcgg	gcctctacag	caaccttcag	cagtatgaca	tcccgtaccc	tgaagccatc	360
tttgaacttg	gctttttctt	tcacaacccc	aagccctttt	tcatgttggt	caaggagctg	420
tacctggggc	actacaggcc	caatgtcact	cactacttcc	tgaggctcct	ccacgacaag	480
gagctgcttc	tgcggctcta	tacacagaac	atcgacgggc	ttgagagagc	atctgggatc	540
cctgcctcaa	agctgggttg	agcccacggg	acctttgtaa	cagctacatg	cacgggtctgt	600
cgaaggctct	tcccaggggg	agacatatgg	gctgatgtga	tggcggacag	ggtgccccgc	660
tgcgctgtct	gtactggcgt	tgtgaaaccc	gacattgtgt	tctttggggg	gcagctgcct	720
gcaaggttcc	tactccatat	ggctgacttc	gctttggcag	atctgctact	cattcttggg	780
acctccctgg	aggtggagcc	ttttgccagc	ttgtctgaag	cagtacagaa	atcagtgcc	840
cgactgctca	tcaatcgaga	cttgggtggg	ccgttcgttc	tgagtcctcg	aaggaaagat	900
gtggtccagc	taggggatgt	agttcatggt	gtggaaaggc	tgggtggacct	cctgggggtg	960
acacaagaac	tgctggatct	tatgcagcgg	gaacgtggca	agctggatgg	acaggacaga	1020
taagactatg	gcttcttcac	ctggggaagt	cacacagcag	atcatcctat	gtccagcaag	1080
acttcatgcc	tgaagacagc	tccaacacgt	ttacaaacat	gaaccagacc	acaacatgtg	1140
gcctggacag	tggtcctccg	aggctgcctt	tggaaaggct	gaccagggat	gtctaccctt	1200
ggggcccttc	catgtgtgcg	ccctgtccac	ctcatcactg	ctgaagggtg	agtgcaggtg	1260
ctgctttctg	cagcggccct	taagttatca	cgagggcagc	acagcacgcc	cgtcgccagg	1320
caggcgatgc	actagggcaa	tctagcatgt	tgatcggtaa	agtggcatct	ttactacaa	1380
catcatttct	tgcatgaaat	aaacttagta	taaaaaaaaa	aaaaaaaaa		1428

&lt;210&gt; 8

&lt;211&gt; 1473

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 8

acttccgcta	aaattctccc	gggtttcttg	ccctgccttt	gaggcattaa	agagtagagg	60
tgcttgggga	cagctagcca	ctgactggtc	acgtagcctc	aagcctgcag	acttgggtcc	120
tctgaaaccg	gatggcggtt	ggcgaggact	agtgttacag	gtgggagaag	gccccatatc	180
ctctgtgtgg	gagcctcagg	cggctttgga	ggtggaggaa	gcagtgagaa	gaagttttct	240

7/29

ctgcaggatg	tagctgagct	gcttcggacc	agagcctgca	gtaggggtggt	ggtcattggtg	300
ggggccggca	tcagcacacc	cagtggcacc	ccggacttca	gatccccagg	gagcgggcctc	360
tacagcaacc	ttcagcagta	tgacatcccg	taccctgaag	ccatccttga	acttggccttt	420
ttctttcaca	accccaagcc	ctttttcatg	ttggccaagg	agctgtaccc	tgggcaactac	480
aggcccaatg	tcactcacta	cttcctgagg	ctcctccacg	acaaggagct	gcttctgcgg	540
ctctatacac	agaacatcga	cgggcttgag	agagcatctg	ggatccctgc	ctcaaagctg	600
gttgaagccc	acgggacctt	tgtaacagct	acatgcacgg	tctgtcgaag	gtccttccca	660
ggggaagaca	tatgggctga	tgtgatggcg	gacaggggtg	cccgtgcgc	tgtctgtact	720
ggcgttggtg	aaccgcacat	tgtgttcttt	ggggagcagc	tgccctgcaag	gttcctactc	780
catatggctg	acttcgcctt	ggcagatctg	ctactcattc	ttgggacctc	cctggagggtg	840
gagccttttg	ccagcttggtc	tgaagcagta	cagaaatcag	tgccccgact	gctcatcaat	900
cgagacttgg	tggggccgtt	cgttctgagt	cctcgaagga	aagatgtggt	ccagtaggg	960
gatgtagttc	atgggtgtgga	aaggctggtg	gacctcctgg	ggtggacaca	agaactgctg	1020
gatcttatgc	agcgggaacg	tggcaagctg	gatggacagg	acagataaga	ctatggcttc	1080
ttcacctggg	gaagtccac	agcagatcat	cctatgtcca	gcaagacttc	atgcctgaag	1140
acagctccaa	cacgtttaca	aacatgaacc	agaccacaac	atgtggcctg	gacagtggtc	1200
ctccgaggct	gcctttggaa	aggctgacca	gggatgtcta	cccttggggc	ccctccatgt	1260
gtgcgccttg	tccacctcat	cactgctgaa	ggtgtagtgc	aggtgctgct	ttctgcagcg	1320
ggccttaagt	tatcacgagg	gcagcacagc	acgcccgtcg	ccaggcaggc	gatgcactag	1380
ggcaatctag	catgttgatc	ggtaaaagtg	catctttaac	tacaacatca	tttcttgcac	1440
gaaataaact	tagtataaaa	aaaaaaaaaa	aaa			1473

&lt;210&gt; 9

&lt;211&gt; 1174

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

gtccgtagag	ctgtgagaga	atgaagatga	gctttgcgtt	gactttcagg	tcagcaaaaag	60
gccgttggtg	cgcaaacccc	agccagccgt	gctcgaaagc	ctccattggg	ttattttgtgc	120
cagcaagtcc	tcctctggac	cctgagaagg	tcaaagagtt	acagcgcttc	atcaccccttt	180
ccaagagact	ccttgatgat	actggggcag	gaatctccac	cgaatcgggg	ataccagact	240
acaggtcaga	aaaagtgggg	ctttatgccc	gcaactgacc	caggcccatc	cagcatgggtg	300
attttgtccg	gagtgcctca	atccgccagc	ggtactgggc	gagaaacttc	gtaggctggc	360
ctcaattctc	ctcccaccag	cctaaccctg	cacactgggc	tttgagcacc	tgggagaaac	420
tcggaagagt	gtactggttg	gtgacccaaa	atgtggatgc	tttgacacac	aaggcgggga	480
gtcggcgcc	gacagagctc	cacggatgca	tggacagggt	cctgtgcttg	gattgtgggg	540
aacagactcc	ccgggggggtg	ctgcaagagc	gtttccaagt	cctgaacccc	acctggagtg	600
ctgaggccca	tggcctggct	cctgatgggtg	acgtctttct	ctcagaggag	caagtccgga	660
gctttcaggt	cccaacctgc	gttcaatgtg	gaggccatct	gaaaccagat	gtcgttttct	720
tcggggacac	agtgaacctt	gacaagggtg	attttgtgca	caagcgtgta	aaagaagccg	780
actccctctt	ggtggtggga	tcatecttgc	aggtatactc	tggttacagg	tttatccctca	840
ctgcctggga	gaagaagctc	ccgattgcaa	tactgaacat	tgggcccaca	cggtcgggatg	900
acttggcggt	tctgaaactg	aattctcgtt	gtggagagtt	gctgcctttg	atagacccat	960
gctgaccaca	gcctgatatt	ccagaacctg	gaacagggac	tttcacttga	atcttgcctgc	1020
taaatgtaaa	tgctttctca	aatgacagat	tccagttccc	attcaacaga	gtaggggtgca	1080
ctgacaaagt	atagaagggtt	ctaggtatct	taatgtgtgg	atattcttaa	ttaaaactca	1140
ttttttttta	ataaaaaatt	gttcagcttt	aaaa			1174

&lt;210&gt; 10

&lt;211&gt; 1633

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

cgcctctagg	agaaagcctg	gaacgcgtac	cggagggtac	cagagctctt	agcggggccgg	60
cagcatgtgc	ggggccaagt	aaatggaaat	gttttctaac	atataaaaaac	ctacagaaga	120
agaaaataat	tttctggatc	aaattagaag	tctgtattat	attgatgtct	ccagattcaa	180
atatattaga	aagcagccgt	ggagacaacc	atcttcattt	tgggagaaat	aactaaagcc	240
cgcctcaagc	attagaacta	cagacaaacc	ctgatgcgac	ctctccagat	tgtcccaagt	300
cgattgattt	cccagctata	ttgtggcctg	aagcctccag	cgtccacacg	aaaccagatt	360

tgcctgaaaa	tggctcggcc	aagttcaagt	atggcagatt	ttcgaaagtt	ttttgcaaaa	420
gcaaagcaca	tagtcatcat	ctcaggagct	ggtgttagtg	cagaaagtgg	tgttccgacc	480
ttcagaggag	ctggaggtta	ttggagaaaa	tggcaagccc	aggacctggc	gactcccctg	540
gcctttgccc	acaaccgctc	ccgggtgtgg	gagttctacc	actaccggcg	ggaggtcatg	600
gggagcaagg	agcccaacgc	cgggcaccgc	gccatagccg	agtgtgagac	ccggctgggc	660
aagcagggcc	ggcgagtctg	ggtcatcacc	cagaacatcg	atgagctgca	ccgcaaggct	720
ggcaccaaga	accttctgga	gatccatggt	agcttatatta	aaactcgatg	tacctcttgt	780
ggagttgtgg	ctgagaatta	caagagtcca	atttgtccag	ctttatcagg	aaaagggtgct	840
ccagaacctg	gaactcaaga	tgccagcatc	ccagttgaga	aacttccccg	gtgtgaagag	900
gcaggctgcg	ggggcttgct	gcgacctcac	gtcgtgtggt	ttggagaaaa	cctggatcct	960
gccattctgg	aggagggtga	cagagagctc	gccactgtg	atttatgtct	agtgggtggc	1020
acttctctg	tgggtgaccc	agcagccatg	tttgccccc	aggtggctgc	caggggcgtg	1080
ccagtggctg	aatttaacac	ggagaccacc	ccagctacga	acagattcag	gtttcatttc	1140
cagggaccct	gtggaacgac	tcttcttgaa	gcccttgcc	gtcatgaaaa	tgaactggt	1200
tcttaagtgt	cctggggaag	aaagaaatta	cagtatatct	aagaactagg	ccacacgcag	1260
aggagaaatg	gtcttatggg	tgggtgagctg	agtactgaac	aatctaaaaa	tagcctctga	1320
ttccctcgct	ggaatccaac	ctggtgataa	gtgatggggg	tttagaagta	gcaaagagca	1380
cccacattca	aaagtcacag	aactggaaa	ttaattcata	ttatttggtt	tgaactgaaa	1440
cgtgaggtat	ctttgatgtg	tatggttggt	tattgggagg	gaaaaatttt	gtaaattaga	1500
ttgtctaaaa	aaaatagtta	ttctgattat	atttttggtta	tctgggcaaa	gtagaagtca	1560
aggggtaaaa	accctactat	tctgattttt	gcacaagttt	tagtggaana	taaaatcaca	1620
ctctacagta	ggt					1633

&lt;210&gt; 11

&lt;211&gt; 1638

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

gcttccggcg	gaagcggcct	caacaaggga	aactttattg	ttcccggtggg	gcagtcgagg	60
atgtcgggtga	attacgcggc	ggggctgtcg	ccgtacgcgg	acaagggcaa	gtgcggcctc	120
ccggagatct	tgcaccccc	ggaggagctg	gagcggaagg	tgtgggaact	ggcgaggctg	180
gtctggcagt	cttccagtgt	ggtgttccac	acgggtgccg	gcatacagac	tgcctctggc	240
atccccgact	tcaggggtcc	ccacggagtc	tggacctagg	aggagcgagg	tctggccccc	300
aagttcgaca	ccacctttga	gagcgcgcgg	cccacgcaga	cccacatggc	gctggtgcag	360
ctgcagcggc	tgggcctcct	ccgcttcctg	gtcagccaga	acgtggacgg	gctccatgtg	420
cgctcaggct	tccccaggga	caaaactggca	gagctccacg	ggaacatggt	tgtggaagaa	480
tgtgccaaagt	gtaagacgca	gtacgtccga	gacacagtcg	tgggcaccat	gggcctgaag	540
gccacggggc	ggctctgcac	cgtggctaag	gcaagggggc	tgcgagcctg	caggggagag	600
ctgagggaca	ccatcctaga	ctgggaggac	tccctgccc	accgggacct	ggcactcgcc	660
gatgaggcca	gcaggaacgc	cgacctgtcc	atcacgctgg	gtacatcgct	gcagatccgg	720
cccagcggga	acctgccgct	ggctaccaag	cgccggggag	gccgcctggt	catcgctcaac	780
ctgcagccca	ccaagcacga	ccgccatgct	gacctccgca	tccatggcta	cgttgacgag	840
gtcatgacct	ggctcatgga	gcacctgggg	ctggagatcc	ccgcctggga	cggccccctg	900
gtgctggaga	gggcgctgcc	acccctgccc	cgcccgccca	cccccaagct	ggagcccaag	960
gaggaatctc	ccacccggat	caacggctct	atccccgccc	gccccaaagca	ggagccctgc	1020
gccacgcaca	acggctcaga	gcccgcacg	cccaaacggg	agcggccac	cagccctgcc	1080
ccccacagac	ccccaaaaag	ggtgaaggcc	aaggcggctc	ccagctgacc	aggggtgctt	1140
gggaggggtg	ggctttttgt	agaaaactgtg	gattcttttt	ctctcgtggt	ctcactttgt	1200
tacttgtttc	tgtccccggg	agcctcaggg	ctctgagagc	tgtgctccag	gccagggggt	1260
acacctgccc	tccgtggtcc	ctccctgggc	tccaggggccc	tctggtgcgg	ttccgggaag	1320
aagccacacc	ccagaggtga	cagctgagcc	cgtgccacac	cccagcctct	gacttgctgt	1380
ttgttcacaga	ggtgaggctg	ggccctccct	ggtctccagc	ttaaacagga	gtgaactccc	1440
tctgtcccca	gggcctccct	tctgggcccc	ctacagccca	ccctaccct	cctccatggg	1500
ccctgcagga	ggggagaccc	accttgaagt	gggggatcag	tagaggcttg	cactgccttt	1560
ggggctggag	ggagacgtgg	gtccaccagg	cttctggaaa	agtcctcaat	gcaataaaaa	1620
caatttcttt	cttgcaaa					1638

&lt;210&gt; 12

&lt;211&gt; 1682

&lt;212&gt; DNA

9/29

&lt;213&gt; Mus musculus

&lt;400&gt; 12

cgtgcggcag	cgccggcgac	gatgtcgggtg	aattatgcag	caggggtgtc	gccttacgcg	60
gataagggca	agtgcgggct	gcccagagatc	ttcgacccac	cagaggagct	ggaacgcaag	120
gtgtgggagc	tgcccggtct	aatgtggcag	tcctccagcg	tggttttcca	cacgggcgcc	180
ggcatcagca	ccgcctctgg	catccccgac	ttcagaggcc	cccatggcgt	gtggaccatg	240
gaggaacgcg	gcctggcccc	caagtttgac	accaccttcg	agaatgctcg	gccctcgaag	300
accacatgg	ccctggttca	gctagaacgc	atgggcttcc	tcagcttcc	ggtcagccag	360
aacgtagacg	ggctgcacgt	gcgctcgggc	ttccccagg	acaagctggc	agagctgcac	420
ggaacatgt	ttgtagagga	atgtcccaag	tgtaagacgc	agtacgtcag	agacacggtt	480
gtgggcacca	tgggcctcaa	ggccacaggc	cggctctgca	ccgtggccaa	gaccagggga	540
cttcgggcct	gtagagggga	gctgagagac	accattctgg	actgggagga	ctcgttgcct	600
gaccgggacc	tgatgctcgc	tgatgaggcc	agcaggaccg	cagacctgtc	tgtcacctcg	660
ggtacctcgc	tgcagatccg	ccccagtggt	aacctgcccc	ttgccactaa	gcgcgagga	720
ggcgtctg	tcattgtcaa	cctgcaaccc	acaaaacatg	accgccaggc	tgacctgcgc	780
atccacggct	acgtggatga	ggtgatgtgc	agactcatga	agcatctggg	gctggagatt	840
ccagcctgg	atggaccctg	cgtgctagac	aaagccctgc	cacctctgcc	tcgccagta	900
gcactcaagg	ctgagcccc	cgtgcatctc	aatggtgcag	tgcatgtttc	gtataagtc	960
aagcccaaca	gccctatact	ccacaggccc	cccaaaaagag	tgaagaccga	ggctgcccc	1020
agctgacccg	ggtatgtggg	gcgggagggg	aacttgaagg	aaccacacat	ggtgaggttt	1080
ttgtttgttt	gtttgtttgt	ttgtttttta	tattctgggg	actgagccca	ggtttgcata	1140
tctcacctcg	gtgtcttttc	agattttttt	tttttttttt	tttttttttg	agaccaggac	1200
tccttagatc	gctcaggctg	gtctggaact	cactgctata	gcccgaggctg	gcctggaact	1260
agcctgcctg	cctcagcctc	tactgtagta	gggacagcgg	gcaggtacac	catgtccaac	1320
acagctcctt	tcttcaaagt	ctcactgtgt	cccttgtcca	ggtccttcca	gggaatctca	1380
gggcatgggg	aatcccacac	atgtggaaga	ggcctgtgcc	cagggatcca	cgtgcctctc	1440
taccaatcac	accgcctcgt	gactcaggat	gtgcgcggag	cagcagtctc	acacactcca	1500
cacaccattg	ctgccccctg	cacgcattct	ccccccatcc	cctggccctg	acacagagcc	1560
accaagggcc	caccaggcac	ccatctgtgc	taagggtccc	aggctcccag	aagctcccaa	1620
tgcaataaat	acaaaatccc	ttccattctt	ttaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1680
aa						1682

&lt;210&gt; 13

&lt;211&gt; 1718

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

gcggaagcgg	aagagcaggt	ctccagggga	gcgatggcag	ccgggggtct	gagccgctcc	60
gagcgcaaa	cggcggagcg	ggtccggagg	ttgcgggagg	agcagcagag	ggagcgctc	120
cgccaggtgt	cgcgatcct	gaggaaggcg	gcggcgagc	gcagcgccga	ggagggccgg	180
ctgctggccg	agagcgcgga	cctggtaacg	gagctgcagg	gccggagccg	gcggcgcgag	240
ggcctgaagc	ggcggcagga	ggaggtgtgc	gacgaccgg	aggagctgcg	ggggaaggtc	300
cgggagctgg	ccagcgccgt	ccggaacgcc	aaatacttgg	tcgtctacac	aggcgcgga	360
atcagcacgg	cagcgtctat	cccagactac	cggggcccta	atggagtgtg	gacactgctt	420
cagaaaggga	gaagcgttag	tgctgccgac	ctgagcgagg	ccgagccaac	cctcacccac	480
atgagcatca	ccgctctgca	tgagcagaag	ctggtgcagc	atgtggtgtc	tcagaactgt	540
gacgggctcc	acctgaggag	tgggtgcgg	cgcacggcca	tctccgagct	ccacgggaac	600
atgtacattg	aagtctgtac	ctcctgcgtt	cccaacaggg	agtacgtgcg	ggtgttcgat	660
gtgacggagc	gcactgcctt	ccacagacac	cagacaggcc	ggacctgcca	caagtgtggg	720
accagctgc	gggacccat	tgtgcacttt	ggggagaggg	ggacgttggg	gcagcctctg	780
aactgggaag	ggcgaccga	ggctgccagc	agagcagaca	ccatcctgtg	tctagggtcc	840
agcctgaagg	ttctaaagaa	gtacccacgc	ctctggtgca	tgaccaagcc	ccctagccgg	900
cggccgaagc	tttacatcgt	gaacctgcag	tggaccccca	aggatgactg	ggctgcccctg	960
aagctacatg	ggaagtgtga	tgacgtcatg	cggctcctca	tggccgagct	gggcttggag	1020
atccccgcct	atagcagggtg	gcaggatccc	attttctcac	tggcgactcc	cctgcgtgct	1080
ggtgaagaag	gcagccacag	tcggaagtgc	ctgtgcagaa	gcagagagga	ggccccgcct	1140
ggggaccggg	gtgcaccgct	tagctcggcc	cccatcctag	ggggctggtt	tggcaggggc	1200
tgcaaaaaac	gcacaaaaag	gaagaaagtg	acgtaatcac	gtgctcgatg	aagaacagtt	1260
ggcactttgc	agatggccag	tgtcacgggtg	aaggctgggt	tgccccacag	ggtctagggga	1320

10/29

```

gaacgaactc tttggggatg acattttcac cgtgacattt ttagccattt gtccttgagg 1380
aagccccctg cactgctgcg gttgtaccct gatacggcct ggccatcgag gacacctgcc 1440
catccggcct ctgtgtcaag aggtggcagc cgcaccttcc tgtgagaacg gaactcgggt 1500
tatttcagcc cggcctgca gagggaagc gccagcggc ctttcctcgc tcaccaggcc 1560
agtctcaggg cctcacgcta tttctactac tacttaatga aaaagtgtga actttataga 1620
atcctctctg tactggatgt gcggcagagg ggtggctccg agcctcggct ctatgcagac 1680
ctttttatct ctattaaacg tttctgcact ggcaaaaa 1718

```

&lt;210&gt; 14

&lt;211&gt; 1712

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 14

```

agccggtggc ggtctgagcc gctcggagcg caaagctgct gagcgggtcc ggaggctgcg 60
ggaggagcag cagcgggagc gcctccgcca ggtgtcacgc atcctgagga aggcggctgc 120
agagcgcagc gcggaggagg gccggctctt ggccgagagc gaggatctgg tgaccgagct 180
gcagggtcga agtcggcgcc gtgagggcct caagcgccgc caggaggagg tgtgtgatga 240
cccggaggag ctgaggagga aggtccgcga actggccgga gctgtccgaa gtgccaggca 300
cttggttgtc tacacgggcg ctggaatcag cacagcagct tctatcccag attatcgggg 360
tcctaattga gtatggacac tgcttcagaa aggaaggcct gtgagtgtg cgcacctaag 420
cgaagcggag cctaccctca cccacatgag catcacccgt ttgcatgagc aaaagctggt 480
gcaacacgtg gtgtctcaga actgtgatgg gctccacctg cggagtgggt tgccccggac 540
cgccatctca gagctccatg ggaatatgta tattgaagtc tgcacctcct gcatccctaa 600
cagagagtat gtacgagtgt ttgatgtgac tgagcgtact gcccttcacc gacacctgac 660
aggccggacc tgccacaagt gcgggaccca gcttcgggat accattgtgc actttgggga 720
gagggggaca ttagggcagc ctctgaactg ggaggcagcg accgaggctg ctagcaaagc 780
agacacaatc ctgtgttttag ggtccagctt gaaggtacta aagaaatata cccgcctctg 840
gtgcatgacg aagcctccaa gccgtcgacc caaactctac atcgtgaacc tgcagtggac 900
cccgaaggat gactgggctg ccctgaaact ccatgggaag tgtgatgatg tcatgcaact 960
cctcatgaat gaactgggcc tggagattcc tgtctacaac cgggtggcagg atccaatctt 1020
ctccttggcg accccctcc gtgctggtga agaaggcagc cacagtagga agtcactatg 1080
cagaagcaga gaagaagccc cacctgggga ccagagtgac ccccttgccct cagctcccc 1140
tatcctagga ggctggtttg gcaggggttg tgccaagcgt gcaaaaagga agaaagtggc 1200
atagcccgga gttgacaaag aacagttggc actttgcaga tggcttgacc cttgttcagg 1260
ggctccgccc gtgtcgccgt gaaggcgaga gtgccccctc cggctctagt ggggtgccggc 1320
ttcgcggtga cggctgtctt tagccatttg tccttgtgga aaggctctct tgcactgtg 1380
tgactgcccc gctatgggct tgatcttcaa ggacacctcc ctccgtttca cccctgtaca 1440
aaggtggcag caaggcctct gtgagaagag ctccggccct tcccaggcct ggccagcagg 1500
agagtccacc actgccttac ctactctccc aggctagtct cagggcctcc ctctttctac 1560
tccttatcac gtacaagtgt tcactttata gaagcctttt tctgtattgg gtatgcggca 1620
cagggagaat ctaactaagc ctccagctctg agcaagtctt attaaacatc tctcaattgc 1680
taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1712

```

&lt;210&gt; 15

&lt;211&gt; 747

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

```

Met Ala Asp Glu Ala Ala Leu Ala Leu Gln Pro Gly Gly Ser Pro Ser
 1           5           10           15
Ala Ala Gly Ala Asp Arg Glu Ala Ala Ser Ser Pro Ala Gly Glu Pro
 20           25           30
Leu Arg Lys Arg Pro Arg Arg Asp Gly Pro Gly Leu Glu Arg Ser Pro
 35           40           45
Gly Glu Pro Gly Gly Ala Ala Pro Glu Arg Glu Val Pro Ala Ala Ala
 50           55           60
Arg Gly Cys Pro Gly Ala Ala Ala Ala Leu Trp Arg Glu Ala Glu
 65           70           75           80
Ala Glu Ala Ala Ala Ala Gly Gly Glu Gln Glu Ala Gln Ala Thr Ala

```

11/29

				85					90					95			
Ala	Ala	Gly	Glu	Gly	Asp	Asn	Gly	Pro	Gly	Leu	Gln	Gly	Pro	Ser	Arg		
			100					105					110				
Glu	Pro	Pro	Leu	Ala	Asp	Asn	Leu	Tyr	Asp	Glu	Asp	Asp	Asp	Asp	Glu		
		115					120					125					
Gly	Glu	Glu	Glu	Glu	Glu	Ala	Ala	Ala	Ala	Ala	Ile	Gly	Tyr	Arg	Asp		
		130				135					140						
Asn	Leu	Leu	Phe	Gly	Asp	Glu	Ile	Ile	Thr	Asn	Gly	Phe	His	Ser	Cys		
145				150						155					160		
Glu	Ser	Asp	Glu	Glu	Asp	Arg	Ala	Ser	His	Ala	Ser	Ser	Ser	Asp	Trp		
			165						170					175			
Thr	Pro	Arg	Pro	Arg	Ile	Gly	Pro	Tyr	Thr	Phe	Val	Gln	Gln	His	Leu		
			180					185						190			
Met	Ile	Gly	Thr	Asp	Pro	Arg	Thr	Ile	Leu	Lys	Asp	Leu	Leu	Pro	Glu		
		195					200					205					
Thr	Ile	Pro	Pro	Pro	Glu	Leu	Asp	Asp	Met	Thr	Leu	Trp	Gln	Ile	Val		
		210				215					220						
Ile	Asn	Ile	Leu	Ser	Glu	Pro	Pro	Lys	Arg	Lys	Lys	Arg	Lys	Asp	Ile		
225					230				235						240		
Asn	Thr	Ile	Glu	Asp	Ala	Val	Lys	Leu	Leu	Gln	Glu	Cys	Lys	Lys	Ile		
			245					250						255			
Ile	Val	Leu	Thr	Gly	Ala	Gly	Val	Ser	Val	Ser	Cys	Gly	Ile	Pro	Asp		
		260					265						270				
Phe	Arg	Ser	Arg	Asp	Gly	Ile	Tyr	Ala	Arg	Leu	Ala	Val	Asp	Phe	Pro		
		275					280					285					
Asp	Leu	Pro	Asp	Pro	Gln	Ala	Met	Phe	Asp	Ile	Glu	Tyr	Phe	Arg	Lys		
		290				295					300						
Asp	Pro	Arg	Pro	Phe	Phe	Lys	Phe	Ala	Lys	Glu	Ile	Tyr	Pro	Gly	Gln		
305				310					315						320		
Phe	Gln	Pro	Ser	Leu	Cys	His	Lys	Phe	Ile	Ala	Leu	Ser	Asp	Lys	Glu		
			325					330						335			
Gly	Lys	Leu	Leu	Arg	Asn	Tyr	Thr	Gln	Asn	Ile	Asp	Thr	Leu	Glu	Gln		
		340					345						350				
Val	Ala	Gly	Ile	Gln	Arg	Ile	Ile	Gln	Cys	His	Gly	Ser	Phe	Ala	Thr		
		355					360					365					
Ala	Ser	Cys	Leu	Ile	Cys	Lys	Tyr	Lys	Val	Asp	Cys	Glu	Ala	Val	Arg		
		370				375					380						
Gly	Asp	Ile	Phe	Asn	Gln	Val	Val	Pro	Arg	Cys	Pro	Arg	Cys	Pro	Ala		
385				390					395						400		
Asp	Glu	Pro	Leu	Ala	Ile	Met	Lys	Pro	Glu	Ile	Val	Phe	Phe	Gly	Glu		
			405					410						415			
Asn	Leu	Pro	Glu	Gln	Phe	His	Arg	Ala	Met	Lys	Tyr	Asp	Lys	Asp	Glu		
		420						425					430				
Val	Asp	Leu	Leu	Ile	Val	Ile	Gly	Ser	Ser	Leu	Lys	Val	Arg	Pro	Val		
		435					440					445					
Ala	Leu	Ile	Pro	Ser	Ser	Ile	Pro	His	Glu	Val	Pro	Gln	Ile	Leu	Ile		
		450				455					460						
Asn	Arg	Glu	Pro	Leu	Pro	His	Leu	His	Phe	Asp	Val	Glu	Leu	Leu	Gly		
465				470					475						480		
Asp	Cys	Asp	Val	Ile	Ile	Asn	Glu	Leu	Cys	His	Arg	Leu	Gly	Gly	Glu		
			485					490						495			
Tyr	Ala	Lys	Leu	Cys	Cys	Asn	Pro	Val	Lys	Leu	Ser	Glu	Ile	Thr	Glu		
		500						505					510				
Lys	Pro	Pro	Arg	Thr	Gln	Lys	Glu	Leu	Ala	Tyr	Leu	Ser	Glu	Leu	Pro		
		515					520					525					
Pro	Thr	Pro	Leu	His	Val	Ser	Glu	Asp	Ser	Ser	Ser	Pro	Glu	Arg	Thr		
		530				535					540						
Ser	Pro	Pro	Asp	Ser	Ser	Val	Ile	Val	Thr	Leu	Leu	Asp	Gln	Ala	Ala		
545				550					555						560		
Lys	Ser	Asn	Asp	Asp	Leu	Asp	Val	Ser	Glu	Ser	Lys	Gly	Cys	Met	Glu		
			565					570						575			



12/29

Glu	Lys	Pro	Gln	Glu	Val	Gln	Thr	Ser	Arg	Asn	Val	Glu	Ser	Ile	Ala	
			580					585					590			
Glu	Gln	Met	Glu	Asn	Pro	Asp	Leu	Lys	Asn	Val	Gly	Ser	Ser	Thr	Gly	
		595					600					605				
Glu	Lys	Asn	Glu	Arg	Thr	Ser	Val	Ala	Gly	Thr	Val	Arg	Lys	Cys	Trp	
		610				615					620					
Pro	Asn	Arg	Val	Ala	Lys	Glu	Gln	Ile	Ser	Arg	Arg	Leu	Asp	Gly	Asn	
625					630					635					640	
Gln	Tyr	Leu	Phe	Leu	Pro	Pro	Asn	Arg	Tyr	Ile	Phe	His	Gly	Ala	Glu	
			645						650				655			
Val	Tyr	Ser	Asp	Ser	Glu	Asp	Asp	Val	Leu	Ser	Ser	Ser	Ser	Cys	Gly	
			660					665					670			
Ser	Asn	Ser	Asp	Ser	Gly	Thr	Cys	Gln	Ser	Pro	Ser	Leu	Glu	Glu	Pro	
		675					680					685				
Met	Glu	Asp	Glu	Ser	Glu	Ile	Glu	Glu	Phe	Tyr	Asn	Gly	Leu	Glu	Asp	
	690					695					700					
Glu	Pro	Asp	Val	Pro	Glu	Arg	Ala	Gly	Gly	Ala	Gly	Phe	Gly	Thr	Asp	
705					710					715					720	
Gly	Asp	Asp	Gln	Glu	Ala	Ile	Asn	Glu	Ala	Ile	Ser	Val	Lys	Gln	Glu	
			725						730					735		
Val	Thr	Asp	Met	Asn	Tyr	Pro	Ser	Asn	Lys	Ser						
			740					745								

&lt;210&gt; 16

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Met	Ala	Glu	Pro	Asp	Pro	Ser	His	Pro	Leu	Glu	Thr	Gln	Ala	Gly	Lys	
1				5					10					15		
Val	Gln	Glu	Ala	Gln	Asp	Ser	Asp	Ser	Asp	Ser	Glu	Gly	Gly	Ala	Ala	
			20					25					30			
Gly	Gly	Glu	Ala	Asp	Met	Asp	Phe	Leu	Arg	Asn	Leu	Phe	Ser	Gln	Thr	
		35					40					45				
Leu	Ser	Leu	Gly	Ser	Gln	Lys	Glu	Arg	Leu	Leu	Asp	Glu	Leu	Thr	Leu	
	50					55					60					
Glu	Gly	Val	Ala	Arg	Tyr	Met	Gln	Ser	Glu	Arg	Cys	Arg	Arg	Val	Ile	
65				70						75					80	
Cys	Leu	Val	Gly	Ala	Gly	Ile	Ser	Thr	Ser	Ala	Gly	Ile	Pro	Asp	Phe	
			85						90					95		
Arg	Ser	Pro	Ser	Thr	Gly	Leu	Tyr	Asp	Asn	Leu	Glu	Lys	Tyr	His	Leu	
		100						105					110			
Pro	Tyr	Pro	Glu	Ala	Ile	Phe	Glu	Ile	Ser	Tyr	Phe	Lys	Lys	His	Pro	
		115					120					125				
Glu	Pro	Phe	Phe	Ala	Leu	Ala	Lys	Glu	Leu	Tyr	Pro	Gly	Gln	Phe	Lys	
	130					135					140					
Pro	Thr	Ile	Cys	His	Tyr	Phe	Met	Arg	Leu	Leu	Lys	Asp	Lys	Gly	Leu	
145				150						155					160	
Leu	Leu	Arg	Cys	Tyr	Thr	Gln	Asn	Ile	Asp	Thr	Leu	Glu	Arg	Ile	Ala	
			165						170					175		
Gly	Leu	Glu	Gln	Glu	Asp	Leu	Val	Glu	Ala	His	Gly	Thr	Phe	Tyr	Thr	
			180					185						190		
Ser	His	Cys	Val	Ser	Ala	Ser	Cys	Arg	His	Glu	Tyr	Pro	Leu	Ser	Trp	
		195					200					205				
Met	Lys	Glu	Lys	Ile	Phe	Ser	Glu	Val	Thr	Pro	Lys	Cys	Glu	Asp	Cys	
	210					215					220					
Gln	Ser	Leu	Val	Lys	Pro	Asp	Ile	Val	Phe	Phe	Gly	Glu	Ser	Leu	Pro	
225					230					235					240	
Ala	Arg	Phe	Phe	Ser	Cys	Met	Gln	Ser	Asp	Phe	Leu	Lys	Val	Asp	Leu	
				245					250						255	

Leu Leu Val Met Gly Thr Ser Leu Gln Val Gln Pro Phe Ala Ser Leu  
 260 265 270  
 Ile Ser Lys Ala Pro Leu Ser Thr Pro Arg Leu Leu Ile Asn Lys Glu  
 275 280 285  
 Lys Ala Gly Gln Ser Asp Pro Phe Leu Gly Met Ile Met Gly Leu Gly  
 290 295 300  
 Gly Gly Met Asp Phe Asp Ser Lys Lys Ala Tyr Arg Asp Val Ala Trp  
 305 310 315 320  
 Leu Gly Glu Cys Asp Gln Gly Cys Leu Ala Leu Ala Glu Leu Leu Gly  
 325 330 335  
 Trp Lys Lys Glu Leu Glu Asp Leu Val Arg Arg Glu His Ala Ser Ile  
 340 345 350  
 Asp Ala Gln Ser Gly Ala Gly Val Pro Asn Pro Ser Thr Ser Ala Ser  
 355 360 365  
 Pro Lys Lys Ser Pro Pro Pro Ala Lys Asp Glu Ala Arg Thr Thr Glu  
 370 375 380  
 Arg Glu Lys Pro Gln  
 385

<210> 17  
 <211> 352  
 <212> PRT  
 <213> Homo sapiens

<400> 17  
 Met Asp Phe Leu Arg Asn Leu Phe Ser Gln Thr Leu Ser Leu Gly Ser  
 1 5 10 15  
 Gln Lys Glu Arg Leu Leu Asp Glu Leu Thr Leu Glu Gly Val Ala Arg  
 20 25 30  
 Tyr Met Gln Ser Glu Arg Cys Arg Arg Val Ile Cys Leu Val Gly Ala  
 35 40 45  
 Gly Ile Ser Thr Ser Ala Gly Ile Pro Asp Phe Arg Ser Pro Ser Thr  
 50 55 60  
 Gly Leu Tyr Asp Asn Leu Glu Lys Tyr His Leu Pro Tyr Pro Glu Ala  
 65 70 75 80  
 Ile Phe Glu Ile Ser Tyr Phe Lys Lys His Pro Glu Pro Phe Phe Ala  
 85 90 95  
 Leu Ala Lys Glu Leu Tyr Pro Gly Gln Phe Lys Pro Thr Ile Cys His  
 100 105 110  
 Tyr Phe Met Arg Leu Leu Lys Asp Lys Gly Leu Leu Leu Arg Cys Tyr  
 115 120 125  
 Thr Gln Asn Ile Asp Thr Leu Glu Arg Ile Ala Gly Leu Glu Gln Glu  
 130 135 140  
 Asp Leu Val Glu Ala His Gly Thr Phe Tyr Thr Ser His Cys Val Ser  
 145 150 155 160  
 Ala Ser Cys Arg His Glu Tyr Pro Leu Ser Trp Met Lys Glu Lys Ile  
 165 170 175  
 Phe Ser Glu Val Thr Pro Lys Cys Glu Asp Cys Gln Ser Leu Val Lys  
 180 185 190  
 Pro Asp Ile Val Phe Phe Gly Glu Ser Leu Pro Ala Arg Phe Phe Ser  
 195 200 205  
 Cys Met Gln Ser Asp Phe Leu Lys Val Asp Leu Leu Val Met Gly  
 210 215 220  
 Thr Ser Leu Gln Val Gln Pro Phe Ala Ser Leu Ile Ser Lys Ala Pro  
 225 230 235 240  
 Leu Ser Thr Pro Arg Leu Leu Ile Asn Lys Glu Lys Ala Gly Gln Ser  
 245 250 255  
 Asp Pro Phe Leu Gly Met Ile Met Gly Leu Gly Gly Gly Met Asp Phe  
 260 265 270  
 Asp Ser Lys Lys Ala Tyr Arg Asp Val Ala Trp Leu Gly Glu Cys Asp  
 275 280 285

Gln Gly Cys Leu Ala Leu Ala Glu Leu Leu Gly Trp Lys Lys Glu Leu  
 290 295 300  
 Glu Asp Leu Val Arg Arg Glu His Ala Ser Ile Asp Ala Gln Ser Gly  
 305 310 315 320  
 Ala Gly Val Pro Asn Pro Ser Thr Ser Ala Ser Pro Lys Lys Ser Pro  
 325 330 335  
 Pro Pro Ala Lys Asp Glu Ala Arg Thr Thr Glu Arg Glu Lys Pro Gln  
 340 345 350

&lt;210&gt; 18

&lt;211&gt; 399

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

Met Ala Phe Trp Gly Trp Arg Ala Ala Ala Ala Leu Arg Leu Trp Gly  
 1 5 10 15  
 Arg Val Val Glu Arg Val Glu Ala Gly Gly Gly Val Gly Pro Phe Gln  
 20 25 30  
 Ala Cys Gly Cys Arg Leu Val Leu Gly Gly Arg Asp Asp Val Ser Ala  
 35 40 45  
 Gly Leu Arg Gly Ser His Gly Ala Arg Gly Glu Pro Leu Asp Pro Ala  
 50 55 60  
 Arg Pro Leu Gln Arg Pro Pro Arg Pro Glu Val Pro Arg Ala Phe Arg  
 65 70 75 80  
 Arg Gln Pro Arg Ala Ala Pro Ser Phe Phe Phe Ser Ser Ile Lys  
 85 90 95  
 Gly Gly Arg Arg Ser Ile Ser Phe Ser Val Gly Ala Ser Ser Val Val  
 100 105 110  
 Gly Ser Gly Gly Ser Ser Asp Lys Gly Lys Leu Ser Leu Gln Asp Val  
 115 120 125  
 Ala Glu Leu Ile Arg Ala Arg Ala Cys Gln Arg Val Val Val Met Val  
 130 135 140  
 Gly Ala Gly Ile Ser Thr Pro Ser Gly Ile Pro Asp Phe Arg Ser Pro  
 145 150 155 160  
 Gly Ser Gly Leu Tyr Ser Asn Leu Gln Gln Tyr Asp Leu Pro Tyr Pro  
 165 170 175  
 Glu Ala Ile Phe Glu Leu Pro Phe Phe Phe His Asn Pro Lys Pro Phe  
 180 185 190  
 Phe Thr Leu Ala Lys Glu Leu Tyr Pro Gly Asn Tyr Lys Pro Asn Val  
 195 200 205  
 Thr His Tyr Phe Leu Arg Leu Leu His Asp Lys Gly Leu Leu Leu Arg  
 210 215 220  
 Leu Tyr Thr Gln Asn Ile Asp Gly Leu Glu Arg Val Ser Gly Ile Pro  
 225 230 235 240  
 Ala Ser Lys Leu Val Glu Ala His Gly Thr Phe Ala Ser Ala Thr Cys  
 245 250 255  
 Thr Val Cys Gln Arg Pro Phe Pro Gly Glu Asp Ile Arg Ala Asp Val  
 260 265 270  
 Met Ala Asp Arg Val Pro Arg Cys Pro Val Cys Thr Gly Val Val Lys  
 275 280 285  
 Pro Asp Ile Val Phe Phe Gly Glu Pro Leu Pro Gln Arg Phe Leu Leu  
 290 295 300  
 His Val Val Asp Phe Pro Met Ala Asp Leu Leu Leu Ile Leu Gly Thr  
 305 310 315 320  
 Ser Leu Glu Val Glu Pro Phe Ala Ser Leu Thr Glu Ala Val Arg Ser  
 325 330 335  
 Ser Val Pro Arg Leu Leu Ile Asn Arg Asp Leu Val Gly Pro Leu Ala  
 340 345 350  
 Trp His Pro Arg Ser Arg Asp Val Ala Gln Leu Gly Asp Val Val His  
 355 360 365

15/29

Gly Val Glu Ser Leu Val Glu Leu Leu Gly Trp Thr Glu Glu Met Arg  
 370 375 380  
 Asp Leu Val Gln Arg Glu Thr Gly Lys Leu Asp Gly Pro Asp Lys  
 385 390 395

<210> 19  
 <211> 314  
 <212> PRT  
 <213> Homo sapiens

<400> 19  
 Met Lys Met Ser Phe Ala Leu Thr Phe Arg Ser Ala Lys Gly Arg Trp  
 1 5 10 15  
 Ile Ala Asn Pro Ser Gln Pro Cys Ser Lys Ala Ser Ile Gly Leu Phe  
 20 25 30  
 Val Pro Ala Ser Pro Pro Leu Asp Pro Glu Lys Val Lys Glu Leu Gln  
 35 40 45  
 Arg Phe Ile Thr Leu Ser Lys Arg Leu Leu Val Met Thr Gly Ala Gly  
 50 55 60  
 Ile Ser Thr Glu Ser Gly Ile Pro Asp Tyr Arg Ser Glu Lys Val Gly  
 65 70 75 80  
 Leu Tyr Ala Arg Thr Asp Arg Arg Pro Ile Gln His Gly Asp Phe Val  
 85 90 95  
 Arg Ser Ala Pro Ile Arg Gln Arg Tyr Trp Ala Arg Asn Phe Val Gly  
 100 105 110  
 Trp Pro Gln Phe Ser Ser His Gln Pro Asn Pro Ala His Trp Ala Leu  
 115 120 125  
 Ser Thr Trp Glu Lys Leu Gly Lys Leu Tyr Trp Leu Val Thr Gln Asn  
 130 135 140  
 Val Asp Ala Leu His Thr Lys Ala Gly Ser Arg Arg Leu Thr Glu Leu  
 145 150 155 160  
 His Gly Cys Met Asp Arg Val Leu Cys Leu Asp Cys Gly Glu Gln Thr  
 165 170 175  
 Pro Arg Gly Val Leu Gln Glu Arg Phe Gln Val Leu Asn Pro Thr Trp  
 180 185 190  
 Ser Ala Glu Ala His Gly Leu Ala Pro Asp Gly Asp Val Phe Leu Ser  
 195 200 205  
 Glu Glu Gln Val Arg Ser Phe Gln Val Pro Thr Cys Val Gln Cys Gly  
 210 215 220  
 Gly His Leu Lys Pro Asp Val Val Phe Phe Gly Asp Thr Val Asn Pro  
 225 230 235 240  
 Asp Lys Val Asp Phe Val His Lys Arg Val Lys Glu Ala Asp Ser Leu  
 245 250 255  
 Leu Val Val Gly Ser Ser Leu Gln Val Tyr Ser Gly Tyr Arg Phe Ile  
 260 265 270  
 Leu Thr Ala Trp Glu Lys Lys Leu Pro Ile Ala Ile Leu Asn Ile Gly  
 275 280 285  
 Pro Thr Arg Ser Asp Asp Leu Ala Cys Leu Lys Leu Asn Ser Arg Cys  
 290 295 300  
 Gly Glu Leu Leu Pro Leu Ile Asp Pro Cys  
 305 310

<210> 20  
 <211> 310  
 <212> PRT  
 <213> Homo sapiens

<400> 20  
 Met Arg Pro Leu Gln Ile Val Pro Ser Arg Leu Ile Ser Gln Leu Tyr  
 1 5 10 15  
 Cys Gly Leu Lys Pro Pro Ala Ser Thr Arg Asn Gln Ile Cys Leu Lys

```
<210> 21
<211> 299
<212> PRT
<213> Homo sapiens
```

<400> 21

Met	Arg	Pro	Leu	Gln	Ile	Val	Pro	Ser	Arg	Leu	Ile	Ser	Gln	Leu	Tyr
1				5					10					15	
Cys	Gly	Leu	Lys	Pro	Pro	Ala	Ser	Thr	Arg	Asn	Gln	Ile	Cys	Leu	Lys
			20				25						30		
Met	Ala	Arg	Pro	Ser	Ser	Ser	Met	Ala	Asp	Phe	Arg	Lys	Phe	Phe	Ala
		35					40					45			
Lys	Ala	Lys	His	Ile	Val	Ile	Ile	Ser	Gly	Ala	Gly	Val	Ser	Ala	Glu
	50					55					60				
Ser	Gly	Val	Pro	Thr	Phe	Arg	Gly	Ala	Gly	Gly	Tyr	Trp	Arg	Lys	Trp
65				70					75						80
Gln	Ala	Gln	Asp	Leu	Ala	Thr	Pro	Leu	Ala	Phe	Ala	His	Asn	Pro	Ser
			85						90				95		
Arg	Val	Trp	Glu	Phe	Tyr	His	Tyr	Arg	Arg	Glu	Val	Met	Gly	Ser	Lys
			100				105					110			
Glu	Pro	Asn	Ala	Gly	His	Arg	Ala	Ile	Ala	Glu	Cys	Glu	Thr	Arg	Leu
		115					120				125				
Gly	Lys	Gln	Gly	Arg	Arg	Val	Val	Val	Ile	Thr	Gln	Asn	Ile	Asp	Glu

130	135	140
Leu His Arg Lys Ala Gly Thr Lys Asn Leu Leu Glu Ile His Gly Ser		
145	150	155
Leu Phe Lys Thr Arg Cys Thr Ser Cys Gly Val Val Ala Glu Asn Tyr		160
	165	170
Lys Ser Pro Ile Cys Pro Ala Leu Ser Gly Lys Gly Ala Pro Glu Pro		175
	180	185
Gly Thr Gln Asp Ala Ser Ile Pro Val Glu Lys Leu Pro Arg Cys Glu		190
	195	200
Glu Ala Gly Cys Gly Gly Leu Arg Pro His Val Val Trp Phe Gly		205
	210	215
Glu Asn Leu Asp Pro Ala Ile Leu Glu Glu Val Asp Arg Glu Leu Ala		220
225	230	235
His Cys Asp Leu Cys Leu Val Val Gly Thr Ser Ser Val Val Tyr Pro		240
	245	250
Ala Ala Met Phe Ala Pro Gln Val Ala Ala Arg Gly Val Pro Val Ala		255
	260	265
Glu Phe Asn Thr Glu Thr Thr Pro Ala Thr Asn Arg Phe Ser His Leu		270
	275	280
Ile Ser Ile Ser Ser Leu Ile Ile Ile Lys Asn		285
290	295	

<210> 22  
 <211> 355  
 <212> PRT  
 <213> Homo sapiens

<400> 22

Met Ser Val Asn Tyr Ala Ala Gly Leu Ser Pro Tyr Ala Asp Lys Gly	
1	5
Lys Cys Gly Leu Pro Glu Ile Phe Asp Pro Pro Glu Glu Leu Glu Arg	10
	20
Lys Val Trp Glu Leu Ala Arg Leu Val Trp Gln Ser Ser Ser Val Val	25
	30
	35
Phe His Thr Gly Ala Gly Ile Ser Thr Ala Ser Gly Ile Pro Asp Phe	40
	45
	50
Arg Gly Pro His Gly Val Trp Thr Met Glu Glu Arg Gly Leu Ala Pro	55
65	60
Lys Phe Asp Thr Thr Phe Glu Ser Ala Arg Pro Thr Gln Thr His Met	65
	70
	75
	80
	85
Ala Leu Val Gln Leu Glu Arg Val Gly Leu Leu Arg Phe Leu Val Ser	90
	95
	100
Gln Asn Val Asp Gly Leu His Val Arg Ser Gly Phe Pro Arg Asp Lys	105
	110
	115
Leu Ala Glu Leu His Gly Asn Met Phe Val Glu Glu Cys Ala Lys Cys	120
	125
	130
Lys Thr Gln Tyr Val Arg Asp Thr Val Val Gly Thr Met Gly Leu Lys	135
145	140
	145
Ala Thr Gly Arg Leu Cys Thr Val Ala Lys Ala Arg Gly Leu Arg Ala	150
	155
	160
	165
Cys Arg Gly Glu Leu Arg Asp Thr Ile Leu Asp Trp Glu Asp Ser Leu	170
	175
	180
Pro Asp Arg Asp Leu Ala Leu Ala Asp Glu Ala Ser Arg Asn Ala Asp	185
	190
	195
Leu Ser Ile Thr Leu Gly Thr Ser Leu Gln Ile Arg Pro Ser Gly Asn	200
	205
	210
Leu Pro Leu Ala Thr Lys Arg Arg Gly Gly Arg Leu Val Ile Val Asn	215
225	220
	225
Leu Gln Pro Thr Lys His Asp Arg His Ala Asp Leu Arg Ile His Gly	230
	235
	240
	245
	250
	255
Tyr Val Asp Glu Val Met Thr Arg Leu Met Glu His Leu Gly Leu Glu	

18/29

```

      260      265      270
Ile Pro Ala Trp Asp Gly Pro Arg Val Leu Glu Arg Ala Leu Pro Pro
      275      280      285
Leu Pro Arg Pro Pro Thr Pro Lys Leu Glu Pro Lys Glu Glu Ser Pro
      290      295      300
Thr Arg Ile Asn Gly Ser Ile Pro Ala Gly Pro Lys Gln Glu Pro Cys
305      310      315      320
Ala Gln His Asn Gly Ser Glu Pro Ala Ser Pro Lys Arg Glu Arg Pro
      325      330      335
Thr Ser Pro Ala Pro His Arg Pro Pro Lys Arg Val Lys Ala Lys Ala
      340      345      350
Val Pro Ser
      355

```

<210> 23  
 <211> 400  
 <212> PRT  
 <213> Homo sapiens

```

<400> 23
Met Ala Ala Gly Gly Leu Ser Arg Ser Glu Arg Lys Ala Ala Glu Arg
 1      5      10      15
Val Arg Arg Leu Arg Glu Glu Gln Gln Arg Glu Arg Leu Arg Gln Val
      20      25      30
Ser Arg Ile Leu Arg Lys Ala Ala Glu Arg Ser Ala Glu Glu Gly
      35      40      45
Arg Leu Leu Ala Glu Ser Ala Asp Leu Val Thr Glu Leu Gln Gly Arg
      50      55      60
Ser Arg Arg Arg Glu Gly Leu Lys Arg Arg Gln Glu Glu Val Cys Asp
      65      70      75      80
Asp Pro Glu Glu Leu Arg Gly Lys Val Arg Glu Leu Ala Ser Ala Val
      85      90      95
Arg Asn Ala Lys Tyr Leu Val Val Tyr Thr Gly Ala Gly Ile Ser Thr
      100      105      110
Ala Ala Ser Ile Pro Asp Tyr Arg Gly Pro Asn Gly Val Trp Thr Leu
      115      120      125
Leu Gln Lys Gly Arg Ser Val Ser Ala Ala Asp Leu Ser Glu Ala Glu
      130      135      140
Pro Thr Leu Thr His Met Ser Ile Thr Arg Leu His Glu Gln Lys Leu
      145      150      155      160
Val Gln His Val Val Ser Gln Asn Cys Asp Gly Leu His Leu Arg Ser
      165      170      175
Gly Leu Pro Arg Thr Ala Ile Ser Glu Leu His Gly Asn Met Tyr Ile
      180      185      190
Glu Val Cys Thr Ser Cys Val Pro Asn Arg Glu Tyr Val Arg Val Phe
      195      200      205
Asp Val Thr Glu Arg Thr Ala Leu His Arg His Gln Thr Gly Arg Thr
      210      215      220
Cys His Lys Cys Gly Thr Gln Leu Arg Asp Thr Ile Val His Phe Gly
      225      230      235      240
Glu Arg Gly Thr Leu Gly Gln Pro Leu Asn Trp Glu Ala Ala Thr Glu
      245      250      255
Ala Ala Ser Arg Ala Asp Thr Ile Leu Cys Leu Gly Ser Ser Leu Lys
      260      265      270
Val Leu Lys Lys Tyr Pro Arg Leu Trp Cys Met Thr Lys Pro Pro Ser
      275      280      285
Arg Arg Pro Lys Leu Tyr Ile Val Asn Leu Gln Trp Thr Pro Lys Asp
      290      295      300
Asp Trp Ala Ala Leu Lys Leu His Gly Lys Cys Asp Asp Val Met Arg
      305      310      315      320
Leu Leu Met Ala Glu Leu Gly Leu Glu Ile Pro Ala Tyr Ser Arg Trp

```

19/29

				325						330					335				
Gln	Asp	Pro	Ile	Phe	Ser	Leu	Ala	Thr	Pro	Leu	Arg	Ala	Gly	Glu	Glu				
				340				345					350						
Gly	Ser	His	Ser	Arg	Lys	Ser	Leu	Cys	Arg	Ser	Arg	Glu	Glu	Ala	Pro				
		355					360					365							
Pro	Gly	Asp	Arg	Gly	Ala	Pro	Leu	Ser	Ser	Ala	Pro	Ile	Leu	Gly	Gly				
	370					375				380									
Trp	Phe	Gly	Arg	Gly	Cys	Thr	Lys	Arg	Thr	Lys	Arg	Lys	Lys	Val	Thr				
385					390				395						400				

&lt;210&gt; 24

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Control vector

&lt;400&gt; 24

gatgaagttg acctcctca

19

&lt;210&gt; 25

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Control vector

&lt;400&gt; 25

gatgaagtcg acctcctca

19

&lt;210&gt; 26

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 26

aaattcagaa gaaagtaa acattatt

28

&lt;210&gt; 27

&lt;211&gt; 17

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 27

atgccctgac catgtga

17

&lt;210&gt; 28

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer



<400> 28  
 gagcaagggtc ttcatcatta cg 22

<210> 29  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Primer

<400> 29  
 cccctggagc tggagttac 19

<210> 30  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Promoter

<400> 30  
 ctctcccacc ctgcataac 20

<210> 31  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Promoter

<400> 31  
 ttgccagaga agccagtgac a 21

<210> 32  
 <211> 798  
 <212> PRT  
 <213> Homo sapiens

<400> 32  
 Met Ala Trp Asp Met Cys Asn Gln Asp Ser Glu Ser Val Trp Ser Asp  
 1 5 10 15  
 Ile Glu Cys Ala Ala Leu Val Gly Glu Asp Gln Pro Leu Cys Pro Asp  
 20 25 30  
 Leu Pro Glu Leu Asp Leu Ser Glu Leu Asp Val Asn Asp Leu Asp Thr  
 35 40 45  
 Asp Ser Phe Leu Gly Gly Leu Lys Trp Cys Ser Asp Gln Ser Glu Ile  
 50 55 60  
 Ile Ser Asn Gln Tyr Asn Asn Glu Pro Ser Asn Ile Phe Glu Lys Ile  
 65 70 75 80  
 Asp Glu Glu Asn Glu Ala Asn Leu Leu Ala Val Leu Thr Glu Thr Leu  
 85 90 95  
 Asp Ser Leu Pro Val Asp Glu Asp Gly Leu Pro Ser Phe Asp Ala Leu  
 100 105 110  
 Thr Asp Gly Asp Val Thr Thr Asp Asn Glu Ala Ser Pro Ser Ser Met  
 115 120 125  
 Pro Asp Gly Thr Pro Pro Pro Gln Glu Ala Glu Glu Pro Ser Leu Leu  
 130 135 140

Lys	Lys	Leu	Leu	Leu	Ala	Pro	Ala	Asn	Thr	Gln	Leu	Ser	Tyr	Asn	Glu
145					150					155					160
Cys	Ser	Gly	Leu	Ser	Thr	Gln	Asn	His	Ala	Asn	His	Asn	His	Arg	Ile
				165					170					175	
Arg	Thr	Asn	Pro	Ala	Ile	Val	Lys	Thr	Glu	Asn	Ser	Trp	Ser	Asn	Lys
			180					185					190		
Ala	Lys	Ser	Ile	Cys	Gln	Gln	Gln	Lys	Pro	Gln	Arg	Arg	Pro	Cys	Ser
		195					200					205			
Glu	Leu	Leu	Lys	Tyr	Leu	Thr	Thr	Asn	Asp	Asp	Pro	Pro	His	Thr	Lys
	210					215					220				
Pro	Thr	Glu	Asn	Arg	Asn	Ser	Ser	Arg	Asp	Lys	Cys	Thr	Ser	Lys	Lys
225					230					235					240
Lys	Ser	His	Thr	Gln	Ser	Gln	Ser	Gln	His	Leu	Gln	Ala	Lys	Pro	Thr
				245					250					255	
Thr	Leu	Ser	Leu	Pro	Leu	Thr	Pro	Glu	Ser	Pro	Asn	Asp	Pro	Lys	Gly
			260					265					270		
Ser	Pro	Phe	Glu	Asn	Lys	Thr	Ile	Glu	Arg	Thr	Leu	Ser	Val	Glu	Leu
		275					280					285			
Ser	Gly	Thr	Ala	Gly	Leu	Thr	Pro	Pro	Thr	Thr	Pro	Pro	His	Lys	Ala
	290					295					300				
Asn	Gln	Asp	Asn	Pro	Phe	Arg	Ala	Ser	Pro	Lys	Leu	Lys	Ser	Ser	Cys
305					310					315					320
Lys	Thr	Val	Val	Pro	Pro	Pro	Ser	Lys	Lys	Pro	Arg	Tyr	Ser	Glu	Ser
				325					330					335	
Ser	Gly	Thr	Gln	Gly	Asn	Asn	Ser	Thr	Lys	Lys	Gly	Pro	Glu	Gln	Ser
			340					345					350		
Glu	Leu	Tyr	Ala	Gln	Leu	Ser	Lys	Ser	Ser	Val	Leu	Thr	Gly	Gly	His
	355						360					365			
Glu	Glu	Arg	Lys	Thr	Lys	Arg	Pro	Ser	Leu	Arg	Leu	Phe	Gly	Asp	His
	370					375					380				
Asp	Tyr	Cys	Gln	Ser	Ile	Asn	Ser	Lys	Thr	Glu	Ile	Leu	Ile	Asn	Ile
385					390					395					400
Ser	Gln	Glu	Leu	Gln	Asp	Ser	Arg	Gln	Leu	Glu	Asn	Lys	Asp	Val	Ser
				405					410					415	
Ser	Asp	Trp	Gln	Gly	Gln	Ile	Cys	Ser	Ser	Thr	Asp	Ser	Asp	Gln	Cys
			420					425					430		
Tyr	Leu	Arg	Glu	Thr	Leu	Glu	Ala	Ser	Lys	Gln	Val	Ser	Pro	Cys	Ser
	435						440						445		
Thr	Arg	Lys	Gln	Leu	Gln	Asp	Gln	Glu	Ile	Arg	Ala	Glu	Leu	Asn	Lys
	450					455					460				
His	Phe	Gly	His	Pro	Ser	Gln	Ala	Val	Phe	Asp	Asp	Glu	Ala	Asp	Lys
465					470					475					480
Thr	Gly	Glu	Leu	Arg	Asp	Ser	Asp	Phe	Ser	Asn	Glu	Gln	Phe	Ser	Lys
				485					490					495	
Leu	Pro	Met	Phe	Ile	Asn	Ser	Gly	Leu	Ala	Met	Asp	Gly	Leu	Phe	Asp
			500					505					510		
Asp	Ser	Glu	Asp	Glu	Ser	Asp	Lys	Leu	Ser	Tyr	Pro	Trp	Asp	Gly	Thr
		515					520					525			
Gln	Ser	Tyr	Ser	Leu	Phe	Asn	Val	Ser	Pro	Ser	Cys	Ser	Ser	Phe	Asn
	530					535					540				
Ser	Pro	Cys	Arg	Asp	Ser	Val	Ser	Pro	Pro	Lys	Ser	Leu	Phe	Ser	Gln
545					550					555					560
Arg	Pro	Gln	Arg	Met	Arg	Ser	Arg	Ser	Arg	Ser	Phe	Ser	Arg	His	Arg
				565					570					575	
Ser	Cys	Ser	Arg	Ser	Pro	Tyr	Ser	Arg	Ser	Arg	Ser	Arg	Ser	Pro	Gly
			580					585					590		
Ser	Arg	Ser	Ser	Ser	Arg	Ser	Cys	Tyr	Tyr	Tyr	Glu	Ser	Ser	His	Tyr
			595				600					605			
Arg	His	Arg	Thr	His	Arg	Asn	Ser	Pro	Leu	Tyr	Val	Arg	Ser	Arg	Ser
	610					615					620				
Arg	Ser	Pro	Tyr	Ser	Arg	Arg	Pro	Arg	Tyr	Asp	Ser	Tyr	Glu	Glu	Tyr

22/29

625					630					635					640	
Gln	His	Glu	Arg	Leu	Lys	Arg	Glu	Glu	Tyr	Arg	Arg	Glu	Tyr	Glu	Lys	
				645					650					655		
Arg	Glu	Ser	Glu	Arg	Ala	Lys	Gln	Arg	Glu	Arg	Gln	Arg	Gln	Lys	Ala	
				660					665					670		
Ile	Glu	Glu	Arg	Arg	Val	Ile	Tyr	Val	Gly	Lys	Ile	Arg	Pro	Asp	Thr	
				675					680					685		
Thr	Arg	Thr	Glu	Leu	Arg	Asp	Arg	Phe	Glu	Val	Phe	Gly	Glu	Ile	Glu	
				690					695					700		
Glu	Cys	Thr	Val	Asn	Leu	Arg	Asp	Asp	Gly	Asp	Ser	Tyr	Gly	Phe	Ile	
705					710					715					720	
Thr	Tyr	Arg	Tyr	Thr	Cys	Asp	Ala	Phe	Ala	Ala	Leu	Glu	Asn	Gly	Tyr	
				725					730					735		
Thr	Leu	Arg	Arg	Ser	Asn	Glu	Thr	Asp	Phe	Glu	Leu	Tyr	Phe	Cys	Gly	
				740					745					750		
Arg	Lys	Gln	Phe	Phe	Lys	Ser	Asn	Tyr	Ala	Asp	Leu	Asp	Ser	Asn	Ser	
				755					760					765		
Asp	Asp	Phe	Asp	Pro	Ala	Ser	Thr	Lys	Ser	Lys	Tyr	Asp	Ser	Leu	Asp	
				770					775					780		
Phe	Asp	Ser	Leu	Leu	Lys	Glu	Ala	Gln	Arg	Ser	Leu	Arg	Arg			
785					790					795						

```
<210> 33
<211> 475
<212> PRT
<213> Homo sapiens
```

<400>	33														
Met	Val	Asp	Thr	Glu	Met	Pro	Phe	Trp	Pro	Thr	Asn	Phe	Gly	Ile	Ser
1				5					10					15	
Ser	Val	Asp	Leu	Ser	Val	Met	Glu	Asp	His	Ser	His	Ser	Phe	Asp	Ile
			20					25					30		
Lys	Pro	Phe	Thr	Thr	Val	Asp	Phe	Ser	Ser	Ile	Ser	Thr	Pro	His	Tyr
		35					40					45			
Glu	Asp	Ile	Pro	Phe	Thr	Arg	Thr	Asp	Pro	Val	Val	Ala	Asp	Tyr	Lys
	50					55					60				
Tyr	Asp	Leu	Lys	Leu	Gln	Glu	Tyr	Gln	Ser	Ala	Ile	Lys	Val	Glu	Pro
65					70					75					80
Ala	Ser	Pro	Pro	Tyr	Tyr	Ser	Glu	Lys	Thr	Gln	Leu	Tyr	Asn	Lys	Pro
				85					90					95	
His	Glu	Glu	Pro	Ser	Asn	Ser	Leu	Met	Ala	Ile	Glu	Cys	Arg	Val	Cys
			100					105					110		
Gly	Asp	Lys	Ala	Ser	Gly	Phe	His	Tyr	Gly	Val	His	Ala	Cys	Glu	Gly
		115					120					125			
Cys	Lys	Gly	Phe	Phe	Arg	Arg	Thr	Ile	Arg	Leu	Lys	Leu	Ile	Tyr	Asp
	130					135					140				
Arg	Cys	Asp	Leu	Asn	Cys	Arg	Ile	His	Lys	Lys	Ser	Arg	Asn	Lys	Cys
145					150					155					160
Gln	Tyr	Cys	Arg	Phe	Gln	Lys	Cys	Leu	Ala	Val	Gly	Met	Ser	His	Asn
				165					170					175	
Ala	Ile	Arg	Phe	Gly	Arg	Met	Pro	Gln	Ala	Glu	Lys	Glu	Lys	Leu	Leu
			180					185					190		
Ala	Glu	Ile	Ser	Ser	Asp	Ile	Asp	Gln	Leu	Asn	Pro	Glu	Ser	Ala	Asp
		195					200					205			
Leu	Arg	Ala	Leu	Ala	Lys	His	Leu	Tyr	Asp	Ser	Tyr	Ile	Lys	Ser	Phe
	210					215					220				
Pro	Leu	Thr	Lys	Ala	Lys	Ala	Arg	Ala	Ile	Leu	Thr	Gly	Lys	Thr	Thr
225					230					235					240
Asp	Lys	Ser	Pro	Phe	Val	Ile	Tyr	Asp	Met	Asn	Ser	Leu	Met	Met	Gly
				245					250					255	
Glu	Asp	Lys	Ile	Lys	Phe	Lys	His	Ile	Thr	Pro	Leu	Gln	Glu	Gln	Ser

<400> 34															
Met 1	Gly	Glu	Thr	Leu 5	Gly	Asp	Ser	Pro	Ile 10	Asp	Pro	Glu	Ser	Asp 15	Ser
Phe	Thr	Asp	Thr 20	Leu	Ser	Ala	Asn 25	Ile	Ser	Gln	Glu	Met 30	Thr	Met	Val
Asp	Thr	Glu 35	Met	Pro	Phe	Trp 40	Pro	Thr	Asn	Phe	Gly 45	Ile	Ser	Ser	Val
Asp	Leu 50	Ser	Val	Met	Glu	Asp 55	His	Ser	His	Ser	Phe 60	Asp	Ile	Lys	Pro
Phe 65	Thr	Thr	Val	Asp	Phe 70	Ser	Ser	Ile	Ser	Thr 75	Pro	His	Tyr	Glu	Asp 80
Ile	Pro	Phe	Thr 85	Arg	Thr	Asp	Pro	Val 90	Val	Ala	Asp	Tyr	Lys 95	Tyr	Asp
Leu	Lys	Leu	Gln 100	Glu	Tyr	Gln	Ser	Ala 105	Ile	Lys	Val	Glu	Pro 110	Ala	Ser
Pro	Pro	Tyr 115	Tyr	Ser	Glu	Lys	Thr 120	Gln	Leu	Tyr	Asn	Lys 125	Pro	His	Glu
Glu	Pro 130	Ser	Asn	Ser	Leu	Met 135	Ala	Ile	Glu	Cys	Arg 140	Val	Cys	Gly	Asp
Lys 145	Ala	Ser	Gly	Phe	His 150	Tyr	Gly	Val	His	Ala 155	Cys	Glu	Gly	Cys	Lys 160
Gly	Phe	Phe	Arg 165	Arg	Thr	Ile	Arg	Leu 170	Lys	Leu	Ile	Tyr	Asp 175	Arg	Cys
Asp	Leu	Asn 180	Cys	Arg	Ile	His	Lys 185	Lys	Ser	Arg	Asn	Lys 190	Cys	Gln	Tyr
Cys	Arg 195	Phe	Gln	Lys	Cys	Leu	Ala 200	Val	Gly	Met	Ser	His 205	Asn	Ala	Ile
Arg	Phe	Gly	Arg	Met	Pro	Gln	Ala	Glu	Lys	Glu	Lys	Leu	Leu	Ala	Glu

```

      210              215              220
Ile Ser Ser Asp Ile Asp Gln Leu Asn Pro Glu Ser Ala Asp Leu Arg
225              230              235              240
Ala Leu Ala Lys His Leu Tyr Asp Ser Tyr Ile Lys Ser Phe Pro Leu
      245              250              255
Thr Lys Ala Lys Ala Arg Ala Ile Leu Thr Gly Lys Thr Thr Asp Lys
      260              265              270
Ser Pro Phe Val Ile Tyr Asp Met Asn Ser Leu Met Met Gly Glu Asp
      275              280              285
Lys Ile Lys Phe Lys His Ile Thr Pro Leu Gln Glu Gln Ser Lys Glu
      290              295              300
Val Ala Ile Arg Ile Phe Gln Gly Cys Gln Phe Arg Ser Val Glu Ala
305              310              315              320
Val Gln Glu Ile Thr Glu Tyr Ala Lys Ser Ile Pro Gly Phe Val Asn
      325              330              335
Leu Asp Leu Asn Asp Gln Val Thr Leu Leu Lys Tyr Gly Val His Glu
      340              345              350
Ile Ile Tyr Thr Met Leu Ala Ser Leu Met Asn Lys Asp Gly Val Leu
      355              360              365
Ile Ser Glu Gly Gln Gly Phe Met Thr Arg Glu Phe Leu Lys Ser Leu
      370              375              380
Arg Lys Pro Phe Gly Asp Phe Met Glu Pro Lys Phe Glu Phe Ala Val
385              390              395              400
Lys Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp Leu Ala Ile Phe Ile
      405              410              415
Ala Val Ile Ile Leu Ser Gly Asp Arg Pro Gly Leu Leu Asn Val Lys
      420              425              430
Pro Ile Glu Asp Ile Gln Asp Asn Leu Leu Gln Ala Leu Glu Leu Gln
      435              440              445
Leu Lys Leu Asn His Pro Glu Ser Ser Gln Leu Phe Ala Lys Leu Leu
      450              455              460
Gln Lys Met Thr Asp Leu Arg Gln Ile Val Thr Glu His Val Gln Leu
465              470              475              480
Leu Gln Val Ile Lys Lys Thr Glu Thr Asp Met Ser Leu His Pro Leu
      485              490              495
Leu Gln Glu Ile Tyr Lys Asp Leu Tyr
500              505

```

```

<210> 35
<211> 2440
<212> PRT
<213> Homo sapiens

```

```

<400> 35
Met Ser Ser Ser Gly Tyr Pro Pro Asn Gln Gly Ala Phe Ser Thr Glu
 1              5              10              15
Gln Ser Arg Tyr Pro Pro His Ser Val Gln Tyr Thr Phe Pro Asn Thr
      20              25              30
Arg His Gln Gln Glu Phe Ala Val Pro Asp Tyr Arg Ser Ser His Leu
      35              40              45
Glu Val Ser Gln Ala Ser Gln Leu Leu Gln Gln Gln Gln Gln Gln
      50              55              60
Leu Arg Arg Arg Pro Ser Leu Leu Ser Glu Phe His Pro Gly Ser Asp
65              70              75              80
Arg Pro Gln Glu Arg Arg Thr Ser Tyr Glu Pro Phe His Pro Gly Pro
      85              90              95
Ser Pro Val Asp His Asp Ser Leu Glu Ser Lys Arg Pro Arg Leu Glu
      100              105              110
Gln Val Ser Asp Ser His Phe Gln Arg Val Ser Ala Ala Val Leu Pro
      115              120              125
Leu Val His Pro Leu Pro Glu Gly Leu Arg Ala Ser Ala Asp Ala Lys

```



Thr	Ser	Arg	Trp	Thr	Glu	Glu	Glu	Met	Glu	Val	Ala	Lys	Lys	Gly	Leu
625					630					635					640
Val	Glu	His	Gly	Arg	Asn	Trp	Ala	Ala	Ile	Ala	Lys	Met	Val	Gly	Thr
				645					650					655	
Lys	Ser	Glu	Ala	Gln	Cys	Lys	Asn	Phe	Tyr	Phe	Asn	Tyr	Lys	Arg	Arg
			660					665					670		
His	Asn	Leu	Asp	Asn	Leu	Leu	Gln	Gln	His	Lys	Gln	Lys	Thr	Ser	Arg
		675					680					685			
Lys	Pro	Arg	Glu	Glu	Arg	Asp	Val	Ser	Gln	Cys	Glu	Ser	Val	Ala	Ser
	690					695					700				
Thr	Val	Ser	Ala	Gln	Glu	Asp	Glu	Asp	Ile	Glu	Ala	Ser	Asn	Glu	Glu
705					710					715					720
Glu	Asn	Pro	Glu	Asp	Ser	Glu	Val	Glu	Ala	Val	Lys	Pro	Ser	Glu	Asp
				725					730					735	
Ser	Pro	Glu	Asn	Ala	Thr	Ser	Arg	Gly	Asn	Thr	Glu	Pro	Ala	Val	Glu
			740					745					750		
Leu	Glu	Pro	Thr	Thr	Glu	Thr	Ala	Pro	Ser	Thr	Ser	Pro	Ser	Leu	Ala
		755					760					765			
Val	Pro	Ser	Thr	Lys	Pro	Ala	Glu	Asp	Glu	Ser	Val	Glu	Thr	Gln	Val
	770					775					780				
Asn	Asp	Ser	Ile	Ser	Ala	Glu	Thr	Ala	Glu	Gln	Met	Asp	Val	Asp	Gln
785					790					795					800
Gln	Glu	His	Ser	Ala	Glu	Glu	Gly	Ser	Val	Cys	Asp	Pro	Pro	Pro	Ala
				805					810					815	
Thr	Lys	Ala	Asp	Ser	Val	Asp	Val	Glu	Val	Arg	Val	Pro	Glu	Asn	His
			820					825					830		
Ala	Ser	Lys	Val	Glu	Gly	Asp	Asn	Thr	Lys	Glu	Arg	Asp	Leu	Asp	Arg
		835					840					845			
Ala	Ser	Glu	Lys	Val	Glu	Pro	Arg	Asp	Glu	Asp	Leu	Val	Val	Ala	Gln
	850					855					860				
Gln	Ile	Asn	Ala	Gln	Arg	Pro	Glu	Pro	Gln	Ser	Asp	Asn	Asp	Ser	Ser
865					870					875					880
Ala	Thr	Cys	Ser	Ala	Asp	Glu	Asp	Val	Asp	Gly	Glu	Pro	Glu	Arg	Gln
				885					890					895	
Arg	Met	Phe	Pro	Met	Asp	Ser	Lys	Pro	Ser	Leu	Leu	Asn	Pro	Thr	Gly
			900					905					910		
Ser	Ile	Leu	Val	Ser	Ser	Pro	Leu	Lys	Pro	Asn	Pro	Leu	Asp	Leu	Pro
		915					920					925			
Gln	Leu	Gln	His	Arg	Ala	Ala	Val	Ile	Pro	Pro	Met	Val	Ser	Cys	Thr
	930					935					940				
Pro	Cys	Asn	Ile	Pro	Ile	Gly	Thr	Pro	Val	Ser	Gly	Tyr	Ala	Leu	Tyr
945					950					955					960
Gln	Arg	His	Ile	Lys	Ala	Met	His	Glu	Ser	Ala	Leu	Leu	Glu	Glu	Gln
				965					970					975	
Arg	Gln	Arg	Gln	Glu	Gln	Ile	Asp	Leu	Glu	Cys	Arg	Ser	Ser	Thr	Ser
			980					985					990		
Pro	Cys	Gly	Thr	Ser	Lys	Ser	Pro	Asn	Arg	Glu	Trp	Glu	Val	Leu	Gln
		995					1000					1005			
Pro	Ala	Pro	His	Gln	Val	Ile	Thr	Asn	Leu	Pro	Glu	Gly	Val	Arg	Leu
	1010					1015					1020				
Pro	Thr	Thr	Arg	Pro	Thr	Arg	Pro	Pro	Pro	Pro	Leu	Ile	Pro	Ser	Ser
1025					1030						1035				1040
Lys	Thr	Thr	Val	Ala	Ser	Glu	Lys	Pro	Ser	Phe	Ile	Met	Gly	Gly	Ser
				1045					1050					1055	
Ile	Ser	Gln	Gly	Thr	Pro	Gly	Thr	Tyr	Leu	Thr	Ser	His	Asn	Gln	Ala
			1060					1065					1070		
Ser	Tyr	Thr	Gln	Glu	Thr	Pro	Lys	Pro	Ser	Val	Gly	Ser	Ile	Ser	Leu
		1075					1080					1085			
Gly	Leu	Pro	Arg	Gln	Gln	Glu	Ser	Ala	Lys	Ser	Ala	Thr	Leu	Pro	Tyr
	1090					1095					1100				
Ile	Lys	Gln	Glu	Glu	Phe	Ser	Pro	Arg	Ser	Gln	Asn	Ser	Gln	Pro	Glu

1105		1110		1115		1120
Gly Leu Leu Val	Arg Ala Gln His Glu Gly Val Val Arg Gly Thr Ala					
	1125		1130		1135	
Gly Ala Ile Gln Glu Gly Ser Ile Thr Arg Gly Thr Pro Thr Ser Lys						
	1140		1145		1150	
Ile Ser Val Glu Ser Ile Pro Ser Leu Arg Gly Ser Ile Thr Gln Gly						
	1155		1160		1165	
Thr Pro Ala Leu Pro Gln Thr Gly Ile Pro Thr Glu Ala Leu Val Lys						
	1170		1175		1180	
Gly Ser Ile Ser Arg Met Pro Ile Glu Asp Ser Ser Pro Glu Lys Gly						
1185	1190		1195		1200	
Arg Glu Glu Ala Ala Ser Lys Gly His Val Ile Tyr Glu Gly Lys Ser						
	1205		1210		1215	
Gly His Ile Leu Ser Tyr Asp Asn Ile Lys Asn Ala Arg Glu Gly Thr						
	1220		1225		1230	
Arg Ser Pro Arg Thr Ala His Glu Ile Ser Leu Lys Arg Ser Tyr Glu						
	1235		1240		1245	
Ser Val Glu Gly Asn Ile Lys Gln Gly Met Ser Met Arg Glu Ser Pro						
	1250		1255		1260	
Val Ser Ala Pro Leu Glu Gly Leu Ile Cys Arg Ala Leu Pro Arg Gly						
1265	1270		1275		1280	
Ser Pro His Ser Asp Leu Lys Glu Arg Thr Val Leu Ser Gly Ser Ile						
	1285		1290		1295	
Met Gln Gly Thr Pro Arg Ala Thr Thr Glu Ser Phe Glu Asp Gly Leu						
	1300		1305		1310	
Lys Tyr Pro Lys Gln Ile Lys Arg Glu Ser Pro Pro Ile Arg Ala Phe						
	1315		1320		1325	
Glu Gly Ala Ile Thr Lys Gly Lys Pro Tyr Asp Gly Ile Thr Thr Ile						
	1330		1335		1340	
Lys Glu Met Gly Arg Ser Ile His Glu Ile Pro Arg Gln Asp Ile Leu						
1345	1350		1355		1360	
Thr Gln Glu Ser Arg Lys Thr Pro Glu Val Val Gln Ser Thr Arg Pro						
	1365		1370		1375	
Ile Ile Glu Gly Ser Ile Ser Gln Gly Thr Pro Ile Lys Phe Asp Asn						
	1380		1385		1390	
Asn Ser Gly Gln Ser Ala Ile Lys His Asn Val Lys Ser Leu Ile Thr						
	1395		1400		1405	
Gly Pro Ser Lys Leu Ser Arg Gly Met Pro Pro Leu Glu Ile Val Pro						
	1410		1415		1420	
Glu Asn Ile Lys Val Val Glu Arg Gly Lys Tyr Glu Asp Val Lys Ala						
1425	1430		1435		1440	
Gly Glu Thr Val Arg Ser Arg His Thr Ser Val Val Ser Ser Gly Pro						
	1445		1450		1455	
Ser Val Leu Arg Ser Thr Leu His Glu Ala Pro Lys Ala Gln Leu Ser						
	1460		1465		1470	
Pro Gly Ile Tyr Asp Asp Thr Ser Ala Arg Arg Thr Pro Val Ser Tyr						
	1475		1480		1485	
Gln Asn Thr Met Ser Arg Gly Ser Pro Met Met Asn Arg Thr Ser Asp						
	1490		1495		1500	
Val Thr Ile Ser Ser Asn Lys Ser Thr Asn His Glu Arg Lys Ser Thr						
1505	1510		1515		1520	
Leu Thr Pro Thr Gln Arg Glu Ser Ile Pro Ala Lys Ser Pro Val Pro						
	1525		1530		1535	
Gly Val Asp Pro Val Val Ser His Ser Pro Phe Asp Pro His His Arg						
	1540		1545		1550	
Gly Ser Thr Ala Gly Glu Val Tyr Arg Ser His Leu Pro Thr His Leu						
	1555		1560		1565	
Asp Pro Ala Met Pro Phe His Arg Ala Leu Asp Pro Ala Ala Ala Ala						
	1570		1575		1580	
Tyr Leu Phe Gln Arg Gln Leu Ser Pro Thr Pro Gly Tyr Pro Ser Gln						
1585	1590		1595		1600	



Tyr Gln Leu Tyr Ala Met Glu Asn Thr Arg Gln Thr Ile Leu Asn Asp  
 1605 1610 1615  
 Tyr Ile Thr Ser Gln Gln Met Gln Val Asn Leu Arg Pro Asp Val Ala  
 1620 1625 1630  
 Arg Gly Leu Ser Pro Arg Glu Gln Pro Leu Gly Leu Pro Tyr Pro Ala  
 1635 1640 1645  
 Thr Arg Gly Ile Ile Asp Leu Thr Asn Met Pro Pro Thr Ile Leu Val  
 1650 1655 1660  
 Pro His Pro Gly Gly Thr Ser Thr Pro Pro Met Asp Arg Ile Thr Tyr  
 1665 1670 1675 1680  
 Ile Pro Gly Thr Gln Ile Thr Phe Pro Pro Arg Pro Tyr Asn Ser Ala  
 1685 1690 1695  
 Ser Met Ser Pro Gly His Pro Thr His Leu Ala Ala Ala Ala Ser Ala  
 1700 1705 1710  
 Glu Arg Glu Arg Glu Arg Glu Arg Glu Lys Glu Arg Glu Arg Glu Arg  
 1715 1720 1725  
 Ile Ala Ala Ala Ser Ser Asp Leu Tyr Leu Arg Pro Gly Ser Glu Gln  
 1730 1735 1740  
 Pro Gly Arg Pro Gly Ser His Gly Tyr Val Arg Ser Pro Ser Pro Ser  
 1745 1750 1755 1760  
 Val Arg Thr Gln Glu Thr Met Leu Gln Gln Arg Pro Ser Val Phe Gln  
 1765 1770 1775  
 Gly Thr Asn Gly Thr Ser Val Ile Thr Pro Leu Asp Pro Thr Ala Gln  
 1780 1785 1790  
 Leu Arg Ile Met Pro Leu Pro Ala Gly Gly Pro Ser Ile Ser Gln Gly  
 1795 1800 1805  
 Leu Pro Ala Ser Arg Tyr Asn Thr Ala Ala Asp Ala Leu Ala Ala Leu  
 1810 1815 1820  
 Val Asp Ala Ala Ala Ser Ala Pro Gln Met Asp Val Ser Lys Thr Lys  
 1825 1830 1835 1840  
 Glu Ser Lys His Glu Ala Ala Arg Leu Glu Glu Asn Leu Arg Ser Arg  
 1845 1850 1855  
 Ser Ala Ala Val Ser Glu Gln Gln Gln Leu Glu Gln Lys Thr Leu Glu  
 1860 1865 1870  
 Val Glu Lys Arg Ser Val Gln Cys Leu Tyr Thr Ser Ser Ala Phe Pro  
 1875 1880 1885  
 Ser Gly Lys Pro Gln Pro His Ser Ser Val Val Tyr Ser Glu Ala Gly  
 1890 1895 1900  
 Lys Asp Lys Gly Pro Pro Pro Lys Ser Arg Tyr Glu Glu Glu Leu Arg  
 1905 1910 1915 1920  
 Thr Arg Gly Lys Thr Thr Ile Thr Ala Ala Asn Phe Ile Asp Val Ile  
 1925 1930 1935  
 Ile Thr Arg Gln Ile Ala Ser Asp Lys Asp Ala Arg Glu Arg Gly Ser  
 1940 1945 1950  
 Gln Ser Ser Asp Ser Ser Ser Ser Leu Ser Ser His Arg Tyr Glu Thr  
 1955 1960 1965  
 Pro Ser Asp Ala Ile Glu Val Ile Ser Pro Ala Ser Ser Pro Ala Pro  
 1970 1975 1980  
 Pro Gln Glu Lys Leu Gln Thr Tyr Gln Pro Glu Val Val Lys Ala Asn  
 1985 1990 1995 2000  
 Gln Ala Glu Asn Asp Pro Thr Arg Gln Tyr Glu Gly Pro Leu His His  
 2005 2010 2015  
 Tyr Arg Pro Gln Gln Glu Ser Pro Ser Pro Gln Gln Gln Leu Pro Pro  
 2020 2025 2030  
 Ser Ser Gln Ala Glu Gly Met Gly Gln Val Pro Arg Thr His Arg Leu  
 2035 2040 2045  
 Ile Thr Leu Ala Asp His Ile Cys Gln Ile Ile Thr Gln Asp Phe Ala  
 2050 2055 2060  
 Arg Asn Gln Val Ser Ser Gln Thr Pro Gln Gln Pro Pro Thr Ser Thr  
 2065 2070 2075 2080  
 Phe Gln Asn Ser Pro Ser Ala Leu Val Ser Thr Pro Val Arg Thr Lys

Thr	Ser	Asn	Arg	Tyr	Ser	Pro	Glu	Ser	Gln	Ala	Gln	Ser	Val	His	His
			2100						2105				2110		
Gln	Arg	Pro	Gly	Ser	Arg	Val	Ser	Pro	Glu	Asn	Leu	Val	Asp	Lys	Ser
		2115					2120					2125			
Arg	Gly	Ser	Arg	Pro	Gly	Lys	Ser	Pro	Glu	Arg	Ser	His	Val	Ser	Ser
	2130				2135						2140				
Glu	Pro	Tyr	Glu	Pro	Ile	Ser	Pro	Pro	Gln	Val	Pro	Val	Val	His	Glu
2145					2150					2155					2160
Lys	Gln	Asp	Ser	Leu	Leu	Leu	Leu	Ser	Gln	Arg	Gly	Ala	Glu	Pro	Ala
			2165						2170					2175	
Glu	Gln	Arg	Asn	Asp	Ala	Arg	Ser	Pro	Gly	Ser	Ile	Ser	Tyr	Leu	Pro
			2180					2185					2190		
Ser	Phe	Phe	Thr	Lys	Leu	Glu	Asn	Thr	Ser	Pro	Met	Val	Lys	Ser	Lys
	2195						2200					2205			
Lys	Gln	Glu	Ile	Phe	Arg	Lys	Leu	Asn	Ser	Ser	Gly	Gly	Gly	Asp	Ser
	2210					2215					2220				
Asp	Met	Ala	Ala	Ala	Gln	Pro	Gly	Thr	Glu	Ile	Phe	Asn	Leu	Pro	Ala
2225					2230					2235					2240
Val	Thr	Thr	Ser	Gly	Ser	Val	Ser	Ser	Arg	Gly	His	Ser	Phe	Ala	Asp
			2245						2250				2255		
Pro	Ala	Ser	Asn	Leu	Gly	Leu	Glu	Asp	Ile	Ile	Arg	Lys	Ala	Leu	Met
			2260					2265					2270		
Gly	Ser	Phe	Asp	Asp	Lys	Val	Glu	Asp	His	Gly	Val	Val	Met	Ser	Gln
	2275						2280					2285			
Pro	Met	Gly	Val	Val	Pro	Gly	Thr	Ala	Asn	Thr	Ser	Val	Val	Thr	Ser
	2290					2295					2300				
Gly	Glu	Thr	Arg	Arg	Glu	Glu	Gly	Asp	Pro	Ser	Pro	His	Ser	Gly	Gly
2305					2310					2315					2320
Val	Cys	Lys	Pro	Lys	Leu	Ile	Ser	Lys	Ser	Asn	Ser	Arg	Lys	Ser	Lys
			2325						2330				2335		
Ser	Pro	Ile	Pro	Gly	Gln	Gly	Tyr	Leu	Gly	Thr	Glu	Arg	Pro	Ser	Ser
			2340					2345				2350			
Val	Ser	Ser	Val	His	Ser	Glu	Gly	Asp	Tyr	His	Arg	Gln	Thr	Pro	Gly
	2355						2360					2365			
Trp	Ala	Trp	Glu	Asp	Arg	Pro	Ser	Ser	Thr	Gly	Ser	Thr	Gln	Phe	Pro
	2370				2375						2380				
Tyr	Asn	Pro	Leu	Thr	Met	Arg	Met	Leu	Ser	Ser	Thr	Pro	Pro	Thr	Pro
2385					2390					2395					2400
Ile	Ala	Cys	Ala	Pro	Ser	Ala	Val	Asn	Gln	Ala	Ala	Pro	His	Gln	Gln
			2405						2410					2415	
Asn	Arg	Ile	Trp	Glu	Arg	Glu	Pro	Ala	Pro	Leu	Leu	Ser	Ala	Gln	Tyr
			2420					2425					2430		